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ABSTRACT 
Cancer is the leading cause of death worldwide. It is estimated that the incidence rate is 
rising despite that in recent decades, the range of treatment options and drugs have 
expanded considerably. Often conventional cancer drugs are also associated with 
significant adverse event profiles from both on- and off-target effects. Thus, there is an 
urgent need for novel treatment options that are more efficient but at the same time safer 
and more specific. Oncolytic viruses (i.e. viruses that specifically kill cancerous cells) have 
shown a solid safety profile with only mild adverse events in several clinical trials, but still 
these treatments are often non-curative. Hence, the efficacy of the oncolytic virotherapies 
needs to be enhanced. Currently researchers are trying to improve the immunogenicity of 
the viruses to boost the activation of anti-tumor immune responses by, for example, 
arming the viruses with immunostimulatory molecules. Actually, oncolytic viruses are 
nowadays considered immunotherapies because of their ability to stimulate many arms of 
the host immune system to fight against cancer. These immunomodulatory viruses have 
shown promising efficacy in some trials, one oncolytic virus (talimogene laherparepvec (T-
Vec), trade name Imlygic), was even approved for clinical use by the FDA (Food and Drug 
Administration) just recently in October 2015; also EMA (European Medicines Agency) 
recommended its approval and it will most probably be accepted for treatment soon in the 
EU as well. However, oncolytic viruses, like most other cancer drugs as well, have only 
been effective in a small group of patients. This is due to genetic and/or other variability 
between the treated patients and their tumors. Understanding the effects of individual 
differences in treatment responses has spurred the era of personalized medicine. Choosing 
only patients who most probably would respond to the treatments, choosing the correct 
dosing for each patient, or tailoring individually designed drugs for each case would enable 
safer, more cost-effective and more efficacious treatments.  
The purpose of this thesis was to improve the efficacy of oncolytic virotherapies by A) 
boosting the immunogenicity of the viruses and B) by finding means to optimize the 
therapies by selecting a favorable patient population and by developing a method to tailor 
the drug individually for each patient.  
We first considered whether the efficacy of oncolytic viruses could be enhanced by 
boosting their immunogenicity. An oncolytic adenovirus was modified to express human 
tumor necrosis factor alpha (hTNFα), which is a potent multifunctional cytokine. TNFα 
expression was hypothesized to improve the cytotoxic potency of the virus and its ability to 
activate and attract immune cells to the tumor site. We showed effective tumor cell killing 
by the Ad5/3-Δ24-hTNFα virus both in vitro and in vivo, which was associated with signs of 
immunogenic cell death. The virus also enhanced recruitment of adaptive immune cells to 
the infection site. We also studied the hTNFα-expressing virus in combination with 
radiotherapy and saw some enhanced tumor-growth control and hence potential for 
combining the Ad5/3-Δ24-hTNFα therapy with radiation. In another study we enhanced 
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the immunogenicity of an oncolytic vaccinia virus by modifying it to express a pattern 
recognition receptor, DNA-dependent activator of interferon-regulatory factors (DAI), 
which was shown to sense vaccinia virus DNA and to induce innate immune responses 
during virus infection. The DAI-producing oncolytic virus was tested in vitro and in vivo for 
anti-tumor efficacy and immunogenic potential. We showed that the virus induces 
expression of several genes involved in immune responses, and treatments with the DAI-
virus showed improved cancer-killing efficacy and immunogenicity in murine and human 
melanoma models. This study suggests that expression of a self-recognizing receptor by 
vaccinia virus could be a novel way to improve the adjuvant potency of viral drugs and 
could have potential applications in vaccine design. 
There is a great deal of variation in the response rates after oncolytic virotherapies 
between the patients, and there is a lack of markers that would help predict the patient 
cohorts who would benefit from the therapy. We screened over 200 cancer patients who 
had received oncolytic adenovirus therapies for two Fc gamma receptor (FcγR) 
polymorphisms to determine if these polymorphisms could serve as biomarkers for 
selection of suitable patients for clinical trials. We hypothesized that FcγRs, as important 
links between cellular and humoral immune responses, could have a role in defining the 
effectiveness of oncolytic virotherapy, which is nowadays known to greatly depend on the 
activity of the immune system. We therefore determined if polymorphic variation in these 
receptors would affect the responsiveness to the treatments. We observed a certain FcγR 
genotype combination (FcγRIIIa-VV + FcγRIIa-HR) to be predictive of poor overall survival 
after oncolytic adenovirus treatments. Additionally, we found some genotype 
combinations to be beneficial for treatments with viruses armed with immunostimulatory 
molecules: FcγRIIIa-FF + FcγRIIa-HR and FcγRIIIa-FF + FcγRIIa-RR combinations for 
treatments with GM-CSF-armed viruses and FcγRIIIa-FF + FcγRIIa-HH combination for 
CD40L-virus treatments. If confirmed in a larger and more controlled study, these genotype 
combinations could serve as exclusion or inclusion markers for the oncolytic adenovirus 
therapy. 
Because each patient and each tumor is unique, the same drug is not effective for all cases. 
To tailor the oncolytic virotherapy for enhanced specificity for different tumors, we 
developed a novel platform to quickly and easily coat a virus with tumor-specific antigens 
(peptides) to improve the induction of cancer-specific immune responses. This peptide-
coated conditionally replicating (i.e. oncolytic) adenovirus is called PeptiCRAd. Efficacy and 
immunogenic potency of the PeptiCRAd coated with known model peptides were shown in 
several in vivo models, both mouse and human melanomas. Our results suggest that 
administration of tumor-specific peptides on the surface of oncolytic viruses increases the 
anti-tumor efficacy compared to treatments with viruses or peptides alone. We think the 
PeptiCRAd platform could in the future be used as a carrier and adjuvant for patient-
specific peptides to trigger anti-tumor immunity in a personalized manner. 
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REVIEW OF LITERATURE 
1. Introduction 
Cancer is a devastating disease and a major cause of death, causing over 8 million deaths a 
year worldwide (IARC-International Agency for Research on Cancer (WHO)). As the 
percentage of aging population is growing, the cancer incidence rates are rising regardless 
of the development of tools for earlier diagnosis. The treatment methods for cancer have 
also developed a great deal during the past decades - still there are some major problems 
that need to be addressed, like side effects, unspecificity, and resistance developed against 
the treatments. New, better targeted, more specific, safer and more efficient treatments 
are needed. 
Oncolytic viruses, i.e. viruses that specifically kill tumor cells, are one potential treatment 
option for cancers, even advanced ones. There are several clinical trials to test oncolytic 
virotherapies for treating cancer (Sheridan 2015). Although this is a highly promising field, 
most trials still have failed to show sufficient efficacy. However, the first oncolytic virus, 
H101, was approved over ten years ago in China for treating head and neck cancer (Yu & 
Fang 2007). And just recently in October 2015, the first oncolytic virus, a herpes simplex 
virus encoding for GM-CSF (talimogene laherparepvec (T-Vec), trade name Imlygic, Amgen) 
was approved by the FDA for the treatment of recurrent melanoma (Andtbacka et al. 
2015); this is a very encouraging step for the field.  
Some of the most commonly used viruses in oncolytic virotherapies are adenoviruses and 
vaccinia viruses, which will be the main focus of this thesis. Both viruses are effective in 
infecting cells and fast in cell lysis. They can be easily modified to be even more efficient 
and immunogenic in order to enhance their tumor killing potency.  
The role of the immune system in the progression and eradication of cancer is widely 
acknowledged nowadays and immunotherapy is a fast evolving and growing form of 
therapy for cancer. Also in the field of oncolytic virotherapies, in recent years, the common 
trend has turned towards “immunovirotherapies”, in which viruses are used as adjuvants 
to boost the host immune responses against cancer (Coffin 2015, Lichty et al. 2014, Tong et 
al. 2011).  
Even though the virus could be engineered to be as efficient as possible, the treatment 
most probably would not work for every patient. Thus, the concept of “personalized 
medicine” is spreading, and selection of the right patients for the treatments is generally 
agreed to be a way to reduce unnecessary use of drugs, to minimize side effects and save 
money (Rodriguez-Antona & Taron 2015, Fisher 2011, Heuckmann & Thomas 2015, 
Gasparini & Longo 2012). The recent innovations also aim to design drugs so that they can 
easily be customized for each patient and even for each tumor.  
17 
 
In the future, patient-tailored drugs, selecting the right patients who most probably 
respond to the treatments and combining different therapies will possibly offer better 
solutions to defeat cancer.  
2. Challenges of cancer treatment 
Cancers are a group of heterogeneous diseases in which cells begin to proliferate 
independently causing a mass of malformed cells – a tumor. Carcinogenesis, the formation 
of a tumor, is a multistep process involving various changes in the genetic material and the 
effect of the environment. Tumors are considered malignant when cells have gained an 
ability to evade the primary tumor to travel to other parts of the body and give rise to new 
secondary tumors called metastases (Leber & Efferth 2009). 
Cancer is caused by multiple gain-of-function and loss-of-function mutations in a single 
cell, which becomes insensitive to growth controlling signals. Mutations can originate from 
any cell type of the body. Usually the mutations leading to the development of cancer take 
place in genes that normally code for proteins that regulate cell growth and proliferation 
(tumor suppressor genes and oncogenes) or DNA repair mechanisms (Osborne, Wilson & 
Tripathy 2004). In 2000, Hanahan and Weinberg proposed the six “hallmarks of cancer” 
(Hanahan & Weinberg 2000) that differentiate tumor cells from normal cells: i) Cancer cells 
stimulate their own growth, ii) they resist anti-growth signals, iii) they can evade apoptotic 
cell death, iv) they can multiply infinitely, v) they stimulate angiogenesis and vi) they 
become invasive and can spread to distant sites (Hanahan & Weinberg 2000). A few years 
ago, in 2011, they added four more traits characteristic to cancer cells, two of which 
recognize the importance of the immune system in the tumor progression and eradication: 
inflammation and immune evasion (Hanahan & Weinberg 2011). The immune system both 
prevents malformed cells from growing and erases them, but if some tumor cells have a 
chance to evade the immune system, they start evolving towards less immunogenic forms 
and eventually hide from the immune system. This development process of the tumor 
towards lower immunogenicity is called “immunoediting” (Dunn et al. 2002). In 2004 Dunn 
et al. divided the main events of immunoediting into “three Es”: in the Elimination phase, 
the immune system is still able to recognize and eliminate cancerous cells from the body, 
but in the Equilibrium phase the surviving cancer cells remain in a dynamic equilibrium 
with the immune system and the “strongest” tumor cells that can hide from the immune 
system are selected by Darwinian law. These strongest cancer cells can eventually grow in 
an immunologically intact environment; this last phase is called the Escape phase. At this 
stage it becomes very challenging to treat the cancer, and today there are many attempts 
to provoke the immunogenicity of the cancer and to wake up the host immune system to 
the “elimination phase” when the tumor cells will again be recognized and destroyed 
(Dunn, Old & Schreiber 2004). 
These characteristics of cancer form the tumor microenvironment, a constantly evolving 
environment where new mutations arise and selections are made. It is a constant battle 
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between the body and a tumor. Immunotherapies have emerged as potential strategies to 
treat certain tumors that tend to overexpress some proteins important for tumor survival 
or that present tumor-specific antigens. Since tumors always originate from the body´s 
own cells, the immune system needs to find epitopes that are foreign for the tumor cell to 
be recognized as malfunctioning and to be killed. Sometimes mistakes in this identification 
process cause a problem, known as autoimmunity, in which the immune system starts to 
attack the body´s own healthy cells (Amos et al. 2011). Thus, it is very important that drugs 
designed to wake up the host immune system against cancer, e.g. peptide vaccines, 
contain only tumor-specific antigens, not self-antigens. Although immunotherapies have 
shown success in some cases, they are often quite limited, targeting only one or two 
pathways, which often is not enough to block the growth of the tumor. Therefore 
combining different therapeutic strategies of therapies would be more efficient.  
Foreign antigens are loaded into MHC I molecules that are recognized by cytotoxic T cells 
(CTLs). Tumor cells, however, have often acquired a way to reduce the presentation of 
tumor antigens by down-regulating MHC I expression and function. Also the activity of T 
cells and antigen presenting cells in the tumors is usually low due to several mechanisms of 
the immunosuppressive microenvironment. Tumor cells secrete immunosuppressive 
cytokines, like transforming growth factor beta (TGF-β), which can recruit regulatory T cells 
(Tregs) and directly inhibit the activity of T cells. Tumors can also overexpress surface 
proteins, like CTLA-4 and PD-1 ligand that also inhibit T cell activation. Myeloid-derived 
suppressor cells (MDSCs) also constitute part of the immunosuppressive environment by 
inducing all the above-mentioned mechanisms. Tumor-associated macrophages with an 
M2 phenotype can as well promote immune evasion by secreting anti-inflammatory 
molecules, such as IL-10 and TGF- β. (Schlosser et al. 2014) 
Heterogeneity is the major challenge for cancer therapies; each patient, each tumor and 
even each cell within the tumor is unique. Finding a cure that works in all cancer cases is 
not possible; thus finding a way to easily customize a drug for each case is the future 
challenge in the field. 
3. Cancer therapies 
3.1. Conventional therapies 
Traditionally cancer is treated first with surgery, if possible, and thereafter by radiation 
and/or chemotherapy to remove the remaining cancerous cells from the body and to 
reduce the re-growth of the tumor or growth of metastases to other parts of the body. 
Often a combination of different therapies provides the best treatment response. 
Surgery is a standard treatment for cancer after the diagnosis, but is sometimes limited by 
the anatomical location or extent of the tumor. Radiation therapy is normally used to 
eliminate the remaining cancerous cells after surgery, but also as a palliative treatment and 
for tumors that are inoperable. Radiation therapy can be divided into three main 
19 
 
categories: i) teletherapy, in which an external source of radiation is used (Pisansky 2006, 
McGovern & Mahajan 2012), ii) brachytherapy, in which the source of radiation is directly 
implanted into the tumor (Pisansky et al. 2008) and iii) systemic radioisotope therapy, in 
which radioisotopes are delivered orally or systemically into tumor sites by specific 
transporters (Porter, Ben-Josef & Davis 1994). The effects of radiotherapy are mediated 
through ionizing radiation that creates single- and double-strand breaks in the cellular DNA 
and it also creates free hydroxyl radicals (Russi, Raber-Durlacher & Sonis 2014, Kavanagh et 
al. 2013). Cells have several mechanisms to repair DNA breaks; nevertheless if the amount 
of radiation is strong enough, damages cannot be compensated and they eventually lead 
to cell cycle arrest and finally induction of cell death in the irradiated area. Thus, cancer 
eradication is dependent on the dose of irradiation (Kavanagh et al. 2013, Valicenti et al. 
2000), although the risks for severe side effects increase with higher doses (Russi, Raber-
Durlacher & Sonis 2014).  
Chemotherapy is a widely used and often effective therapy that uses chemical substances 
to kill cancer cells. Chemotherapeutics can be divided into alkylating agents, 
antimetabolites, cytotoxic antibiotics, plant alkaloids, topoisomerase inhibitors and other 
anti-tumor agents. These drugs are cytotoxic agents that have an effect on cell division or 
DNA synthesis. Chemotherapeutic drugs act dose-dependently, but the effect can be 
directed mostly to fast dividing cells with a controlled dosage. In low doses some 
chemotherapeutics can mediate immunomodulating functions and immunogenic cell 
death (Shevchenko et al. 2013, Tesniere et al. 2010). 
Fortunately conventional therapy methods have developed a great deal over the past 
decades, but some aggressive or advanced cancers typically develop resistance against 
radiation and chemotherapeutics and become refractory to these therapies. These 
therapies are also unspecific, thus similar damage is done to both tumor and normal 
healthy cells, especially rapidly dividing cells. 
3.2. Biological cancer therapies 
In addition to the conventional therapies, several other treatment modalities for cancer 
have been developed. 
In the late 1800s, Dr. William Coley noticed that induction of a fever and immune reactions 
following use of a killed bacterial mixture (called Coley’s toxin) were followed by tumor 
regression in some cancer patients (Coley 1891, Nauts, Swift & Coley 1946). Later, 
following Coley’s observation, a weakened form of a live tuberculosis bacterium originally 
used for vaccination against tuberculosis showed also to have anti-cancer properties, and 
this Bacillus Calmette Guérin (BCG) vaccine became the first biological therapy approved by 
the FDA for treatment of cancer. BCG is still used as an immunomodulatory therapy for 
bladder cancer due to its adjuvant potential (Morales, Eidinger & Bruce 2002).  
In some cancer types, the tumor can use the body’s own hormones as a growth signal, or 
they can even acquire the ability to overexpress hormones. For this kind of hormone-
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sensitive or hormone-dependent cancers, hormonal therapies, in which the excess 
production of hormones is blocked, can be useful. Hormonal therapies have been used for 
cancer treatment since mid-1900s when Drs. Huggins and Hodges showed that patients 
with metastatic prostate cancer benefited from testosterone suppression (Huggins & 
Hodges 2002). Still today it is a widely used therapy option for cancer types like prostate, 
breast, ovarian and thyroidal cancers. However, hormone therapy usually is only palliative 
rather than curative.  
Often when high doses of chemo- and/or radiotherapy are used to treat a patient, it also 
destroys a patient´s stem cell repertoire; thus stem cell transplantation (Weiden et al. 
1979) is a means to replace these cells that have been destroyed and reconstitute the 
body´s ability to produce blood cells. There are two types of stem cell transplants: 
autologous, where the cells are taken from the patient’s own bone marrow and returned 
after treatments, and allogeneic transplants, where the cells are from a donor with a 
matched HLA type. The latter has some advantages over autologous transplant; donated 
transplants are free of cancer cells (that might be present in autologous samples) and 
donor stem cells can produce immune cells that can better recognize tumor cells and 
destroy any remaining cancerous cells; this phenomenon is called the graft-versus-cancer 
effect. Therefore bone marrow transplants have been used to treat leukemia and even 
some solid tumors (Dougan & Dranoff 2009). However, allogeneic transplants also carry 
certain risks. The graft might be rejected, i.e. the donor cells could die or be destroyed by 
the patient’s body before engraftment in the bone marrow. The immune cells from the 
donor might in some cases also attack the patient´s healthy cells in addition to the cancer 
cells, which is referred to as graft-versus-host disease. There is also a small risk of infection 
from the donor cells, even though donors are extensively tested before donation. 
Gene therapy is a relatively novel approach where genetic material, DNA or RNA, is 
introduced into patient’s cells to fight disease (Mulligan 1993). The genetic material is 
delivered into cells inside a vector. Viral vectors are the most used mainly because of their 
efficient gene delivery rates compared to non-viral vectors, like for example liposomes 
(Robbins & Ghivizzani 1998). Previously, most gene therapy approaches concentrated on 
introducing a functional version of a gene mutated in a monogenic disease, but nowadays 
most (64%) of all gene therapy trials focus on cancer (Gene Therapy Trials Worldwide). 
Cancer gene therapy can be used for instance to replace a deficient tumor suppressor gene 
or to silence an activated oncogene. Also various enzyme-activated prodrug systems have 
been constructed, e.g. HSV-TK/GCV combination treatment, where the cells are introduced 
with a herpes simplex virus thymidine kinase (HSV-TK) gene, which encodes an enzyme 
that can convert a separately administered non-toxic prodrug Ganciclovir (GCV) into a toxic 
metabolite GCV triphosphate (GCVTP) (Dachs et al. 2009). Also introducing genes that 
block or silence genes that are essential for tumor growth (like genes related to 
angiogenesis) has been widely investigated (Llovet et al. 2008, Yoo et al. 2007, Guse et al. 
2010).  
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Nowadays it is also known that there are cells in tumors responsible for cancer initiation, 
progression, metastasis, recurrence and drug resistance: cancer stem cells (CSCs). There 
are a growing number of studies on the development of CSC-related therapies and the 
identification of key molecules involved in controlling the properties of CSCs (Chen, Huang 
& Chen 2013). In addition, different immunotherapy methods are rapidly being developed 
to harness a patient´s own immune system to fight the disease. 
3.2.1. Immunotherapies 
Cancer immunotherapy aims at waking up the patient’s own immune system to target and 
kill tumor cells (Mellman, Coukos & Dranoff 2011, Melief 2008). Together with Coley’s 
toxin, recombinant cytokines are one of the oldest applications of using immunologically 
active biological substances for treating cancer. For example interferon-α, TNFα, GM-CSF 
and IL-2 have been used for cancer treatment because of their direct and indirect cytotoxic 
effects as well as immunostimulatory properties.  Interferons (IFNs) are cytokines that the 
body normally produces to fight pathogens. IFNα increases MHC-I expression and thus 
presentation of tumor-associated antigens (Anderson et al. 1994) and is therefore useful 
for treating hematological malignancies, melanomas, hepatocellular carcinomas and 
bladder cancer (Floros & Tarhini 2015). TNFα has several ways to stimulate the immune 
system; it can, e.g., induce production of other inflammatory cytokines and maturation of 
dendritic cells (Mocellin et al. 2005). It also induces necrotic and apoptotic cell death when 
present at high local concentrations (Ashkenazi & Dixit 1998, Salako et al. 2011, van 
Horssen, Ten Hagen & Eggermont 2006, Rath & Aggarwal 1999, Balkwill et al. 1986). 
However, its systemic administration is toxic, so it has only been approved for treatment of 
soft tissue sarcoma and melanoma patients by isolated limb perfusion (Mocellin et al. 
2005, Lienard et al. 1992). GM-CSF, granulocyte-macrophage colony-stimulating factor, 
also promotes DC maturation and antigen presentation and it can activate lymphocytes 
making it a powerful cytokine for immunotherapy. Currently it is used as a combination 
therapy with other therapies, including cancer vaccines and oncolytic virotherapies (Pol et 
al. 2015, Andtbacka et al. 2015, Ranki et al. 2014). IL-2, a T cell growth factor, has shown 
best promise in the treatment of metastatic melanoma (Atkins et al. 1999). Recombinant 
cytokines have shown to be effective in treating some cancers, but their systemic 
administration is often toxic and mediates serious side effects that hinder their use. 
However their local expression by gene therapy approaches is a way to reduce these side 
effects.  
Currently the most predominant forms of immunotherapy are monoclonal antibodies 
(mAbs). These drugs are designed to specifically target cancer-associated proteins that 
block pathways relevant to cancer survival. MAbs act in several ways to kill tumor cells: 
they can directly kill tumor cells by blocking tumor cell signaling or by delivery of cytotoxic 
molecules (antibody-drug conjugates), they can induce tumor eradication by specific 
effects on tumor vasculature or stroma or they can induce immune-mediated cell killing by 
complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity 
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(ADCC) or by regulation of T cell functions. So far 19 mAbs have been approved by the FDA 
(The Antibody Society 2015) as cancer therapeutics of which maybe the best known 
example is trastuzumab (Herceptin, Roche) for treatment of HER2 positive breast cancer 
(Ewer & Ewer 2015). In recent years, the patents on the first approved mAbs have expired; 
thus a rapid development period of biosimilars has recently started (Rak Tkaczuk & Jacobs 
2014).  
Immunomodulatory antibodies have recently achieved clinical success. In many cancers, 
the immune checkpoint pathways that control the immune system´s ability to maintain 
self-tolerance and duration of immune responses are often disrupted; tumors and tumor-
associated cells often produce molecules, like for instance PD-L1, to suppress immunity. 
Therefore there are mAbs designed to target these molecules. For example, ipilimumab 
(Yervoy, Bristol-Myers Squibb) is an antibody against CTLA-4 (cytotoxic T lymphocyte-
associated protein 4) that blocks the interaction of this inhibitory T cell receptor and the B7 
costimulatory molecules on APCs and thus prevents the negative feedback loop of CTL 
activation. Ipilimumab has been approved for treating advanced melanomas by the FDA 
(Hodi et al. 2010). Also antibodies against programmed cell death protein 1 (PD-1) and its 
ligand (PD-L1) are of great interest. There are two mAbs, pembrolizumab (Keytruda, 
Merck) (Khoja et al. 2015) and nivolumab (Opdivo, Bristol-Myers Squibb) (Johnson, Peng & 
Sosman 2015) approved by the FDA and EMA to block the PD-1 pathway, also preventing 
the inhibition of CTL activation.   
The first drug of the novel class of bispecific monoclonal antibodies, blinatumomab 
(Blincyto, Amgen) was just approved in 2014 for treatment of B cell acute lymphoblastic 
leukemia. These bispecific T cell engagers (BiTEs) consist of two monoclonal antibodies 
joined together; one end of the BiTE binds to T cells and the other end binds to a molecule 
on cancer cells (Buie et al. 2015). 
Therapeutic cancer vaccines are also an emerging type of cancer immunotherapy in which 
immunogenic tumor-associated antigens or cell-based strategies are used to induce anti-
tumor immune responses. The greatest success in the field of therapeutic cancer vaccines 
so far is a vaccine against advanced prostate cancer, called sipuleucel-T (Provenge, 
Dendreon). It is a mixture of a patient´s own PBMCs, GM-CSF and a prostate cancer 
associated antigen, prostatic acid phosphatase (Kantoff et al. 2010, Mellman, Coukos & 
Dranoff 2011). The therapeutic cancer vaccine field is intriguing and full of potential, but so 
far it has failed to show decent efficacy (except in the case of sipuleucel-T). There are also 
prophylactic cancer vaccines to protect from oncogenic viruses and formation of cancer, 
e.g. against papilloma virus or hepatitis B virus induced cancers (Dougan & Dranoff 2009).  
There is also a way to engineer a patient´s own immune cells to attack tumor cells. This is 
called adoptive cell therapy. Cells are collected from the patient and modified and 
amplified in laboratory conditions prior to reinfusing them back to the patient (Dudley & 
Rosenberg 2003). For example use of tumor-infiltrated lymphocytes (TILs) showed good 
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anti-tumor responses in metastatic melanoma patients (Rosenberg et al. 2011). 
Alternatively circulating T cells can be adopted from a patient and they can be genetically 
modified to express artificial T cell receptors (TCRs) against tumor antigens. These T cells 
are then able to recognize the tumor antigen bound to MHC-I molecules on tumor cell 
surfaces. This approach is, however, limited, since MHC-I expression is often down-
regulated in many cancer types and it may also cause autoimmune reactions due to off-
target toxicity (Hinrichs & Rosenberg 2014). To circumvent the need of proper MHC-I 
binding, another MHC-independent strategy has been developed. By using artificial 
chimeric antigen receptors (CARs) the T cells can be modified to be more flexible in terms 
of antigen binding. The CAR molecule normally consists of an antigen-binding variable 
fragment of a monoclonal antibody fused to intracellular T cell signaling domains 
(Bridgeman et al. 2010). These CAR T cells have shown promise at least in treating B cell 
leukemia by targeting CD19 antigen on the tumor cell surface (Maude, Shpall & Grupp 
2014).  
It is common that the therapeutic efficacy of immunotherapies is difficult to observe 
reliably, since these therapies often lead to swelling and fibrosis in the tumor site. 
Therefore the Response Evaluation Criteria in Solid Tumors (RECIST), originally developed 
to measure responses of chemotherapy, may not provide decent evaluations for 
immunotherapies. 
4. Oncolytic viruses 
In the mid-1800s and the beginning of 1900s, it was discovered that some cancer patients 
with concurrent infections of e.g. influenza (Kelly & Russell 2007) or chicken pox (Bierman 
et al. 1953) had tumor regression. In the 1950s and 1960s, some of the first clinical trials 
were conducted to study viruses for treating cancer but after this, the field of virotherapy 
was nearly abandoned for almost 50 years due to the lack of technology required to 
modify viruses and the early success stories of chemo- and radiotherapies. However, now 
these virotherapies have gained widespread attention and have shown promise as cancer 
therapeutics.  
Oncolytic viruses (OVs) are viruses that selectively replicate in cancer cells leading to tumor 
cell lysis while leaving normal cells unharmed (Post 2002) (Figure 1). They can be either 
naturally tumor-selective viruses, like reovirus and Seneca Valley virus, or genetically 
modified so that their replication is dependent on cancer-related pathways, like in the case 
of adeno- vaccinia, herpes simplex, measles and Newcastle disease viruses. Ideally, when 
the tumor cells are lysed, the released new virions can also infect surrounding tumor cells 
as a bystander effect and even spread through circulation into distant metastases. 
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Figure 1. Oncolytic virus action. Oncolytic viruses are viruses that can only kill cancer cells. 
They can infect both normal and cancerous cells, but in normal cells the replication is 
inhibited through mutations in the viral genome, therefore leading to virus clearance 
without cell damage. Since most cancer cells bear mutations allowing continuous cell 
proliferation, the modified viruses are able to replicate in them which eventually leads to 
cell lysis and release of a new virus progeny. 
In addition to the lysing effect, oncolytic viruses can act as adjuvants and stimulate host 
immune responses against tumors (Lichty et al. 2014). When the tumor cell is lysed, pieces 
of the cell, i.e. cell-associated antigens are released to the tumor microenvironment (Miller 
& Fraser 2003, Nakamori et al. 2004). Some of these antigens are tumor-specific that can 
be picked up by antigen-presenting cells, like dendritic cells (DCs), which can then process 
and present the antigens to naïve T cells in lymph nodes. The activated anti-tumor T cells 
can then travel to the tumor and recognize and kill cancer cells. This can ideally lead to 
long-term anti-tumor memory. Since OVs can release unique tumor epitopes from each 
patient's own tumor they could thus be considered in situ cancer vaccines (Tuve et al. 
2009). Viruses also induce native immune responses when infecting the tumor cells. The 
viruses are recognized by several pathogen associated molecular pattern (PAMP) 
receptors, which once activated induce production of several chemokines and other 
cytokines that can recruit immune cells into the tumor site. So, oncolytic viruses have the 
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ability to break the immunotolerance of tumors and divert the immunosuppressive tumor 
environment, which can lead to beneficial anti-tumor effects. In fact, the immunological 
mechanisms-of-action of oncolytic viruses are currently the most studied ways to improve 
oncolytic virotherapies and the field has widely shifted towards the concept of 
“immunovirotherapy” and oncolytic viruses are even considered to be part of cancer 
immunotherapeutics (Coffin 2015). 
The clinical and pre-clinical studies on oncolytic viruses have revealed the tested viruses to 
be remarkably safe and there are many candidates that can offer potential for treatment of 
many cancers that currently lack curative therapy (Zamarin & Pesonen 2015). 
 
4.1. Adenoviruses 
Adenovirus (Ad) was discovered in 1953 by Rowe et al. from adenoids, lymphatic tissues 
behind the nasal cavity (Rowe et al. 1953). Since then the culturing and propagation 
methods and the knowledge of the structure of the adenoviruses have developed rapidly, 
which has made it a well-known and easy-to-use vector for several purposes, in fact it is 
the most frequently selected vector for cancer gene therapy applications (Choi et al. 2012).  
Adenoviruses belong to the Adenoviridae family consisting of five genera, of which the 
human adenoviruses constitute the Mastadenovirus genus. So far, over 60 serotypes of 
human Ads have been identified and they are divided into seven species A-G (Liu et al. 
2012, Wadell & Norrby 1969). This thesis focuses on serotype 5 and 3 Ads, which belong to 
species C and B, respectively. These serotypes are commonly found in human populations 
and cause usually mild respiratory diseases or conjunctivitis in healthy people (Kunz & 
Ottolini 2010, Lynch, Fishbein & Echavarria 2011).  
Adenoviruses are attractive cancer gene therapy vectors because of their lytic life cycle, 
ability to infect both dividing and non-dividing cells and due to the fact that their genome 
does not integrate into the host genome, thus the risk for insertional mutagenesis is low. 
Adenoviruses can also be propagated efficiently in high titers (up to 1013 pfu/ml) and are 
easily genetically engineered for various purposes; they can accommodate foreign DNA up 
to 105% of the size of their normal genome (36 kb) (Choi et al. 2012). Adenoviruses have 
the ability to infect a wide range of species but their replication is species-specific, thus the 
viral replication is quickly arrested in foreign host cells (Jogler et al. 2006). 
4.1.1. Adenovirus structure and life cycle 
Adenoviruses are the largest known non-enveloped DNA viruses (~90-100 nm) and they 
have a unique spiked, icosahedral shape (Figure 2). The adenoviral double-stranded DNA 
genome is located in a core inside a protein capsid. In the core, with the linear ~36 kbp 
genome, there are also proteins that provide structure and link the genome to the capsid. 
These core proteins are also needed for packaging of new virions when the virus replicates. 
The terminal core proteins attached to the ITRs (inverted terminal repeats) in both 5´ ends 
26 
 
of the genome, are important for the initiation of viral DNA replication (Rekosh et al. 
1977).  
 
Figure 2. Adenovirus structure. Adenoviruses are ~100 nm sized non-enveloped viruses 
with double- stranded DNA genome (36 kbp). The icosahedral protein capsid is mainly 
composed of hexons and penton bases with protruding fibers. 
The adenoviral nucleocapsid consists mainly of hexon proteins and of penton bases on the 
corners of the capsid where the characteristic ´spikes´, called fibers, protrude. The fibers 
act as moieties that mediate attachment of the viruses to cell surface receptors. 
Adenoviruses have 12 fibers linked to penton bases connected to their shaft, and on the C-
terminus there is a knob structure that is mainly responsible for the receptor interactions. 
Most adenoviruses, including serotype 5 Ads are known to interact primarily with the 
coxsackie-adenovirus receptor (CAR) located in tight junctions between cells. CAR has high 
affinity to all other Ad subgroups except species B. CD46 has been identified to be the main 
cell entry receptor for these species B viruses (Gaggar, Shayakhmetov & Lieber 2003), but 
at least serotype 3 Ads require interaction also with a recently identified high affinity 
receptor called desmoglein-2 (DSG2) (Wang et al. 2011). This interaction has interestingly 
been shown to open tight junctions and this advantage can therefore be used in e.g. Ad5 
therapies to enhance interactions between viruses and CARs.  
After binding to a primary entry receptor, the fiber bends allowing the binding of RGD (Arg-
Gly-Asp) penton base motifs to αβ-integrins. This, with other interactions like the shaft 
binding to heparin sulfate glycosaminoglycans, initiates the internalization of the virus into 
clathrin-coated pits by endocytosis (Roelvink et al. 1999, Wiethoff & Nemerow 2015). The 
change of pH from neutral to acidic inside the endosome induces disruption of the viral 
capsid and release of the viral DNA, which is thereafter transferred to the host cell nucleus 
where the viral replication takes place (Figure 3). 
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Figure 3. Adenovirus life cycle. Serotype 5 adenovirus attaches to the cell membrane by 
binding through CAR (1). The initial virus binding is followed by integrin binding and 
formation of a clathrin-coated vesicle (2) and the virus is then endocytozed (3). Change in 
pH in the late endosome (4) disrupts the viral capsid and releases the viral DNA, which can 
then be transferred into nucleus. Thereafter, viral DNA is replicated in the nucleus (5), while 
the viral capsid proteins are produced in the cytosol (6). Immature viral particles are 
assembled in the nucleus (7) and released into the cytosol for maturation (8). The mature 
viral particles then induce lysis of the cell and virions are released to the cell surroundings 
(9). 
The adenoviral genome can be divided into early (E) and late (L) genes based on their time-
of-function before and after the DNA replication, respectively. The early genes (E1A, E1B, 
E2A, E2B, E3 and E4) encode proteins needed for regulation of DNA synthesis and initiation 
of replication. The late genes (L1-L5) are transcribed after the initiation of DNA replication 
and they encode structural proteins (Russell 2000). E1A is the first gene expressed after the 
viral genome reaches the host cell nucleus (Volpers & Kochanek 2004). It has an important 
role in the initiation of viral replication; it activates the transcription of other early genes. 
E1A binds to retinoblastoma protein (pRb), thus releasing the cellular E2F transcription 
factor that in turn activates transcription of the E2 viral gene and production of cellular S-
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phase proteins. E1B-55K inhibits p53 tumor suppressor thus allowing DNA replication and 
preventing the cell from undergoing apoptosis together with E1B-19K. E2 proteins are 
needed for viral DNA replication, whereas E3 proteins are important in initiation of 
mechanisms against anti-adenoviral immune responses (Russell 2000). For instance the E3-
gp19K protein prevents translocation of major histocompatibilty complex I (MHC I) 
proteins to cell surface, thus reducing the recognition of infected cells by the host immune 
system. The E3-14.5K/10.4K complex and E3-14.7K inhibit TNFα and Fas mediated cytolysis 
and apoptosis (Chen et al. 1998). E3 also encodes for the adenoviral death protein (ADP) 
needed for lysis of the host cell. E4 proteins have many roles for example in viral 
replication and transcription of the late genes. The entire adenovirus life cycle usually takes 
about 24-36 hours (Russell 2000). 
4.1.2. Transduction, transcription and biodistribution: targeting of 
adenoviruses to tumors 
In cancer gene therapy the tumor-restricted replication and tumor-targeted delivery are 
keys to safe and responsive therapy. Many types of adenovirus targeting have been 
investigated, most of which include genetic modifications of viral surface structures or viral 
genes. Transductional targeting goals for increased transduction i.e. vector intake, whereas 
transcriptional targeting methods aim at restricting the viral replication into tumor cells. 
As previously discussed, the expression of CAR on the surface of tumor cells is a limiting 
factor for efficient adenoviral infection, at least for serotype 5 Ads. Because many tumor 
types have down-regulated CAR expression (Okegawa et al. 2004), a great deal of Ad 
research has focused on circumventing the CAR-dependence (Kanerva & Hemminki 2004). 
Fiber pseudotyping is one way to circumvent the lack of CAR expression. For example 
changing the knob structure of serotype 5 adenovirus to a serotype 3 virus knob retargets 
the virus to other entry receptors, CD46 (Gaggar, Shayakhmetov & Lieber 2003) and 
desmoglein 2 (Wang et al. 2011) that have a wider distribution in cancer cells than CAR 
(Tuve et al. 2006). This modification has shown to enhance the transduction of the virus in 
vitro and in vivo (Krasnykh et al. 1996, Kanerva et al. 2002b, Kanerva et al. 2003). These 
pseudotype viruses are called 5/3 chimeras. Also chimeras with other species B Ad knobs 
that use same entry receptors as Ad3 have been developed, like Ad5/35 and Ad5/11 (Yu et 
al. 2007, Suominen et al. 2006). 
Some other attempts to enhance the transduction of adenoviruses include addition of 
tumor-homing peptides on the surface of the virus, e.g. modification of the fibers by 
adding a RGD-4C motif to the HI-loop has been shown to target αv-integrins, which are 
selectively expressed on various cells in tumors (Dmitriev et al. 1998). Also attaching so-
called bridging molecules or adapters (e.g. antibody) that target the virus to some specific 
receptor or epitope on a target cell have been studied (Douglas et al. 1996).  
It is known that adenoviruses are, at least in in vivo settings, rapidly cleared from the 
circulation by specific liver macrophages called Kupffer cells (Alemany, Suzuki & Curiel 
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2000). The entry of adenoviruses into the liver can result in decreased vector delivery into 
the target cells, and might cause some liver toxocity (Ranki et al. 2007). To increase target 
cell transduction and reduce toxicity, liver de-targeted adenoviruses have been 
constructed. For example deleting the KKTK-motif from the fiber shaft makes the virus 
unable to enter the Kupffer cells. Unfortunately KKTK-mutated viruses have shown lower 
transduction efficacy to target tissues (Bayo-Puxan et al. 2006, Koski et al. 2009), this may 
be because the KKTK motif of Ad5 fiber was shown to be important for the fiber interaction 
with heparin sulphate proteoglycans (HSPGs), one of the cell entry receptors of Ad5 viruses 
(Smith et al. 2003, Wu et al. 2003). Some other ways to reduce liver tropism and liver 
toxicity of the systemically administered adenovirus have been suggested too. Chemical 
modifications of the virus capsid or coating it with polymers or usage of delivery vehicles or 
matrix may reduce the toxicity and enable improved delivery and exposure to the target 
tissue. For instance pegylation, attachment of polyethylene glycol (PEG) polymers on the 
surface of adenovirus was shown to reduce the clearance of the virus from blood, but in 
addition it also reduced the infectivity of the virus (Alemany, Suzuki & Curiel 2000). Also 
other polymers have been exploited to prevent Ad interactions with the host immune 
system, like cationic poly-L-lysine polymers (Ahn et al. 2004), N[2-hydroxypropyl] 
methacrylamide (HPMA) copolymers (Fisher, Seymour 2010), arginine-grafted bio-
reducible polymers (ABPs) (Kim et al. 2011) and cationic polyamidoamine (PAMAM) 
cascade dendrimers (Grunwald et al. 2013). Polymers can also include various targeting 
molecules, e.g. tumor-homing peptides (Yao et al. 2012). Silica gels have also been 
successfully used to deliver adenoviruses to the target site without hindering the activity of 
the viruses (Quintanar-Guerrero et al. 2009).  
Adenoviruses can bind to different coagulation factors, such as coagulation factors X (FX) 
and IX (FIX) (Jonsson et al. 2009) and the complement factor C4BP (Shayakhmetov et al. 
2005). The factor X is positively charged, thus the negatively charged Ads easily bind to it in 
the circulation (Waddington et al. 2008). Administration of an anticoagulant drug warfarin 
prior to Ad vector injection has been shown to prevent the formation of functional FX 
leading to decreased binding of the Ad vector (Parker et al. 2006). 
To avoid unwanted damage in normal healthy tissues the oncolytic viruses are usually 
genetically modified so that they can replicate only in tumor cells and are therefore also 
called conditionally replicating viruses.  Usually the design of conditionally replicating 
adenoviruses (CRAds) takes advantage of commonly known mutations present in 
cancerous cells. Type I CRAds bear a deletion in the viral genome important for viral 
transcription and replication, which is compensated by a gain-of-function mutation in 
cancer cells. For example a deletion of 24 base pairs in the viral E1A gene makes the 
expressed mutated E1A protein unable to bind retinoblastoma protein (pRb) (Figure 4). 
This interaction is needed in normal cells to activate the E2F transcription factor that leads 
to induction of S-phase of the cell cycle (Berk 1986). Almost all human tumor cells are 
defective in the pRb/p16-pathway and they constantly express the E2F transcription factor, 
thus making them independent of pRb binding (i.e. they can overcome the G1-S 
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checkpoint) (Imperiale et al. 1984, Sherr & McCormick 2002). The deletion-bearing virus is 
also able to infect normal cells but its replication in these cells is restricted because of the 
dysfunctional E1A protein (Pesonen, Kangasniemi & Hemminki 2011). The viruses bearing 
the 24bp deletion in their E1A gene are commonly referred to as ∆24-viruses. The first and 
most common oncolytic adenovirus in clinical trials, ONYX-015, has a deletion in another 
viral gene, E1B-55K, which makes the virus replication dependent on a deficient p53 
pathway related to most cancers (Bischoff et al. 1996).  
 
Figure 4. Illustration of the mechanism-of-action of Δ24 adenoviruses. A) In normal cells, 
retinoblastoma (Rb) protein binds to transcription factor E2F arresting DNA replication. B) If 
wild-type adenovirus infects normal cells, E1A adenoviral protein binds to and inactivates 
pRb. This results in the release of E2F, which then promotes DNA replication also allowing 
replication of the viral DNA. C) A 24-base-pair deletion in the E1A of a modified adenovirus 
makes the viral E1A unable to bind pRb. The Rb protein remains then bound to the E2F 
halting the replication of the Δ24 adenovirus in normal cells. D) However, if a Δ24 
adenovirus infects a cancer cell, the modified adenovirus will be able to replicate, due to 
loss-of-function of the Rb protein and thus constant E2F activity in most tumor cells. (Figure 
inspired by Gomez-Manzano et al., Neurology, 2004) 
Type II CRAds are restricted to replicate only in cancer cells by regulation of viral early 
genes by a tumor specific promoter that enables the expression of the virus and the 
possible transgenes only in cells where transcription factors for this promoter exist 
(Nettelbeck 2008, Glasgow et al. 2004). For example hTERT (human telomerase reverse 
transcriptase) promoter targets the vector to cells that have high division rates and thus 
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active telomerase production, i.e. preferentially cancer cells (Kim et al. 1994). In addition 
to tissue-specific promoters, treatment-responsive promoters can be used. Transcription 
can in this case be regulated for example by irradiation (Mauceri et al. 2009) or certain 
chemicals (Harrington, Linardakis & Vile 2000), if a radiation- or chemically inducible 
promoter is used to activate gene expression, respectively. 
Even though these above-mentioned strategies have shown enhanced Ad targeting, there 
is still limited efficacy seen in pre-clinical and clinical trials mostly because of insufficient 
transduction and replication rates in target cells (Yamamoto & Curiel 2010). Therefore, 
viruses targeted by multiple strategies simultaneously are an option to circumvent this 
problem. For example, a double-targeted CRAd, Ad5/3-Δ24 has shown increased 
transduction and anti-tumor efficacy both in vitro and in vivo compared to Ad5 virus 
(Kangasniemi et al. 2006, Guse et al. 2007, Raki et al. 2008). 
4.1.3. Immune responses to adenoviruses 
An unfortunate case in a clinical trial of adenoviral gene therapy for ornithine 
transcarbamylase deficiency (OTD), was the death of a patient, Jesse Gelsinger, in 1999, 
after a massive immune response triggered by the viral vector, revealed the immunogenic 
characteristics of the adenovirus (Liu & Muruve 2003). Ads are potent inducers of both 
early innate and later adaptive immune responses. 
4.1.3.1. Innate immune responses  
When adenoviruses infect cells, the structural components of the virus are immediately 
recognized by cellular pattern recognition receptors (PRRs) (Russell 2009, Cerullo et al. 
2007, Hartman et al. 2007). Toll-like receptors (TLRs) are a group of cellular receptors on 
the cell surface or in the cytosol that can sense pathogen-associated molecular patterns 
(PAMPs) (Cerullo et al. 2007, Hartman, Black & Amalfitano 2007, Rhee et al. 2011). The 
most important TLRs reported for adenoviral recognition are TLR-2 and TLR-9, on the cell 
surface and in the endosomes, respectively (Appledorn et al. 2008, Cerullo et al. 2007). 
TLR-9 recognizes the unmethylated CpG-rich sequences of the viral DNA (Hemmi et al. 
2000). The adenoviral DNA can also be sensed by other endosolmal sensors, e.g. DNA-
dependent activator of IFRs (DAI) (Schulte et al. 2013), nucleotide oligomerization domain 
(NOD)-like receptors (Thaci et al. 2011), absent in melanoma 2 (AIM2), gamma-interferon-
inducible protein 16 (IFI16) and cyclic GMP-AMP synthase (cGAS) (Lam, Stein & Falck-
Pedersen 2014). Ad sensing by the PRRs leads to activation of adaptor proteins like MyD88, 
TRIF, TRAFs and MAPKs (Akira 2006) and further to activation of the effector molecules 
such as NF-κB or interferon-regulatory factors (IRFs) depending on the signaling pathway 
(Kawai & Akira 2006, Zhu, Huang & Yang 2007). These signaling cascades finally lead to 
secretion of several inflammatory cytokines like IL-5, IL-6, IL-8, IL-12, TNFα, RANTES, MIP-2 
and type I interferons (Girardin, Sansonetti & Philpott 2002, Inohara & Nunez 2003). 
Adenoviruses can also be opsonized and recognized by the complement system (Appledorn 
et al. 2008, Jiang et al. 2004, Kiang et al. 2006). 
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The adenovirus infection-mediated secretion of interferons and other cytokines recruits 
macrophages and other phagocytic cells to destroy the invader (Muruve 2004, Kiang et al. 
2006). These early inflammatory responses to Ad occur within 24 hours after infection 
(Muruve et al. 1999). NK cells are activated in response to the interferon and macrophage-
derived cytokine release. NK cells are part of the fast-acting innate immune system that 
can recognize infected cells. Their name “natural killer cells” derives from the notion that 
they are able to kill cells that are missing the MHC-I “self”-antigen presentation and they 
do not require activation signals from other cells. NK cells can cause apoptosis of the 
infected cell by releasing cytolytic granzymes into the target cell after binding to a Fas 
ligand, which indicates infection of a cell. They can also kill infected cells by a mechanism 
called antibody-dependent cellular cytotoxicity (ADCC) if the opsonization antibodies are 
recognized by the Fc gamma III (CD16) receptors expressed on NK cells. NK cells also 
secrete cytokines, TNFα and IFNγ, to activate other immune cells (Reefman et al. 2010). 
4.1.3.2. Adaptive immune responses 
The local inflammation leads to recruitment of various effector leukocytes to the infection 
site and the amplification of immune responses finally activate the immune cells belonging 
to the adaptive immune system. Dendritic cells (DCs) are in a key role between the innate 
and to the adaptive immune system, DCs phagocytose viral and tumor antigens and act as 
the principal cross-presenting antigen presenting cells (APCs) (Schulz et al. 2005). When 
matured after antigen intake, they can migrate to secondary lymphoid organs where they 
present the antigens to T cells (Mercier et al. 2004). DCs stimulate the T cells via 
costimulatory molecules CD40, CD80 (B7-1) and CD86 (B7-2) and present the antigens via 
MHC class I or II molecules. CD4+ T cells, the helper T cells, are activated via MHC II 
presentation, whereas CD8+ cytotoxic T cells via MHC I presentation (Perreau & Kremer 
2006). The activated T cells can then migrate to the site of infection and kill the infected 
cells. Recently, oncolytic adenoviruses have been shown to induce immunogenic cell death 
in cancer cells. Virus-treated cells show elevated ATP and High-mobility group box 1 
protein (HMGB-1) secretion and increased exposure of calreticulin on their cell surface 
(Diaconu et al. 2012). All these three marker molecules are known to interact with 
dendritic cells thus leading to activation of T cell immunity (Tesniere et al. 2010, Kepp et al. 
2011). 
This activation of the adaptive cellular responses typically occurs from four to seven days 
after the adenoviral infection, after viral gene expression (Muruve 2004, Liu et al. 2000). In 
addition to the T cell responses, antibodies play an important role in the anti-adenoviral 
immunity. When a B cell encounters a specific antigen via its B cell receptor and receives 
an additional activating signal from a helper T cell, it matures, expands clonally and 
becomes a short-lived plasma B cell able to produce antibodies specific to the encountered 
antigen. Some of the expanded B cells may also become memory cells, which upon 
reencountering the same antigen can expand and start rapidly producing antibodies 
(McHeyzer-Williams & McHeyzer-Williams 2005, Yang, Greenough & Wilson 1996). Also 
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part of the T cells can differentiate into memory subsets, and together these long-living 
memory B and T cells can induce long-term immunity against the virus (Russell 2009). 
Many adenovirus serotypes, including Ad5, are endemic pathogens, thus basically 
everyone has acquired immunological memory and produce neutralizing antibodies (Nabs) 
against Ads (Zaiss, Machado & Herschman 2009, Wadell 1969). Therefore repeated 
administration of an adenoviral vector induces a strong serotype-specific immune reaction 
against the virus, which usually leads to quick neutralization of the systemically 
administered virus by the anti-viral antibodies. Treatments combining different serotypes 
may prevent the neutralizing effect (Hemminki et al. 2011). 
4.1.4. Translation to clinics (clinical studies with oncolytic adenoviruses) 
The first type I CRAd published was ONYX-015, a virus bearing two deletions in its E1B-55K 
protein making it dependent on the inefficient p53/p14-pathway (Bischoff et al. 1996). 
Although safety of this virus has been demonstrated in various clinical studies since 1996 
with MTD up to 2 x 1012 VP (Nemunaitis et al. 2001), its efficacy remains poor (Crompton, 
Kirn 2007). Because of the limited results, ONYX-015 was also studied in combination with 
chemotherapy, which showed substantial objective responses, including several complete 
responses; by 6 months, none of the responding tumors had progressed, whereas all non-
injected tumors treated with chemotherapy alone had progressed (Khuri et al. 2000). H101 
(Oncorine, Shanghai Sunway Biotech), also an E1B-55K deleted adenovirus with additional 
E3 gene deletion, is the first and thus far the only oncolytic adenovirus approved for clinical 
use as a drug. In China it has been available for cancer patients suffering from head and 
neck carcinoma since 2005 (Yu & Fang 2007); however its survival data was inconclusive 
restricting its importation to European or US markets (Guo & Xin 2006, Sheridan 2011, 
Alemany 2007). The first type II CRAd tested in clinical trials was CV706 that contains a PSA 
promoter and enhancer to drive E1A expression. It was well tolerated and showed some 
clinical activity, as reflected by changes in serum PSA, encouraging further clinical 
investigation (DeWeese et al. 2001). There are several ongoing trials with OAds and 
nowadays most of the tested viruses are type II CRAds expressing some 
immunostimulatory molecules to provoke the activation of the host immune system. For 
example CG0070 (Cold Genesys Inc.) and ONCOS-102 (Oncos Therapeutics Ltd.) viruses are 
both serotype 5 Ads targeted to replicate in Rb-mutated cancer cells and they both express 
GM-CSF. CG0070 is already in phase III testing (NCT01438112) for treating non-muscle 
invasive bladder cancer after showing good safety profiles in phase I and II trials (Burke et 
al. 2012, Zamarin & Pesonen 2015). Treatment of refractory solid tumors with ONCOS-102 
in the phase I study were also well tolerated. Intriguingly, it also showed clear evidence of 
anti-tumor immunity established in the treated patients; infiltration of lymphocytes (TILs) 
into treated as well as into untreated lesions were correlated with better OS, suggesting 
involvement of systemic immunity in the treatment efficacy  (Ranki et al. 2014, Vassilev et 
al. 2015, Zamarin & Pesonen 2015).  
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Combinations with conventional therapies, like radio- or chemotherapies, could result in 
additional or even synergistic effects and therefore OV therapies are often tested together 
with other therapies (Ottolino-Perry et al. 2010). At the moment there are over 10 open 
clinical trials testing oncolytic adenoviruses for treating cancer (ClinicalTrials.gov). 
4.1.5. Challenges of adenoviral therapies 
Although adenoviruses are very appealing as cancer gene therapy vectors, they also have 
certain limitations that hinder development of Ad therapies. In addition to the already 
mentioned limitations, like rapid clearance of systemic adenovirus by liver cells (at least in 
mice) and Nabs or the limited transduction efficiency to tumor cells due to low CAR 
expression, the host-specificity of Ads creates an additional problem for Ad-based drug 
development (Jogler et al. 2006). Nevertheless preclinical studies in animal models with 
replicating adenoviruses have shown promising efficacy against cancer, these results 
cannot usually be repeated in human trials. This is at least partly due to the many 
differences between human disease and animal models used. Due to the fact that 
adenovirus replication is very species-specific, oncolytic adenovirus therapies lack proper 
animal models with which the real effects of the oncolysis could be shown. However, a 
Syrian hamster was recently found to be semi-permissive to human Ad5 replication, so its 
use in preclinical studies has expanded (Dhar, Toth & Wold 2012).  
4.1.6. Safety of adenoviruses 
Adenoviruses are common pathogens and normally the adenoviral infection appears 
asymptomatic or causes mild respiratory or conjunctival infections. Because of their low 
pathogenicity in immunocompetent individuals, little effort has been put into development 
of anti-adenoviral drugs. Yet an adenovirus is an immunogenic virus and can potentially 
cause liver toxicity or serious inflammatory symptoms in some immunocompromised 
patients or if used with too large systemic doses as in the unfortunate case of Jesse 
Gelsinger (Raper et al. 2003). However, the modified oncolytic adenoviruses are less 
pathogenic due to the deletions and insertions in their genome, in fact no mortality 
reported related to oncolytic adenovirus treatments has been reported. If uncontrolled 
infection in an adenovirally treated patient occurs and causes health-threatening side 
effects, anti-viral drugs can be used to inhibit viral replication. For example Cidofovir can 
be used to target the viral DNA polymerase and stop the viral replication cycle (Naesens et 
al. 2005). Ribavirin is another drug to inhibit adenovirus infections but it has shown to be 
less effective than Cidofovir (Lenaerts & Naesens 2006).  
4.2. Vaccinia viruses 
Vaccinia viruses belong to the Poxviruses of the Poxviridae family. They are large, 
enveloped DNA-viruses that are perhaps best known of their use as a vaccine against small 
pox, the first human disease completely eradicated through purposeful global vaccination. 
Actually, the word ´vaccine´ derives from this historical use of vaccinia virus as the first 
vaccine, an idea described by Edward Jenner in 1798. Moreover, the vaccinia virus derived 
its name from the organism it was originally discovered from, namely the cow, ´vacca´ in 
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Latin. Vaccinia virus is closely related to the cowpox and variola viruses, but it has been 
attenuated due to repeated cultivation and passaging in the laboratories for several 
decades (Sanchez-Sampedro et al. 2015). Nowadays vaccinia viruses are actively studied 
for the development of next generation vaccines but also commonly for their use as 
vectors in various gene delivery applications, including oncolytic virotherapy (Verheust et 
al. 2012, Gomez et al. 2011). 
Vaccinia viruses have many advantages as vectors for cancer gene therapy. Their wide host 
tropism (various species and cell types) (Kroon et al. 2011), lack of mutagenetic risk due to 
their cytoplasmic life cycle, easily modifiable and large genome, which can take large 
amounts of foreign DNA, and fast replication cycle, makes them desirable study targets 
(Guse, Cerullo & Hemminki 2011). 
4.2.1. Vaccinia virus structure and life cycle 
Vaccinia viruses (VV) are large (360 x 270 x 250 nm) (Cyrklaff et al. 2005) DNA-viruses with 
a linear double-stranded genome of about 190 kb that encodes approximately 250 genes 
(Figure 5). VVs belong to Poxviruses, which are unique among DNA viruses because their 
entire replication cycle takes place in the cytosol, in discrete structures called viral factories 
outside the nucleus. Hence a large number of genes are needed to enable the production 
of new virions. These ~250 viral genes code for different enzymes and other proteins 
needed to initiate viral replication, including DNA polymerase and transcription factors. 
(Chan & McFadden 2014) 
 
Figure 5. Vaccinia virus structure. Vaccinia viruses are relatively large (~360 X 260 nm), 
brick-shaped enveloped viruses. The viral core includes a large dsDNA genome of ~190 kbp 
and viral enzymes for replication. Inside the membrane layers there are two lateral bodies 
composed of proteins that counteract host antiviral defense mechanisms and modulate the 
host cell to facilitate virus replication. 
Vaccinia virus is a brick-shaped virus with one or more lipoprotein envelopes (Figure 5) 
depending on its route of maturation during the replication cycle. VVs can produce four 
infectious forms: intracellular mature virions (IMV), intracellular enveloped virions (IEV), 
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cell-associated enveloped virions (CEV) and extracellular enveloped virions (EEV), IMVs 
being the most abundant form. According to the current knowledge, IMVs have only a 
single membrane, whereas CEVs and EEVs are surrounded by two membranes. The IEV 
particles have three envelopes. The IMVs are thought to be the form responsible for 
spreading between hosts. The CEVs are believed to spread from the infected cell to 
neighboring cells and the EEVs are instead thought to be important for spreading to distant 
sites inside the host. (Ward & Moss 2001) 
Vaccinia viruses have a wide tropism to different mammalian cell types. The specific 
cellular receptors for VV entry are still unknown but it is thought that the virus-cell 
interaction must be through some ubiquitously expressed receptors considering the wide 
tropism of the virus. It is at least known that IMVs use heparan sulfate and/or laminin in 
their attachment to cells (Chan & McFadden 2014). After attachment to the host cell 
surface VV is internalized by fusion of the viral and cellular membranes, thus releasing the 
viral core into the cytosol (Figure 6). Vaccinia virus entry is then followed by the release of 
proteins from the two lateral bodies, which suppress the host anti-viral immune defense 
mechanisms and prepare the host cell for viral replication (Schmidt et al. 2013). The viral 
replication takes place in viral factories where the viral DNA is multiplied, viral proteins are 
transcribed and new virions are assembled. The new virions, intracellular mature virions 
(IMVs) can then be released from the host cell by lysis. The IMV particles can also take 
another route inside the cell and be processed by the Golgi complex receiving an additional 
double membrane. These particles are thereafter called intracellular enveloped virions 
(IEVs), which can bud through the cell membrane. When fusing to the cell membrane they 
lose their outer third membrane leaving only two membranes left. As long as the particle is 
connected to the cell membrane it is called a cell-associated enveloped virion (CEV). CEVs 
can infect adjacent cells by active penetration assisted by actin tails (Figure 6 (9)) or they 
can be budded out from the cell and become EEVs (extracellular enveloped virions) (Figure 
6 (10)). EEVs can also be formed by budding of IMVs through the cell membrane. The 
vaccinia virus infection cycle is fast; the whole replication cycle is completed within 24 
hours after infection (Salzman 1960). 
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Figure 6. Vaccinia virus life cycle. Vaccinia virus attaches to the cell membrane by 
interaction via membrane receptors (1) and is internalized by fusion of viral and cellular 
membranes (2). The viral core is released (3) and viral replication and assembly of new 
virions occur in the cytosol in a so-called virus factory (4).  Intracellular mature viruses 
(IMVs) are formed (5), which can then be released via cell lysis (6). IMVs can also form 
extracellular enveloped viruses (EEVs) by budding through the cell membrane (7). Some 
IMV particles can gain an extra membrane by traversing the Golgi complex and are then 
called IEVs (intracellular enveloped viruses) (8). IEVs can be actively transported via actin 
tails into neighboring cells (9) or fused through the cell membrane (10) and become EEVs. 
As long as the viral particles are attached to the cell membrane, they are called cell-
associated enveloped viruses (CEVs).  
4.2.2. Targeting vaccinia viruses to cancer 
It has been observed that VVs already possess natural tropism towards cancer cells, 
possibly because cancer cells are generally living in a more immunosuppressed 
environment that does not hamper the virus proliferation (Chan & McFadden 2014). A 
higher proliferation rate of tumor cells also enables better conditions for viral replication, 
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and the leaky vasculature of tumors enables a virus to enter cancer cells more readily than 
normal cells (Thorne et al. 2007). However, mechanisms for a more selective replication in 
tumor cells have been investigated for a safer use of VVs as therapeutic agents.  
Due to a scarcity of information on the cell receptor interactions of vaccinia viruses, the 
strategies to target VVs to tumor cells are currently focusing on viral transcriptional 
mechanisms in order to derive methods that take advantage of cancer specific pathways 
differing from those in normal cells. Tumor-targeting of VVs has been achieved by genetic 
mutations in the viral genome. Genes that are needed for viral replication in normal but 
not in tumor cells can be deleted restricting the replication only to cancer cells. 
The vaccinia growth factor (VGF) gene has been deleted to improve the safety of the virus. 
VGF is expressed early during the virus infection and it acts as a virulence factor. It is a 
homologue of the endothelial growth factor (EGF), which is able to bind to EGF receptors 
(EGFR) on the cell surface and activates the Ras-pathway leading to activation of the cell 
cycle and production of factors needed for viral replication. The Ras-pathway is constantly 
activated in most cancers (Hanahan & Weinberg 2000) and therefore the production of 
VGF is not needed in cancer cells to enable viral replication (Chan & McFadden 2014). 
Also deleting the viral thymidine kinase (TK) gene has shown good results in terms of 
selectivity. TK is involved in the synthesis of deoxyribonucleotides needed for DNA 
synthesis. The cellular thymidine kinase is expressed only during the S-phase of the cell 
cycle, i.e. during cellular division; so in normal cells TK is not constantly present. Therefore 
VV needs its own TK production to be able to replicate in normal cells. However, in cancer 
cells the common oncogenic mutations lead to constantly active cell proliferation and TK is 
present in the cells, thus the production of viral TK is not needed in tumor cells. The TK 
deletion therefore restricts the replication to cells that overexpress E2F transcription factor 
(i.e. most tumor cells) that regulates the expression of cellular TK (Chan & McFadden 
2014). 
The deletion of both of the above-mentioned genes, VGF and TK, has been shown to 
reduce the pathogenicity of the virus in normal tissues and to increase the selectivity to 
tumors compared to the single-deleted controls (McCart et al. 2001) (Figure 7). These 
double-deleted VVs are referred to as vvdd. 
39 
 
 
Figure 7. Illustration of the controlled replication of double-deleted vaccinia viruses. A) In 
normal cells, the wild-type virus produces viral proteins that adapt the cell for viral 
replication: viral thymidine kinase (TK) and vaccinia growth factor (VGF), which activates 
the epidermal growth factor receptor (EGFR) and thereafter the Ras pathway. B) Oncolytic 
vaccinia viruses that carry deletions in the viral VGF and TK genes are unable to adapt the 
normal cell for viral replication and production of the virus is blocked. C) In cancer cells, 
common oncogenic mutations compensate for viral gene deletions allowing viral 
replication. 
4.2.3. Vaccinia virus induced immune responses 
Vaccinia viruses have been considered immunogenic viruses based on their successful use 
as a small pox vaccine. It is true, the infection sets alarm signals to the host immune system 
to destroy the invader and many antiviral responses are activated. However, vaccinia 
viruses are well prepared to hide from the host immune attack and they actually encode 
several immunosuppressive genes and they also carry immunosuppressive proteins in their 
lateral bodies, which are released immediately after the viral core is released following the 
internalization of the virus into the host cell. These proteins can for instance bind and 
neutralize host cytokines (Smith, Bryant & Alcami 2000, Smith et al. 2013, Schmidt et al. 
2013). 
4.2.3.1. Innate immune responses 
Immediately after VV infection the host innate immune responses are evoked by secretion 
of proinflammatory cytokines, like type I interferons (IFNα and IFNβ) (Samuel 1991). The 
IFN response is initiated upon sensing of viral PAMPs by pattern recognition receptors 
(PRRs), such as toll-like receptors (TLRs) and cytosolic DNA sensors. At least TLR-2 (Zhu, 
Huang & Yang 2007, Quigley et al. 2009), TLR-8 (Martinez, Huang & Yang 2010) and AIM2 
(Rathinam et al. 2010) have been reported to sense VV infections. Also recently, a newly 
discovered DNA sensor cGAS (cyclic GMP-AMP synthase) was reported to induce IFN 
responses upon vaccinia virus infection through STING (stimulator of IFN genes) -mediated 
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pathway (Dai et al. 2014). PRR activation induces activation of transcription factors, such as 
IFN-regulatory factor (IRF) 3 and IRF7, and NF-κB, whose translocation into the nucleus 
induces production of type I IFNs, cytokines and chemokines (Dai et al. 2014). 
Also the complement system is quickly activated and the enveloped viral particles and the 
infected cells can be directly destroyed by lysis (by the membrane attack complex) or the 
viruses can be opsonized and phagocytized by macrophages and neutrophils. VVs have 
developed a method to evade the complement though, they encode a vaccinia virus 
complement control protein (VCP) that can bind complement proteins C3b and C4b and 
thus blocks the activation of the complement cascade (Girgis et al. 2011, Kotwal & Moss 
1988). Nevertheless, neutralizing antiviral antibodies can hamper the efficacy of VV 
therapies by clearance of viral particles before they have even infected the target cell. EEV 
particles are more resistant than IMVs to the neutralizing antibodies, because they have 
the outer membrane originating from the host cell membrane, and can thus evade the 
inactivation by the complement system (Smith, Vanderplasschen & Law 2002). Vaccinia 
virus, however, is not an endemic virus and the last worldwide vaccinations for small pox 
were given in the 1970s; therefore only elderly people could have pre-existing antiviral 
antibodies in their circulation. 
The interferons and macrophage-derived inflammatory cytokines attract natural killer (NK) 
cells to the site of infection. They can directly kill VV infected cells by lysis or apoptosis by 
releasing granzymes. Antibody-opsonized infected cells can also be recognized by NK cell 
Fc gamma III (CD16) receptors, which induced antibody-dependent cellular cytotoxicity 
(ADCC). NK cells can also secrete cytokines (IFNγ and TNFα) and thus work to control viral 
infections. IFNγ activates phagocytosis by macrophages and TNFα promotes direct NK-
dependent cell killing. Upon infection, vaccinia viruses, as many other viruses, down-
regulate the surface exposure of MHC-I molecules, thus minimizing the presentation of 
viral antigens to immune cells. NK cells are able to recognize infected cells from healthy 
cells by a so-called “missing-self recognition”: it has been shown that NK cells can 
recognize cells that express low levels of MHC I on their surface indicating viral infection 
(or cancer). Indeed, depletion of NK cells has been shown to enhance the virulence of 
vaccinia virus (Bukowski et al. 1983). 
As the infection leads to elevated immunoreactivity in the infection site, the increased 
amounts of pro-inflammatory cytokines, chemokines and activated innate immune cells 
can not only induce immune responses against the virus but also against the infected cells, 
e.g. tumor cells in the case of cancer therapy (Chan & McFadden 2014). This advantage can 
be exploited e.g. in the concept of oncolytic cancer vaccines where the virus is used as an 
adjuvant.  
4.2.3.2. Adaptive immune responses 
Advanced, cellular responses are also developed later following the VV infection. Antigen 
presenting cells, such as dendritic cells (DCs) orchestrate the development of the adaptive 
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immune responses by presenting antigens to other immune cells. DCs can engulf free VV 
particles and process them for presentation on their cell surface receptors. These 
exogenously derived antigens are loaded on MHC II molecules and presented to CD4+ 
helper T cells (Th) (Guidotti & Chisari 2001). The activated Th cells can then stimulate B 
cells to produce antibodies against the viral antigen. When a tumor cell is lysed after VV 
multiplication, antigens of both the endogenously produced virions and the lysed tumor 
cell (self and cancer-specific antigens) will spread to the cell surroundings and the antigens 
can be phagocytized by DCs. Before lysis the infected cell can present viral antigens and 
tumor antigens on their MHC I molecules. Immature dendritic cells are also able to 
phagocytize pieces of cell membrane, a process called nibbling. DCs migrate to lymph 
nodes where they mature and present the endogenously derived antigens on MHC I to 
CD8+ cytotoxic T cells (CTLs). When activated, these CTLs can migrate to the infection site 
(tumor) and kill the target cell. The antigen-specific T and B cells may further become 
memory cells that retain long-lasting immunity against the virus or the tumor.  
VVs have developed mechanisms to suppress development of Th responses, i.e. VVs are 
naturally not so efficient in cross-priming antigen-specific immune responses (Xu et al. 
2004, Smith et al. 2013). However, some oncolytic VVs with enhanced immunogenic 
potential have shown to enhance activation of adaptive immune responses, and even an 
increase of anti-tumor CTLs has been observed in infections with CD40L expressing VV 
(Parviainen et al. 2014).  
4.2.4. Translation to clinics (clinical studies with oncolytic vaccinia viruses) 
The wide tropism to various tissues including most cancer types and the naturally lytic life 
cycle exhibited by VV make it appealing to use as an oncolytic agent. The different strains 
of VV, Western Reserve, Wyeth, Lister and Copenhagen are currently being developed as 
oncolytic virotherapeutics for several types of cancer, including melanoma, hepatocellular 
carcinoma and lung cancer (Chan & McFadden 2014). The highly attenuated strains 
Modified Vaccinia Ankara (MVA) and New York Vaccinia (NYVAC) do not replicate in 
mammalian cells, thus lacking utility in oncolytic applications. The Western Reserve strain 
seems to bear the strongest efficacy in vitro and in vivo (Naik et al. 2006) and has been 
safely used in humans (Zeh et al. 2015). 
The first clinical trial using vaccinia virus to treat cancer was in 1964, when wild-type VV 
was repeatedly injected into melanoma lesions. The results were encouraging, almost 50% 
of the 44 treated patients had objective tumor response and even 25% of the cases had 
complete regression (Burdick & Hawk 1964, Hunter-Craig et al. 1970, Thorne, Bartlett & 
Kirn 2005). Afterwards, several trials for testing the safety and efficacy of oncolytic vaccinia 
viruses were conducted. At the moment the most studied drug candidate is a TK-deleted 
Wyeth strain VV that expresses human GM-CSF, called Pexa-Vec (Pexastimogene 
devacirepvec, also known as JX-594, Jennerex Inc. & co.). Pexa-Vec treatments have been 
well tolerated up to MTD of 1 x 109 pfu (Park et al. 2008, Merrick, Ilett & Melcher 2009) 
and the virus has been tested so far for treating melanoma (Mastrangelo et al. 1999) and 
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hepatocellular carcinoma (HCC) (Park et al. 2008, Merrick, Ilett & Melcher 2009) in phase I 
and II trials. Pexa-Vec has shown immunological responses, like inflammation and 
infiltrated eosinophils and lymphocytes in the injected tumors as well as perivascular 
lymphocyte infiltration (Mastrangelo et al. 1999). Intriguingly, responses were seen also in 
non-injected tumor lesions (Park et al. 2008, Merrick, Ilett & Melcher 2009). Pexa-Vec has 
been also tested in combination with a multikinase inhibitor drug sorafenib (Nexavar, 
Bayer) for the treatment of HCC (Llovet et al. 2008). The results indicated that Pexa-Vec 
could sensitize the tumor cells for sorafenib treatment leading to fast necrosis of treated 
tumors (Heo et al. 2011).  
There has also been a completed phase I trial with a double-deleted (TK- and VGF-deleted) 
Western Reserve strain oncolytic vaccinia virus that expresses cytosine deaminase (CD) and 
somatostatin receptor (SR). This vvdd-CDSR (also known as JX-929) virus did not show 
dose-limiting toxicity with doses up to 3 x 109 pfu and some evidence of anti-tumor 
immunity has been reported (Zeh et al. 2015). The side effects seen in the clinical trials are 
usually mild flu-like symptoms including fever, fatigue, musculoskeletal pain, nausea, and 
vomiting. Currently the oncolytic VVs in ongoing clinical trials include the above-mentioned 
Jennerex viruses and another virus developed by Genelux, GL-ONC1. GL-ONC1 is an 
attenuated Lister strain VV. It was well tolerated with minimal toxicity in the phase I trial 
where it also showed preliminary evidence of anti-tumor activity (NCT01584284).  
4.2.5. Safety concerns 
Normally, vaccinia virus infections are mild in otherwise healthy people causing only mild 
rash and fever. But in immunocompromised individuals wild-type vaccinia viruses may 
cause even life-threatening complications: encephalitis, vaccinia necrosum, eczema 
vaccinatum, or roseola vaccinia (Isaacs 2012). It has to be taken into consideration with VV 
therapies and vaccinations that the treated person may disseminate the virus through the 
sites of infection and through secretions. VV is quite stable in the environment. Infectious 
VV has been recovered from a scab collected from the site of small pox vaccination even 
after storing it at room temperature for 13 years (Wolff & Croon 1968). VV can also remain 
infectious in +4°C water for at least four months (Essbauer et al. 2007) and infectious VV 
has been found in feces, urine, and intestines of infected mice (Ferreira et al. 2008). 
Normally wild-type VV spreads through contact with eyes or wounds in the skin, so safety 
precautions must be followed if working with VVs. However, the genetically modified 
oncolytic vaccinia viruses are much less pathogenic than the wild-type VV, since they are 
able to replicate only in cancer cells. Moreover, the double deleted VV (-VGF, -TK) has a 
low risk of recovering wild-type functions by homologous recombination with the wt virus. 
The double-deleted (vvdd) virus backbone has been used already in clinical trials and has 
been reported to be safe (Breitbach et al. 2011, Zeh et al. 2015). The tumor-selectivity of 
this viral backbone has already been proven decades ago (Buller et al. 1985, Gnant et al. 
1999, Thorne et al. 2007). 
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Fortunately, there are several antiviral agents available, like vaccinia immunoglobulin and 
Cidofovir that are effective against undesirable replication in patients. In case adverse 
events or excessive viral replication occurs after VV therapy, these drugs can be used to 
stop the virus from spreading.  
4.3. Armed oncolytic viruses and cancer immunovirotherapy 
To further improve the efficacy of an oncolytic virus, an anti-tumor transgene can be 
integrated into the viral genome (Alemany 2007). The transgene can code for example for 
a directly cytotoxic protein, an anti-angiogenic (Yoo et al. 2007, Buckel et al. 2013) or a pro-
apoptotic protein (Sathaiah et al. 2012). Also suicide genes, which convert non-toxic 
prodrugs to cytotoxic compounds, have been introduced in oncolytic viruses (Dias et al. 
2010, Price et al. 2010). 
Formerly it was thought that the host immune response against the oncolytic virus 
treatment only hinders the efficacy of the therapy and was considered an unwanted side 
effect. It was even proposed to use immunosuppressive drugs in combination with the OV 
therapy to minimize the anti-viral responses. For example cyclophosphamide, an alkylating 
agent that can inhibit innate immunity and down-regulate regulatory T-cells, has been used 
to enhance virotherapy (Di Paolo et al. 2006, Fulci et al. 2006, Ghiringhelli et al. 2007). 
However, the current approach considers that the immune system is “a friend” and OVs 
are even considered immunotherapy agents (Alemany & Cascallo 2009).  
It has been recently observed that oncolysis by oncolytic viruses can trigger immunogenic 
cell death that leads to release of danger-signals (DAMPs) (Liikanen et al. 2013, Parviainen 
et al. 2014, Diaconu et al. 2012, Workenhe & Mossman 2014). Oncolysis also releases 
tumor-associated antigens to the tumor microenvironment. These, together with sufficient 
cytokine stimuli after the virus infection can outbalance the immunotolerance of the 
advanced tumors. This can eventually promote the mounting of antitumor immune 
responses (Melcher et al. 2011, Steele et al. 2011) (Figure 8). Furthermore, the anti-viral 
immune responses can actually nowadays be seen as beneficial. It has been shown that 
anti-viral T cells are able to attack the infected tumor cells thus enhancing the anti-tumor 
responses (Tuve et al. 2009). It has indeed been demonstrated in several preclinical 
experiments with various tumor models and with different oncolytic viruses that OVs are 
able to promote the activation of anti-tumor immune responses (Tuve et al. 2009, Diaz et 
al. 2007, Prestwich et al. 2009, Fukuhara & Todo 2007, Choi et al. 2006, Parviainen et al. 
2014, Diaconu et al. 2012). Immune activation at the tumor site has been shown to 
correspond to treatment benefits in humans as well (Zamarin & Pesonen 2015, Lichty et al. 
2014). 
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Figure 8. Oncolytic immunovirotherapy. Infection of a tumor cell by an oncolytic virus 
triggers several anti-tumor actions. First of all, oncolytic viruses induce direct cell killing by 
oncolysis. The new virions released after lysis of the cell can trigger a so-called bystander 
effect by spreading to, replicating in, and killing the surrounding tumor cells. Oncolytic 
viruses can also act as adjuvants, as infection induces production and release of different 
cytokines and danger signals that can activate and attract immune cells to the tumor site. 
Tumor cell lysis also releases tumor-associated antigens (“in situ cancer vaccination”), 
which can be picked up by dendritic cells. The matured DCs can then cross-present the 
antigens to T and B cells; this can lead to activation of long-term adaptive anti-tumor 
immune responses. Abbreviations: Ag = antigen; B = B cell; CD4 T = CD4+ helper T cell; CD8 
T = CD8+ cytotoxic T cell; DC = dendritic cell; MØ = macrophage; NK = natural killer cell; OV 
= oncolytic virus; PAMP/DAMP = pathogen/damage associated molecular pattern; TAA = 
tumor-associated antigen. 
4.3.1. Arming with cytokines 
Nowadays oncolytic viruses are increasingly modified to become even more immunogenic 
and they are used to promote the activation of anti-tumor immune responses (Lichty et al. 
2014). Immunostimulatory molecules have been inserted into the viral genome to further 
enhance the immune cell attack against infected cancer tissue (Chang et al. 2009, Cerullo 
et al. 2010). For instance, oncolytic viruses expressing interleukins, such as IL-12, IL-4 or IL-
24 have shown to enhance anti-tumor immune responses in murine models (Lee et al. 
2006, Zhang et al. 2009, Post et al. 2007). Also in studies using an oncolytic adenovirus 
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expressing RANTES the researchers observed recruitment of dendritic cells, NK cells, 
macrophages, and CTLs into the tumor (Lapteva et al. 2009). 
Maybe the most frequently applied immunostimulatory molecule is the granulocyte-
macrophage colony-stimulating factor (GM-CSF), which has been used to arm many 
different oncolytic viruses and actually the leading OV candidates harnessed in recent 
clinical trials, like Pexa-Vec (Breitbach et al. 2015b), T-VEC (Andtbacka et al. 2015, Senzer et 
al. 2009), ONCOS-102 (Vassilev et al. 2015) and CG0070 (Burke et al. 2012) express GM-
CSF. GM-CSF can mediate antitumor effects by recruiting natural killer cells and by 
activation of tumor-specific cytotoxic T-lymphocytes as it stimulates proliferation and 
maturation of dendritic cells (Cerullo et al. 2010). However, its high systemic 
concentrations can activate immunosuppressive myeloid-derived suppressor cells (MDSCs) 
(Serafini et al. 2004), which may hinder the therapeutic efficacy of oncolytic viruses. 
Also CD40-ligand (CD40L) has been used as an immunomodulatory transgene to arm 
oncolytic viruses (Gomes et al. 2009, Parviainen et al. 2014, Diaconu et al. 2012). CD40L 
acts as a costimulatory ligand mostly on the CD4+ T cell surface, whose binding to the CD40 
receptor on APCs and B cells enables antigen presentation (Grewal & Flavell 1998, van 
Kooten 2000). CD40L expression by an OV can also induce apoptosis (Gomes et al. 2009, 
Diaconu et al. 2012, Loskog, Fransson & Totterman 2005) as well as immunogenic cell 
death in preclinical models (Parviainen et al. 2014, Autio et al. 2014). An oncolytic Ad 
expressing CD40L was already shown to be safe and to induce T cell immune responses in 
patients with solid tumors (Malmstrom et al. 2010, Pesonen et al. 2012b). 
Arming an oncolytic virus with a cytokine has advantages over the traditional method of 
systemic cytokine therapy. Local replication of the virus restricts the expression of the 
cytokine to the target site thus reducing systemic toxicity often related to cytokine 
therapies (Arellano & Lonial 2008). 
4.3.1.1. Tumor necrosis factor alpha (TNFα) 
Tumor necrosis factor alpha (TNFα) is a multifunctional cytotoxic molecule that has 
multiple properties of a powerful anti-cancer agent. In fact, already in 1975, TNFα was 
noticed to have anti-cancer properties (Carswell et al. 1975, Old 1985). It has also been 
proposed that TNFα is the “active ingredient” in Coley’s toxin (Old 1985, Balkwill 2009). In 
the first clinical studies performed with recombinant TNFα in the 1980s, its antitumor 
properties were confirmed but it also led to severe systemic toxicity, such as septic shock 
or even death (Mueller 1998, Schiller et al. 1991). Thus, systemic use was soon abandoned 
and its only current clinical use is in isolated limb perfusion (Lienard et al. 1992, 
Eggermont, de Wilt & ten Hagen 2003). 
TNFα can induce tumor cell death directly by apoptosis and necrosis (Kobelt et al. 2014, 
Rath, Aggarwal 1999); it induces apoptosis via TNF receptor 1 (TNF-RI) (Ashkenazi, Dixit 
1998, Salako et al. 2011) and it can induce secretion of blood clotting and adhesion 
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proteins in vascular endothelium resulting in vascular thrombosis and necrosis of the 
tumor tissue (van Horssen, Ten Hagen & Eggermont 2006). It can also stimulate release of 
other cytokines (such as GM-CSF, IFN-γ, IL-6, IL-1 and IL-8) and activate and recruit immune 
cells, including macrophages, neutrophils, DCs, T cells and NK cells (van Horssen, Ten 
Hagen & Eggermont 2006, Fiers 1991). TNFα is also able to synergize with radiation and 
chemotherapy by increasing the apoptotic and necrotic cell death and vascular damage 
(Seki et al. 2011, Balkwill 2009, Hallahan et al. 1990, Mauceri et al. 2009). These multiple 
cytotoxic mechanisms make TNFα an appealing molecule to be used to enhance oncolytic 
virotherapies. Introducing TNFα as a transgene expressed by a viral vector enables its 
delivery and production locally and therefore reduces systemic toxicity. For example 
TNFerade (GenVec, Inc.), a replication deficient adenovirus with human TNFα expression 
and a radiation-inducible promoter, has already been studied in phase I, II, and III trials. It 
was well tolerated and showed good response rates in preclinical studies and in phase I 
and II trials, but unfortunately failed to show a statistically significant efficiency in the 
phase III trial of advanced pancreatic cancer (Mauceri et al. 2009, Fisher 2011).  
Interestingly, TNFα has been shown to increase viral entry into tumors by extravasation 
through a Rho A/Rho kinase pathway (Seki et al. 2011) and actually many cell types are 
known to become highly susceptible to the cytotoxic effects of TNFα after viral infection 
(Fiers 1991). However, at least adenoviruses have evolved a mechanism to protect the cell 
from apoptosis, they encode two inhibitor proteins, E3-14.5K/10.4K complex and E3-14.7K, 
which can inhibit TNFα and Fas mediated cytolysis and apoptosis (Li et al. 1999, Chen et al. 
1998). 
4.3.2. Improving the viral immunogenicity by stimulating pattern 
recognition pathways 
In addition to arming the virus with a single cytokine, another way to improve the 
immunogenicity of the viruses is to arm them with molecules that can orchestrate the 
regulation of a set of different cytokines. This strategy has potential to generate a more 
robust immunological response (Lladser et al. 2011, Smith et al. 2013). For example a non-
replicating adenovirus was armed with myeloid differentiation primary response gene 88 
(MyD88) to amplify the TLR-mediated adenovirus immune response (Hartman et al. 2010). 
MyD88 acts as a universal adapter protein for almost all TLRs (except TLR-3) to activate NF-
κB. Overexpression of MyD88 by an adenoviral vector was shown to enhance adaptive 
immune responses and to inhibit local tumor immunosuppression, resulting in significantly 
inhibited local and systemic growth of multiple tumor types (Hartman et al. 2010). MyD88 
was also used as a genetic adjuvant to enhance intrinsic immunogenic properties of a DNA 
vaccine (Ullas, Desai & Madhusudana 2014). Also another approach to stimulate TLR-9 
signaling has been explored. Cerullo et al. introduced repeated CpG sequences into the 
oncolytic adenovirus backbone, which was shown to increase anti-tumor T cells and to 
decrease the activation of MDSCs (Cerullo et al. 2012). Similarly oncolytic parvovirus 
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carrying CpG islands showed enhanced immunogenicity, induced markers of cellular 
immunity and dendritic cell activation (Raykov et al. 2008).  
Arming the virus with a molecule that induces production of anti-viral cytokines may sound 
controversial; however, it has been shown that arming viruses with e.g. some anti-viral 
cytokines like IFN-γ or type I interferons have potential to enhance also anti-tumor 
responses (Li, Huang & Kung 2005, Chiocca et al. 2008, Sterman et al. 2010, Odaka et al. 
2002), perhaps by sending alarm signals to immune cells in the tumor site and by 
stimulating expression of MHC molecules on cancer cells (Propper et al. 2003).   
4.3.2.1. DNA-dependent activator of interferon-regulatory responses (DAI) 
DAI, DNA-dependent activator of IFN-regulatory responses (also known as Z-binding 
protein, ZBP1 or DLM-1) is a sensor of double-stranded DNA. It is a pattern recognition 
receptor (PRR) located in the cytoplasm of cells and acts as a potent activator of innate 
immune responses (Takaoka et al. 2007, Wang et al. 2008). DNA sensing by DAI 
consequently activates NF-κB and interferon regulatory factor 3 (IRF3) signaling pathways 
(Zhang et al. 2013), which first leads to production of IFN-β. IFN-β promotes gene 
expression of IFN-inducible genes and eventually leads to production of IFN-α, chemokines 
and pro-inflammatory cytokines (Lladser et al. 2011, Wang et al. 2008). The secretion of 
pro-inflammatory molecules and type I IFNs may ultimately promote adaptive T cell 
responses. Lladser et al. actually showed that a DAI-expressing plasmid could efficiently be 
used as a genetic vaccine to generate a pro-inflammatory microenvironment essential for 
activation of antigen-specific T cell responses and long-lasting antitumor immunity in 
tumor-bearing mice (Lladser et al. 2011). DAI has been reported to sense DNA of different 
viruses, at least adenoviruses (Schulte et al. 2013) and HSVs (Triantafilou, Eryilmazlar & 
Triantafilou 2014, Pham et al. 2013, Furr et al. 2011).  
5. Personalized cancer therapies 
Today it is known that an individual´s genetic background can influence responsiveness to 
treatments and drugs, as well as susceptibility to certain diseases. The Human Genome 
Project, a large-scale automated sequencing project begun in 1984 and completed in 2003, 
enabled assessment of the entire genetic code of a man. Together with the fast 
development of techniques, such as genome-wide association studies (GWAS) and 
genotyping, the Human Genome Project has enabled fast identification of genetic 
variations between individuals for diagnostic and therapeutic purposes (Low et al. 2014). 
The concept of “personalized medicine” is emerging as a new way to ensure safer and 
more efficient treatments. It may also provide earlier diagnoses of diseases if predictive 
biomarkers are found to correlate with a disease (Rodriguez-Antona & Taron 2015).  
The genomic information of cancer patients and especially their tumors is essential as 
many novel cancer therapies rely on certain mutations. Thus, tumor genotyping aimed at 
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matching the patient with the right drug has been foreseen to become a clinical routine 
(Heuckmann & Thomas 2015).  
As the regulatory authorities, such as the Food and Drug Administration and the European 
Medicines Agency are responsible for ensuring that drugs are safe and effective, the 
agencies have become increasingly interested in personalized medicine and are trying to 
integrate genetic and biomarker information with drug development for clinical use (FDA, 
Paving the Way for Personalized Medicine 2013). The FDA has suggested that patient-
specific genetic background variation should be taken into account when dosing the drugs, 
and the FDA already requires certain genetic biomarker data on patients before the use of 
targeted drugs in order to ensure safety and correct dosing.  
There are some ethical issues that have been raised since the rapid accumulation of 
personal genetic information. Patient privacy needs to be respected, for instance the 
questions about the owner rights to the results and data from the gene tests. For example, 
is it good for a person to know about a possible predisposition to disease? Or, should other 
family members also have the right to know about genetic predispositions or risks? It 
should also be ensured that the test results are well explained to the patients by educated 
professionals and that the information will not eventually be misused by employers or 
insurers.  
The efficacy of oncolytic virotherapies also seems to vary between patients, some 
benefitting more than the others. The reason for this remains unknown, but it can be 
presumed that patients’ genetic background and for example differences in the immune 
system functions may play a role.  
5.1. Finding the right patients for a given therapy 
Researches are with increasing energy trying to find biomarkers that would help predict 
treatment responses to enable better targeted use of drugs. This is especially important in 
the field of cancer therapies, since these drugs often cause serious side effects. Thus the 
use of drugs with predicted inefficiency or toxicity in given patients should be avoided. 
Assessing cancer biomarkers for each patient would markedly increase diagnostics costs 
though, and drugs that would benefit only a small cohort of patients would of course 
become more expensive. Personalized medication could, however, also have clear 
economic benefits. The ability to identify patients who benefit most from a treatment 
would reduce unnecessary costs caused by ineffective or toxic drug use. Use of genetic 
information would also enable more refined selection of patients for clinical tests and trials 
resulting in smaller cohorts, and faster throughput and would increase the probability of 
drug approval. 
5.1.1. Biomarkers 
Biomarkers are measurable indicators used for diagnostic, prognostic or therapeutic 
purposes (Strimbu, Tavel 2010, Biomarkers Definitions Working Group. 2001). Commonly, 
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biomarkers are changes in the expression levels of certain proteins known to correlate with 
susceptibility to or progression of a disease, or with the treatment responsiveness. 
However, genetic variations (polymorphisms, copy number variations, chromosomal 
abnormalities and epigenetic variations) or anatomical and physiological phenotypes can 
be considered biomarkers as well.  
A commonly used diagnostic and/or prognostic biomarker in cancer medicine is the 
prostate-specific antigen (PSA), which is overexpressed in most prostate cancers and some 
other cancers too (Duffy 2014). PSA levels in blood correlate with progression to prostate 
cancer. Other well-known diagnostic biomarkers are mutations in the tumor suppressor 
genes BRCA 1 and 2. These mutations indicate risk to at least breast and ovarian cancers 
(Struewing et al. 1997). 
Cancer tissues are highly heterogeneous and bear often multiple unique, but also some 
common mutations found among different cancers. The realization that these mutations 
cause a differentiation of cancer cells from normal cells has led to the development of 
cancer-specific drugs that use the mutated phenotype of the cancer. These drugs are 
designed to work only if the mutation occurs, thus there are several biomarkers defined for 
various cancer therapeutics to predict the effectiveness of a certain drug in the patient. 
There are already several cancer drugs that have been approved for the use in patients 
whose tumors display specific genetic characteristics. Maybe the most familiar example of 
targeted cancer drugs is trastuzumab (trade names Herceptin and Herclon), which only 
works in cancers that overexpress HER2 (human epidermal growth factor receptor 2) 
protein. Slamon et al. discovered in 1987 that mutation in the HER2 gene could cause 
overexpression of HER2 on the surface of breast cancer cells (Slamon et al. 1987). This 
overexpression has been observed to occur in about 20-30% of breast cancers and it has 
been associated with an aggressive form of the disease (Slamon et al. 1987). These 
observations made HER2 an appealing biomarker and target for breast cancer treatment. 
Eleven years after (1998) Dr. Slamon’s discovery, the FDA approved trastuzumab for 
treating HER2-positive breast cancers. Trastuzumab is only useful for cancer patients with 
the HER2 mutation and can even cause harm to patients who do not overexpress the 
protein, thus underscoring the need for genetic screening prior to starting the trastuzumab 
therapy. Also several other cancer biomarkers have been discovered and are being used to 
assist cancer diagnosis and to develop targeted therapies as well as predict treatment 
responsiveness (Kelloff & Sigman 2012). For instance EGFR and KRAS are used as 
biomarkers for cetuximab therapy, BRAF for dabrafenib therapy (Rodriguez-Antona & 
Taron 2015), and mutations in the EGFR1 gene indicate patients' risk for non-small cell lung 
cancer (NSCLC) and the probability to respond to gefitinib or erlotinib therapies (Herbst et 
al. 2005, Lynch et al. 2004). Chronic myelogenous leukemia (CML) patients are known to 
feature a reciprocal translocation (“Philadelphia” translocation) between chromosome 9 
and 22, which gives rise to an oncogenic fusion gene called BCR-ABL. BCR-ABL is used as a 
biomarker for CML, and a specific drug, a tyrosinase kinase inhibitor called imatinib (trade 
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names Gleevec and Glivec) has been developed to specifically target and inhibit 
proliferation of BCR-ABL-expressing hematopoietic cells (Moen et al. 2007). 
5.1.2. Polymorphisms 
Polymorphisms are genetic variations between individuals. Polymorphisms are often 
related to the susceptibility to many diseases and severity of the illness. They can also be 
the reason why some patients respond differently to drugs, chemicals, vaccines or 
pathogens for instance. Some, for example, metabolize certain drugs faster than others. 
Usually polymorphisms are variations of single nucleotides (SNPs) in the genome. 
Nowadays the role of polymorphisms (SNPs) in therapy responsiveness is widely 
recognized and they are studied for personalized medicine purposes (Low et al. 2014). 
5.1.2.1. Fc gamma receptor polymorphisms 
Fc gamma receptors (FcγR) are cell surface receptors expressed on leukocytes. They play 
an important role in host defense and immune regulation mechanisms; they serve as a link 
between humoral and cell-mediated immune systems (Li et al. 2009, Forthal & Moog 
2009). FcγRs bind to the Fc part of immunoglobulin G (IgG). 
FcγRs are divided into three classes, FcγRI, FcγRII and FcγRIII, which differ in structure, cell 
distribution and affinity to different IgG subtypes. The classes can be split into subclasses, 
indicated with letters (a, b or c).  FcγRI exhibits high affinity to monomeric IgG, while FcγRII 
and FcγRIII bind effectively only aggregated, multimeric IgG, which is bound to an antigen 
(van Sorge, van der Pol & van de Winkel 2003). 
Depending on whether the FcγRs stimulate or inhibit the effector leukocyte functions, they 
can be defined as activatory or inhibitory receptors depending on their signaling subunit 
type. FcγRIIb is the only inhibitory receptor subtype having an ITIM (immunoreceptor 
tyrosine-based inhibition motif) signaling unit in its cytoplasmic domain. All other FcγRs are 
activatory receptors and they have an ITAM subunit (immunoreceptor tyrosine-based 
activation motif). The function of the effector cell is determined by the ratio of inhibitory 
and activatory receptors activated (Nimmerjahn & Ravetch 2008). When the FcγR binds to 
an antigen-bound IgG, the ITAM/ITIM signaling unit becomes phosphorylated by tyrosine 
kinases, which then leads to changes in the effector cell functions. The effector cells (i.e. 
leukocytes) can destroy the antigen-antibody complex by multiple mechanisms: 
phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), degranulation, cytokine 
and chemokine expression or activation of B cells to produce antibodies (Cohen-Solal et al. 
2010, Nimmerjahn & Ravetch 2008, van Sorge, van der Pol & van de Winkel 2003). 
Altogether eleven polymorphic regions have been identified in the Fc gamma receptor 
genes (Bournazos et al. 2009). The polymorphisms have an effect on the binding affinity to 
IgG and thus on the efficacy of immunological defense mechanisms (van Sorge, van der Pol 
& van de Winkel 2003). As Fc gamma receptors serve as a crucial link between the innate 
and adaptive branches of the immune system, their polymorphisms are commonly 
accepted to have potential in predicting the outcome of cancer immunotherapies (Concetti 
51 
 
& Napolioni 2010). FcγRIIa and FcγRIIIa subclasses are the most common receptor types 
and play important roles in the immune regulation. Polymorphisms found in these genes 
are often associated with diseases and disease severity in previous studies. 
FcγRII is the most widely distributed Fc gamma receptor among different cell types. FcγRIIa 
(CD32a), one of the FcγRII subtypes, has a wide cellular distribution. It is mainly expressed 
on phagocytic cells such as macrophages and neutrophils (Huang et al. 2011), but is also 
found on platelets (Li et al. 2009). A SNP in the amino acid position 131 in the FcγRIIa 
receptor´s extracellular ligand-binding domain, FcγRIIa-H131R (rs1801274), alters the 
binding affinity of the receptor to IgG between the two possible receptor allotypes. This 
missense mutation (adenine (A) to guanine (G)) results in an amino acid change (histidine 
(H) to arginine (R)). The FcγRIIa-R allotype binds weaker to IgG than the ancestral H-
allotype, thus, individuals homozygous for FcγRIIa-H are more effective in clearing Ag-Ab 
immunocomplexes from the body than FcγRIIa-R homozygous individuals. Heterozygous 
individuals (FcγRIIa-HR) have effector cells bearing both allotypes of the receptor and are 
referred to as “intermediate immune responders” (van Sorge, van der Pol & van de Winkel 
2003). 
FcγRIIIa receptors instead, are found mostly on NK cells, but also on tissue-specific 
macrophages (e.g. Kupffer cells in the liver) and on small subsets of monocytes, γδ T cells 
and DCs. Another polymorphism in FcγRIIIa, V158F (rs396991), also leads to different IgG 
binding affinity between the two different isoforms of the receptor. A thymine (T) to 
guanine (G) codon missense mutation in the amino acid position 158 changes the valine (V) 
to phenylalanine (F) in the ligand-binding domain of the receptor. Of these two allotypes, 
the V allotype binds stronger to IgG than the F form (van Sorge, van der Pol & van de 
Winkel 2003).  
SNPs in FcγRIIa and FcγRIIIa have been associated with susceptibility to various diseases, 
such as autoimmune diseases (Ravetch & Bolland 2001, Dijstelbloem, van de Winkel & 
Kallenberg 2001), infectious diseases (Pleass & Woof 2001) and coagulation disorders 
(Forthal & Moog 2009). They have also been linked to responsiveness to immunotherapies, 
such as mAb therapies (Clynes et al. 2000, Musolino et al. 2008) and cancer vaccines 
(Weng, Czerwinski & Levy 2007, Wang et al. 2010). Usually individuals carrying the allotype 
that binds weaker to IgG (FcγRIIIa-F or FcγRIIa-R allotypes) are more susceptible to certain 
immunologic diseases or more severe disease because of insufficient clearance of 
immunocomplexes (Li et al. 2009). Surprisingly though, the strong-binding FcγRIIIa-V 
allotype was associated with the severity and progression of systemic lupus erythematosus 
(SLE) an autoimmune disease affecting intracellular structures. This was supposed to be 
due to more fulminant local inflammatory responses in the V allotype carrying patients 
(Alarcon et al. 2006). However, on the contrary, the weakly binding R allotype of FcγRIIa 
was related to higher risk and disease severity of SLE (Duits et al. 1995, Karassa et al. 2002, 
Haseley et al. 1997). Furthermore, the FcγRIIa-RR genotype was associated with 
progression of HIV infection (Forthal et al. 2007), whereas it was shown to be beneficial for 
52 
 
anti-TNFα therapy (infliximab) for rheumatoid arthritis because of slower clearance of Ab-
Ag complexes (Canete et al. 2009). It has actually been shown in multiple studies that FcγR-
mediated ADCC plays a clear role in the efficacy of mAb therapies (Gianni 2008, Musolino 
et al. 2008). For example, Musolino et al. reported that the “strong-binding” genotypes 
FcγRIIIa-VV and FcγRIIa-HH both correlate with an objective response rate and progression-
free survival of trastuzumab treated breast cancer patients; also the combination of these 
genotypes, VVHH was found beneficial. They actually showed that the PBMCs of these 
patients induce higher trastuzumab-mediated ADCC (Musolino et al. 2008). Usually the 
results logically indicate that the patients homozygous for the strong-binding allotypes 
benefit more from the mAb therapies, however, there are conflicting data for the genotype 
providing the best outcome (Bibeau et al. 2009, Zhang et al. 2007, Pander et al. 2010).  
NK cells are considered the most important mediators of innate immune responses against 
malignancies. Triggering of FcγRIIIa on NK cells induces ADCC and lymphokine production 
to defend the organism against viral infections and malignancies (Iwasaki et al. 2011, van 
Sorge, van der Pol & van de Winkel 2003). FcγRIIIa on macrophages (e.g. Kupffer cells in 
the liver) are thought to play a role in the clearance of viruses (Li et al. 2009, van Sorge, van 
der Pol & van de Winkel 2003). Furthermore, FcγR-bearing immune cells can prevent viral 
infections by neutralization and degradation of cell-free viral particles in the circulation 
(Cotter, Zaiss & Muruve 2005, Leopold et al. 2006, Triulzi et al. 2010). 
5.2. Tailoring the therapy for the patient 
In addition to the selection of the right patients for defined therapies, personalized 
medicine may also be thought of as tailoring the treatment according to the specific 
characteristics and needs of the patient.  
Formerly the ideology of medication relied more on a concept of “one-dose-fits-all” but 
nowadays it is generally thought that it would be safer and much more efficient to tailor 
the treatments individually for each patient. It is known that genetic variations can 
influence the pharmacokinetic (PK) profile of a drug. Knowing the PK variability in patients 
would enable more optimal dosing of drugs thus minimizing toxic side effects as well as too 
low, ineffective doses (Rodriguez-Antona & Taron 2015). The study of an individual’s 
genome to provide a more tailored drug prescription is commonly referred to as 
pharmacogenomics. 
The metabolic rate of a patient is known to highly influence the drug therapy efficacy and 
toxicity. Cytochrome P450 proteins (CYPs) are enzymes responsible of regulating the 
metabolism of most drugs. For example, the efficacy of tamoxifen cancer therapy has been 
shown to depend on the CYP2D6 phenotype. Patients with the CYP2D6*1 allele are slower 
metabolizers, thus the drug is less effective and can cause more serious side effects in 
these patients (Jin et al. 2005, de Leon, Armstrong & Cozza 2006). 
In addition to more optimal dosing, cancer therapies can be designed to fit certain patients 
who e.g. express specific tumor-epitopes or antigens. There are several tumor-associated 
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antigens (TAAs) that are known to be present in various cancers. These TAAs are used to 
vaccinate cancer patients in several platforms (Melief & van der Burg 2008, Okada et al. 
2015). There are currently several Phase III trials ongoing to test tumor-peptide vaccines 
(Aranda et al. 2013) for example to treat melanoma by a melanoma-associated antigen-A3 
(MAGE-A3) vaccine (Kruit et al. 2013, Ulloa-Montoya et al. 2013) and to treat metastatic 
pancreatic cancer with a telomerase reverse transcriptase peptide TERT611–626 (GV1001) 
vaccine (Kyte 2009). Also for gliblastoma an EGFRvIII peptide is going through phase III 
testing. The EGRFvIII vaccination has shown promising responses in newly diagnosed 
glioblastoma patients prolonging both PFS and OS compared to historically matched 
controls (Batich & Sampson 2014). Even though the tumor peptide vaccines have shown 
promising results in some patients, they still suffer from low efficacy in most cases, 
especially in cases of advanced diseases (Middleton et al. 2014). This may be due to the 
highly immunosuppressed tumor microenvironment, and thus the peptide vaccines need a 
powerful adjuvant that could break the immunosuppression (Rhee et al. 2011). Several 
adjuvants to enhance peptide vaccinations have been tried, such as CpG 
oligodeoxynucleotides (Murad et al. 2007, Ashkar & Rosenthal 2002), poly-ICLC (Ming Lim 
et al. 2013), and IFN-α (Kameshima et al. 2013, Zeestraten et al. 2013). Also the low 
antigen presentation by tumor cells can hinder the effect of peptide vaccines (Aranda et al. 
2013). 
Because of the tumor heterogeneity and the constantly changing chemical, physical and 
cellular environment in the tumors, there will never be one cancer drug that would work in 
all cancer cases. Finding a way to design the drug individually for each case taking into 
account the patient- and tumor-specific characteristics would perhaps offer even safer and 
more efficient cancer therapies. Researchers have already started to establish methods to 
identify specific antigens from each individual tumor that can be used as cancer 
immunotherapeutics (Admon & Bassani-Sternberg 2011). Tumor cells produce disease-
associated proteins, which are presented as foreign antigens on the tumor cell surface by 
MHC molecules, which can then be recognized by specific CTLs. This presented peptide 
repertoire (immunopeptidome) is therefore a very valuable source for antitumor vaccine 
development (Purcell, McCluskey & Rossjohn 2007). There are already some protocols 
established to study the immunopeptidomes from tumors by extracting the peptides from 
MHC molecules and analyzing the yielded peptide pools by LC-MS/MS (Antwi et al. 2009, 
Fortier et al. 2008). Still, it is challenging to distinguish peptides that are truly tumor-
specific to avoid possible auto-immune and inflammatory responses due to undesirable 
use of self-peptides (Marcilla & Lopez de Castro 2008) and to find the peptides that are 
most immunogenic.  
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6. AIMS OF THE STUDY 
The aim of the thesis studies was to improve the efficacy of oncolytic virotherapies by A) 
boosting the immunogenicity of the viruses in order to enhance the activation of anti-
tumor immune responses and by B) finding means to personalize the therapies to provide 
the right treatment for the right patients. 
 
The more specific aims for each study are: 
Study I:  To boost immunogenicity and cytotoxic potential of an oncolytic 
adenovirus by arming it with TNFα. 
Study II:  To improve the vaccine and adjuvant potency of an oncolytic vaccinia virus 
by arming it with a self-recognizing receptor DAI. 
Study III:  To study the role of FcγR polymorphisms in the efficacy of oncolytic 
virotherapy to find the patient populations that would benefit the most 
from the oncolytic adenovirus treatments. 
Study IV:  To develop a novel oncolytic vaccine platform (PeptiCRAd) that carries 
tumor-associated antigens on the adenoviral surface to induce tumor-
specific immune responses. 
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7. MATERIALS AND METHODS 
The studies in which the following methods have been used are marked with the 
corresponding Roman numerals in parentheses. 
7.1. Cell lines 
All cells were cultured in the recommended conditions and maintained in humidified 37°C 
incubators with 5% CO2. 293, 911, A549, PC-3MM2, UT-SCC8, CACO-2, A2058 and HS294T 
cells were cultured in DMEM supplemented with 10% FBS, 1% L-glutamine and 1% 
penicillin-streptomycin antibiotics. RPMI-1640 with 10% FBS and 1% L-glutamine and 1% 
penicillin-streptomycin was used for B16-F10, B16-OVA, EJ, THP-1, Jurkat, MDA-MB-435 
and WEHI-13VAR cells. EMEM with 1% L-glut and 1% Pen-Strep was used for SK-MEL-2 and 
CV-1 cells. Some cell lines needed additional supplements. The growth medium of PC-
3MM2 cells was supplemented with 1% sodium pyruvate, UT-SCC8 with 1% non-essential 
amino acids and B16-OVA with 5mg/ml G-418 (Gentamicin). 
Characteristics of the cell lines used are described in Table 1. 
Table 1. Cell lines used in studies. 
Cell line (name) Species Description Source Used in study 
293 (HEK-293) human embryonic kidney cells ATCC1 I 
911 human embryonic retinoblasts ATCC I 
A2058 human melanoma ATCC II 
A549 human lung adenocarcinoma ATCC I, II, IV 
B16-F10 mouse melanoma ATCC II, IV 
B16-OVA mouse melanoma, expresses chicken 
ovalbumine 
Dr. Vile2 I, II, IV 
CACO-2 human colorectal adenocarcinoma  ATCC IV 
CV-1 monkey kidney epithelial cells ATCC II 
EJ human bladder carcinoma Dr. Eliopoulos3 I 
HS294T human melanoma ATCC II, IV 
Jurkat human immortalized T lymphocytes Dr. Tienari4 II 
MDA-MB-435 human breast cancer ATCC I 
PC-3MM2 human prostate adenocarcinoma Dr. Fidler5 I, II 
SK-MEL-2 human melanoma ATCC II, IV 
THP-1 human monocytes ATCC II 
UT-SCC8 human head and neck squamous cell 
carcinoma 
PromoCell6 I 
WEHI-13VAR mouse fibroblasts, sensitive to TNFα ATCC I 
1American Type Culture Collection, Manasas, VA, USA 
2Provided by Professor R. Vile, Mayo Clinic, Rochester, MN, USA 
3Provided by Dr. A.G. Eliopoulos, University of Crete Medical School and Laboratory of Cancer Biology, Heraklion, Crete, Greece 
4Provided by Dr. P. Tienari, Program of Molecular Neurology, University of Helsinki, Helsinki, Finland 
5Provided by Dr. I. J. Fidler, MD Anderson Cancer Center, Houston, TX, USA 
6PromoCell GmbH, Heidelberg, Germany 
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7.2. Viruses 
7.2.1. Adenoviruses 
Adenoviruses used in the studies of this thesis were serotype 5 viruses and genetically 
modified (except the wild-type Ad300Wt control) to be cancer specific by a 24 bp deletion 
(Δ24) in the constant region CR2 of the E1A gene. This deletion averts binding of E1A to Rb 
protein, which then disrupts the viral replication in normal cells, whereas in cancer cells 
the replication is still possible despite the deletion since in most of the cancers (Sherr 
1996) the Rb-p16 pathway is continuously active because of the Rb mutation (see 
Figure 4). 
Some viruses were also modified for increased transductional targeting to tumor cells by 
changing the knob structure of the fiber of serotype 5 to a serotype 3 knob. These viruses 
are thus called 5/3 chimeric viruses. 
The replication-deficient adenovirus, Ad5/3-Luc1, used as control, is an E1 and E3 deleted 
first-generation adenovirus. The luciferase transgene is located in the deleted E1 under the 
control of a cytomegalovirus (CMV) promoter. 
The replication-competent i.e. oncolytic adenoviruses were produced in A549 cells and the 
replication-deficient adenovirus, Ad5/3-Luc1, was amplified in 293 cells. Viruses were 
purified following a standard protocol on double cesium chloride gradients (Luo et al. 
2007). The titers of the produced viruses were measured by OD260 spectroscopy to 
determine the amount of viral particle concentration (VP/ml) and by TCID50 assay on 293 
cells to determine the amount of infectious viral particles (pfu/ml). In Study IV the protein 
concentrations of the virus preparations were determined by Bradford assay (Bradford 
1976) using the Biorad Protein Assay Dye Reagent Concentrate (Biorad Laboratories; 
Hercules, CA, US). Viruses were also characterized by PCR and restriction enzyme analysis 
for the presence of gene deletions and transgenes and for absence of wild-type virus 
contamination. 
The viruses used to treat patients included in Study III were produced according to Good 
Manufacturing Practices (GMP) by Oncos Therapeutics, Inc. (Helsinki, Finland), which was 
regulated by the Gene Technology Board. 
In Study I, we generated a new oncolytic adenovirus expressing human tumor necrosis 
factor alpha (hTNFα). To create the oncolytic Ad5/3-Δ24-hTNFα (see Figure 10), we 
constructed a pTHSN-hTNFα plasmid containing the human TNFα transgene in the E3 
region of the adenoviral genome deleted for 6.7K/gp19K. To construct the pTHSN-hTNFα, 
pORF-hTNFα (InvivoGen, San Diego, CA, US) was digested with SgrAI and MheI restriction 
enzymes and then ligated with BsiWI and MfeI-linearized pTHSN. pAdEasy-1.5/3-Δ24-
hTNFα was generated by homologous recombination in Escherichia coli BJ5183 cells 
(Qbiogene Inc., Irvine, CA, USA) between FsbI-linearized pTHSN-hTNFα and SfrI-linearized 
pAdEasy-1.5/3-Δ24 (Kanerva et al. 2005), a rescue plasmid containing the serotype 3 knob 
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and a 24-bp deletion in E1A. The genome of Ad5/3-Δ24-hTNFα was released by PacI 
digestion and subsequently transfected into 911 cells. 
All the adenoviruses used in the thesis studies are listed in Table 2. 
Table 2. Adenoviruses used in the studies. 
 Virus (name) Transductional 
targeting  
(Fiber 
modification) 
Transcriptional 
targeting  
(E1 gene 
modification) 
Transgene 
(E3 gene 
modification) 
Reference Used 
in 
study 
Replication 
deficient 
Ad5/3-Luc1 Ad3 knob E1 deleted luciferase (Kanerva et 
al. 2002b)  
I 
 
 
 
 
Oncolytic 
Ad300Wt (wt Ad5) Wt Ad5 wt - ATCC I 
Ad5/3-Δ24 Ad3 knob 24bp deletion in 
E1A 
- (Kanerva et 
al. 2003) 
I 
Ad5/3-Δ24-hTNFα Ad3 knob 24bp deletion in 
E1A 
human TNF 
alpha 
Study I I 
Ad5-Δ24 Wt Ad5 24bp deletion in 
E1A 
- (Heise et al. 
2000)  
IV 
Ad5-Δ24-CpG Wt Ad5 24bp deletion in 
E1A 
CpG (Cerullo et 
al. 2012) 
IV 
Ad5-Δ24-GM-CSF Wt Ad5 24bp deletion in 
E1A 
GM-CSF (Cerullo et 
al. 2010)  
IV 
 
7.2.1.1. PeptiCRAd – Peptide-coated adenovirus 
In Study IV we generated a novel system where tumor-specific peptides can be attached 
onto the surface of an oncolytic adenovirus to boost the anti-peptide, i.e. the anti-tumor 
immunity. We call this technology PeptiCRAd (Peptide-coated Conditionally Replicating 
Adenovirus). To allow electrostatic interactions between peptides and the negative viral 
surface, we added a positively charged poly-lysine (polyK) chain to the peptide sequence. 
PeptiCRAd complex formation 
PeptiCRAd complexes were prepared by mixing oncolytic adenoviruses and polyK-peptides 
using a 1:500 ratio: i) for each??L of virus used, the corresponding ug of protein was 
calculated; ii) then, for each ?g of viral protein 500 ?g of peptides was added; iii) after 
vortexing, the mix was incubated at room temperature for 15 minutes; iv) the solution was 
again vortexed before use (Figure 9). New PeptiCRAds were prepared before each 
experiment by using fresh reagents every time. All the dilutions of virus and peptides 
required before the incubation were made in sterile MilliQ water adjusted to pH 7.4. Then, 
the PeptiCRAds were diluted with the buffer required by the assay. 
The peptides used for preparation of different PeptiCRAds were polyK-SIINFEKL (OVA257-
264), SIINFEKL-polyK, polyK-AHX-SIINFEKL, polyK-SVYDFFVWL (TRP-2180-188), polyK-
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KVPRNQDWL (hgp10025-33) and polyK-SLFRAVITK (MAGE-A196-104). The peptides were 
purchased from Zhejiang Ontores Biotechnologies Co. (Zhejiang; CN). The purity of all the 
peptides was estimated to be >80% and they were analyzed by mass spectrometry. 
 
Figure 9. Conceptual scheme of the PeptiCRAd cancer vaccine platform. (A) MHC-I 
restricted tumor epitopes are modified in order to display a strong positive charge by 
adding a poly lysine mini-chain at their N-terminus. (B) The positive tumor epitopes interact 
with the negative capsid of the adenovirus by electrostatic interaction. A saturating amount 
of peptide in the reaction ensures the efficient coating of the viral surface, and prevents the 
aggregation of viral particles, thus stabilizing the complex. (C) The complex is allowed to 
stabilize for 15 minutes at room temperature. 
7.2.2. Vaccinia viruses 
Vaccinia viruses used in this thesis work belong to Western Reserve (WR) strain and they 
have been made cancer specific by deletions in two viral genes: the vaccinia growth factor 
(VGF) and thymidine kinase (TK). These deletions make the vaccinia virus selective for 
epidermal growth factor receptor pathway mutations and hypermetabolism, respectively, 
which are common defects in tumor cells. All viruses have also been modified to contain a 
marker gene (tdTomato, GFP or luciferase) for imaging and biosafety purposes.  
Viruses were produced in CV-1 cells and amplified in A549 cells. Virus purification was 
done with sucrose gradient centrifugation, a general method described in (Earl et al. 2001, 
McCart et al. 2001). Virus concentrations (pfu/ml) were determined by a standard crystal 
violet staining assay (Hemminki et al. 2003) on A549 cells. 
In Study II we cloned to new oncolytic vaccinia viruses, one expressing human DAI and one 
expressing mouse DAI. For generation of the vvdd-tdTomato-mDAI and vvdd-tdTomato-
hDAI (see Figure 28), the mDAI and hDAI cDNA was inserted under the control of the pE/L 
promoter of pSC65-tdTomato plasmid (Parviainen et al. 2015, Chakrabarti, Sisler & Moss 
1997) to create pSC65-tdTomato-mDAI and pSC65-tdTomato-hDAI. These shuttle plasmids 
were co-transfected with vvdd-luc in CV-1 cells, and the produced viruses were amplified 
and purified as described above.  
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The oncolytic vaccinia viruses used are listed in Table 3.  
Table 3. Vaccinia viruses used in the studies. 
Virus (name) Marker gene Transgene Reference Used in 
study 
vvdd-GFP green 
fluorescent 
protein 
- (McCart et al. 2001) II 
vvdd-luc luciferase - (Guse et al. 2010) II 
vvdd-tdTomato tdTomato - (Parviainen et al. 
2014) 
II 
vvdd-tdTomato-hDAI tdTomato human DAI Study II II 
vvdd-tdTomato-mDAI tdTomato mouse DAI Study II II 
 
7.3. Human specimens 
7.3.1. Patients included in the genotyping of FcγR polymorphisms (III) 
For Study III, 235 cancer patients were analyzed for two Fc gamma receptor 
polymorphisms, FcγRIIa-H131R and FcγRIIIa-V158F. These patients (98 males and 137 
females; median age 58 years) had advanced solid tumors refractory to conventional 
treatment modalities. The patients were treated with oncolytic adenoviruses in an 
Advanced Therapy Access Program (ATAP) (see more below). 169 (71.9 %) of patients 
included in Study III had been treated with GM-CSF-armed viruses and 39 (15.7 %) with 
CD40L-armed viruses (all viruses used are listed in Table 4). 17 (7.2 %) of these patients 
had received both GM-CSF- and CD40L-armed viruses and 42 (17.9 %) patients received 
viruses not armed with either GM-CSF or CD40L. Other relevant patient data can be found 
in Table 5. 
7.3.1.1. Advanced Therapy Access Program (ATAP) 
ATAP (ISRCTN ID 10141600) was a personalized therapy program (not a clinical trial) where 
cancer patients with advanced solid tumors refractory to available treatment modalities 
received oncolytic adenovirus therapies between years 2007 and 2012. Altogether 290 
patients were treated during these years at Docrates Hospital, Helsinki, Finland. ATAP was 
regulated by the Finnish Medicines Agency (FIMEA) as determined by European Committee 
regulation No 1394/2007 on advanced therapy medicinal products, amending directive 
2001/83/EC and regulation No 726/2004. ATAP was also evaluated by the Gene 
Technology Board and the Medicolegal Department of the Finnish Ministry of Social Affairs 
and Health. 
All patients treated in ATAP voluntarily contacted the clinic and provided written informed 
consent for experimental therapy. Treatments were performed according to Good Clinical 
Practice (GCP) and based on Section 35 of the Helsinki Declaration of World Medical 
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Association. Treatment decisions were based on individual characteristics of the patients 
and their tumors. 
Patients included in ATAP treatments had advanced solid tumors refractory to other 
treatments and a WHO performance score ≤3 at baseline. Patients who had major organ 
dysfunctions, organ transplants, known brain metastasis, HIV or other major 
immunosuppression, elevated bilirubin, alanine transaminase (ALT) or aspartate 
transaminase (AST) levels ≥ 3x normal limits, severe thrombocytopenia or other severe 
diseases were excluded from the ATAP program. 
Table 4. Oncolytic adenoviruses used to treat ATAP patients included in Study III. 
 
 
 
 
 
Virus (name) Transductional 
targeting  
(Fiber 
modification) 
Transcriptional 
targeting  
(E1 gene 
modification) 
Transgene 
(E3 gene 
modification) 
Reference 
ICOVIR-7 RGD E2F promoter - (Rojas et al. 
2009) 
Ad5/3-Cox2L-Δ24 Ad3 knob Cyclooxygenase 
2 (COX-2) 
promoter and 
24bp deletion in 
E1A 
- (Bauerschmitz 
et al. 2006) 
Ad5-Δ24-GMCSF  
(=CGTG-101) 
Wt Ad5 24bp deletion in 
E1A 
GM-CSF (Cerullo et al. 
2010)  
Ad5/3-Δ24-GMCSF 
(=CGTG-102 
/ONCOS-102) 
Ad3 knob 24bp deletion in 
E1A 
GM-CSF (Koski et al. 
2010) 
Ad5-RGD-Δ24-GMCSF 
(=CGTG-103) 
RGD 24bp deletion in 
E1A 
GM-CSF (Pesonen et al. 
2012a) 
Ad3-hTERT-E1A 
(=CGTG-201) 
Wt Ad3 hTERT promoter - (Hemminki et 
al. 2012)  
Ad5/3-hTERT-CD40L 
(=CGTG-401) 
 
Ad3 knob hTERT promoter CD40L (Diaconu et al. 
2012) 
Ad5/3-E2F-Δ24-GMCSF  
(=CGTG-602) 
Ad3 knob E2F1 promoter 
and 24bp 
deletion in E1A 
GM-CSF (Cerullo et al. 
2010) 
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Table 5. Characteristics of patients included in Study III. 
No. of patients 235 
 
Age (age when treatments started) 
   Range 
   Median 
 
 
3 - 82 
58 
Sex (n (%)) 
   Female 
   Male 
  
137 (58.3%) 
98 (41.7%) 
Cancer type (n (%)) 
   Colorectal, intestinal and anal 
   Ovarian (also tubal) 
   Breast 
   Sarcomas 
   Pancreatic and papilla vater 
   Lung 
   Neuroblastoma, neuroendocrine or head and neck 
   Prostate 
   Skin and melanomas 
   Liver and mesothelioma 
   Gastric 
   Biliary tract or cholangio 
   Urinary tract or bladder 
   Cervix and endometrial 
   Renal 
   Thyroid, thymus or parathydoid 
   Esophageal 
  
42 (17.9%) 
35 (14.9%) 
29 (12.3%) 
21 (8.9%) 
20 (8.5%) 
18 (7.7%) 
14 (6.0%) 
12 (5.1%) 
11 (4.7%) 
9 (3.8%) 
6 (2.6%) 
5 (2.1%) 
4 (1.7%) 
3 (1.3%) 
3 (1.3%) 
2 (0.9%) 
1 (0.4%) 
 
Survival and response evaluation 
For evaluation of the effectiveness of the oncolytic adenovirus treatments on the ATAP 
patients, survival and treatment response criteria were applied.  
Overall survival (OS) was calculated from the date of initiation of the adenovirus therapy 
until death or to the date of last follow-up when data were censored. 
To evaluate the treatment response tumors were monitored before and after treatments. 
Tumor sizes were assessed by contrast-enhanced computed tomography (CT), positron 
emission tomography-computed tomography (PET-CT) or magnetic resonance imaging 
(MRI). Response evaluations were performed by professional radiologists. Maximum tumor 
diameters were determined according to RECIST v1.1 (Eisenhauer et al. 2009). Evaluations 
applied to overall disease status including injected and non-injected lesions. The criteria 
were: CR = complete response (complete disappearance of all tumors), PR = partial 
response (≥ 30% reduction in the sum of tumor diameters), SD = stable disease (no 
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response and no progression), PD = progressive disease (≥ 20% increase in the sum of 
tumor diameters or appearance of a new lesion). MR = minor response (10-29% reduction 
in the sum of tumor diameters) was also added to the criteria to better determine small 
changes in response. Also tumor markers were evaluated before and after treatments, the 
same percentages were used to determine the tumor marker responses.  
In Study III, all the outcome (i.e. response) data were combined, averaged and divided into 
categories, disease control (DC) = stable disease or better, or to progressive disease (PD) to 
make the analyses clearer. 
7.3.2. Blood samples for genotyping of FcγR polymorphisms (III) 
Peripheral blood samples that had originally been collected between years 2007 and 2011 
from patients for assessing presence of virus (biosafety, efficacy and safety implications) 
were used in this study for genotyping the FcγR polymorphisms with permission by the 
HUCH Operative Ethics committee (HUS 62/13/03/02/2013). 
7.3.3. Buffy coats for PBMC extraction (II, IV) 
Buffy coats (i.e. blood from which most of the plasma and erythrocytes have been 
removed by gradient centrifugation) from healthy donors were obtained from Finnish Red 
Cross Blood service. 
 
7.4. In vitro studies 
7.4.1. Cytokine expression/production analyses (I, II) 
In Study I, the expression levels of the hTNFα transgene were examined from the 
supernatants of Ad5/3-Δ24-hTNFα infected (10 VP/cell) human cell lines and from tumor 
lysates and serum samples of virus treated mice. In Study II, IL-6 and TNFα concentrations 
in the supernatants of vaccinia virus infected cells were determined. Analyses were done 
by FACSarray (BD Biosciences, San Jose, CA) using Cytometric Bead Array (CBA) Human 
Soluble Protein Flex Sets and Human Soluble Protein Master Buffer Kit (BD Biosciences) 
according to manufacturer’s instructions. BD FACS Array System software and FCAP Array 
v1.0.2 software (BD Biosciences) were used for data analysis.  
7.4.2. Biofunctionality assay for TNFα (I) 
hTNFalpha expressed by the Ad5/3-Δ24-hTNFα virus was tested using WEHI-13VAR mouse 
fibrolast cells, which are highly sensitive to TNFα when the assay is performed in the 
presence of 500 ng/ml actinomycin D. Supernatants from Ad5/3-Δ24-hTNFα and Ad5/3-
Δ24 infected A549 cells 48 h after infection were added onto WEHI-13VAR cells and 
cultured in actinomycin D containing medium. After 24 hours, MTS cell viability assay was 
performed. 
63 
 
7.4.3. Cell viability assays (I, II, IV) 
Tumor cells were seeded at 1 × 104 cells per well on 96-well plates. On the next day, viruses 
were diluted in growth media with 2% fetal calf serum, cells were infected for 1 h at 37 °C 
and then incubated in 5% FCS containing media at 37 °C for 3 to 5 days. Cell viability was 
determined by MTS assay according to the manufacturer's protocol (Cell Titer 96 AQueous 
One Solution Cell Proliferation Assay; Promega, Nacka, Sweden), measuring optical density 
with spectrophotometer at 490 nm. 
7.4.4. Infectivity assay (immunocytochemistry (ICC) assay) (IV) 
Tumor cells were seeded at 2 × 105 cells per well on 24-well plates in 3 or 5 replicates. On 
the following day, the cells were infected with 100 ?l of viral dilutions. The plates were 
centrifuged for 90 minutes at 1000 rcf at +37°C and then transferred to the incubators for 
48 hours. After the incubation period, the culture medium was removed and cells were 
fixed with 250 ?l of ice-cold methanol for 15 minutes. Once methanol was disposed, cells 
were washed 3 times with 300 ?l of PBS supplemented with 1% Bovine Serum Albumin 
(BSA). Afterwards, cells were stained with 250 ?l of 1:2000 diluted mouse monoclonal anti-
hexon antibody (Novus Biologicals, Littleton, CO, US) for 1 hour at RT in the dark. Cells 
were washed and stained with 250 ?l of 1:500 diluted Biotin-Streptiavidin-conjugated goat 
anti-mouse antibody with PBS/1% BSA for 1 hour at RT in the dark. Cells were then 
incubated for 30 minutes at RT with 250 ?l of 1:200 diluted extravidin-peroxidase (Sigma-
Aldrich, St. Louis, MO, US). Cells were washed extensively and DAB staining solution 
(Sigma-Aldrich, St. Louis, MO, US) was prepared according to manufacturer´s instruction. A 
total of 250 ?l of DAB staining solution was applied to each well. Cells were monitored 
under microscope for the appearance of dark spots. When optimal signal to noise ratio was 
reached the reaction was quenched by addition of PBS/1% BSA (500 ?l per well). For each 
replicate (i.e. well) 5 images of non-overlapping fields were acquired using an AMG EVO XL 
microscope. For determinig the infectious titer, the following formula was used: 
 
7.4.5. Jurkat cell silencing for DAI (II) 
Jurkat cells (kindly provided by Dr. Pentti Tienari, Program of Molecular Neurology, 
University of Helsinki, Finland), which are immortalized human T lymphocytes, were 
transfected with psiRNA-DAI or the control plasmid psiRNA-luc (Invivogen, San Diego, CA), 
both of which carry the zeocin resistance gene, using GenCarrier Cell Transfection Reagent 
(Epoch Biolabs, Sugar Land, TX). Stably transfected clones were selected after culturing in 
growth medium supplemented with 0.25 mg/ml zeocin (Invitrogen, Carlsbad, CA) for 6 
weeks.  
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7.4.6. ELISA assays (I, II) 
In Study II, hTNFα levels after Ad5/3-Δ24-hTNFα infection (100 VP/cell) were determined 
from the growth media of murine cells (B16-OVA) using a human TNFα ELISA kit (KHC3011, 
Invitrogen, Frederick, MD, US). 
To study the IFN-β production from Jurkat cells infected with vvdd-GFP (in Study II), a high 
sensitive human interferon beta ELISA (PBL interferon source, Piscataway, NJ) was 
performed on growth media from infected and non-infected cells according to 
manufacturer’s instructions. 
7.4.7. IFN-beta qPCR (II) 
Total cellular RNA was isolated with the Qiagen RNeasy kit. Isolated RNA (2 μg) was 
reverse-transcribed into cDNA in TaqMan RT buffer with 5.5 mM MgCl2, 500 μM dNTPs, 
2.5 μM oligo d(T)16, 0.4 U/μL RNase inhibitor, and 1.25 U/μL MultiScribe RT (Applied 
Biosystems, Foster City, CA, USA). cDNA samples were then amplified in TaqMan universal 
PCR master mix buffer (Applied Biosystems) with TaqMan Pre-Developed Assay-on-
demand Gene Expression Reagent kits (Applied Biosystems) to analyze mRNA levels for 
IFN-β1 (Hs00277188_s1). GAPDH was used as endogenous control for normalization. Each 
sample was amplified in duplicate or triplicate with a Roche Lightcycler sequence detector 
(Roche, Basel, Switzerland). 
7.4.8. Whole genome gene expression profiling (II) 
Human HS294T and THP-1 cells were treated with vvdd-tdTomato-hDAI, vvdd-tdTomato or 
PBS as a non-infected control. Total RNA was purified from tumor cells after infection with 
0.1 pfu/cell of virus for 16 hours. RNeasy Plus Mini kit (Qiagen, Venlo, NL) was used 
according to manufacturer´s instructions.  
Independent pools of two RNA samples each (total of 600 ng) were labeled using a T7 RNA 
polymerase amplification method (Low Input Quick Amp Labeling Kit, Agilent Technologies, 
Inc., Santa Clara, CA, USA), according to the instructions of the manufacturer. cRNAs were 
then labeled with Cy3 and Cy5 dyes (Agilent Technologies) and hybridized to the Agilent 2-
color 60-mer oligo arrays (Agilent SurePrint G3 Human GE 8x60K). The slides were washed 
and scanned with a G2505C Agilent Microarray Scanner (Agilent Technologies) and the raw 
intensity values were obtained with the Feature Extraction software, version 11.0.1.1 
(Agilent Technologies). Raw data was quality checked according to Agilent standard 
procedures. The microarray data were deposited in NCBI Gene Expression Omnibus (GEO) 
database and are accessible through GEO Series accession number GSE76208. 
Data pre-processing and differential expression analysis of the gene expression data were 
done in R. First, the probe profile expression data were normalized using quantile 
normalization and corrected for batch processing effects using ComBat function. Next, 
after mapping from probsets to Ensemble gene IDs, the differentially expressed genes (DE 
genes) between pre- and post-treatment samples were identified using a limma package. 
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For the analysis using the limma package, genes were defined as being differentially 
expressed after satisfying a minimum fold-change of ±1.5 and a maximum Benjamini-
Hochberg adjusted p-value of 0.01. Finally, functional categorization of DE genes was 
performed using a novel R-based package namely BACA. It queries the DAVID knowledge 
base and builds a chart showing multiple enrichment analysis results across different 
conditions/treatments. Each annotation in the BACA chart is represented as a bubble with 
a size indicating how many genes in a list of DE genes are associated with it, and a color 
indicating whether the genes are down-regulated (green) or up-regulated (red). 
7.4.9. Analysis of apoptotic and necrotic cells (I) 
Cells were plated onto 6-well plates, 2 x 105 cells/well. Cells were infected with 10 VP/cell 
of adenovirus (or PBS for mock). The amounts of apoptotic and necrotic cells were 
measured 48 hours post infection with a TACS Annexin V-FITC kit (Trevigen Inc., 
Gaitherburg, MD, US) and BD Accuri C6 flow cytometer (BD Biosciences) according to 
manufacturer´s instructions.  
7.4.10.  Immunogenic cell death (ICD) (I) 
Calreticulin exposure:  
Cells in triplicate were infected for 2 hours with 100 VP/cell of adenovirus. Twelve hours 
(human cells) or 48 hours (mouse cells) later, cells were harvested and stained with 1:1000 
diluted rabbit polyclonal Anti-Calreticulin antibody (ab2907, Abcam, Cambridge, UK) for 40 
min at 4 °C and then with 1:100 diluted Alexa-Fluor 488 IgG as secondary antibody 
(A21206, Invitrogen, Carlsbad, CA) for flow cytometric analysis. 
ATP release: 
Cells in triplicate were infected for 2 hours with 100 VP/cell of adenovirus. Supernatants 
were collected after 12 hours (human cells) or 48 hours (mouse cells) and analyzed with 
ATP Determination Kit (A22066, Molecular Probes; Invitrogen).  
HMGB-1 release: 
Cells in triplicate were infected with 100 VP/cell. 24 hours later, supernatant was collected 
and HMGB-1 was measured with an ELISA kit (ST51011; IBL International GmbH, Hamburg, 
DE).  
7.4.11.  Zeta potential and Dynamic Light Scattering (DLS) analysis (IV) 
Virus-peptide complexes were vortexed and diluted to a final volume of 700 ul with sterile 
MilliQ water adjusted to pH 7.4. Then the samples were transferred to a polystyrene 
disposable cuvette, to determine the size of the complex (DLS). Afterwards, the samples 
were recovered from the cuvettes and transferred to the disposable capillary cell DTS1070 
(Malvern; Worcestershire, UK) for zeta potential measurements. All the measurements 
were taken at 25°C with the Nanosizer ZS (Malvern). 
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7.4.12.  Surface Plasmon Resonance (SPR) (IV) 
Virus-peptide interaction was measured by Surface Plasmon Resonance. A multi-
parametric SPR Navi™ 220A instrument (Bionavis Ltd, Tampere, Finland) was used for 
measurements. Milli-Q water (pH 7.4) was used as a running solution. A constant flow rate 
of 30 μl/min, a temperature of +20°C and a 670-nm laser light were used for all 
experiments. A sensor slide with a silicon dioxide surface was activated by treatment with 
plasma for 3 minutes followed by coating with APTES ((3-aminopropyl)triethoxysilane) by 
incubating the sensor in 50 mM APTES in toluene solution for 1 h. The sensor was then 
placed into the SPR device, and the viruses were immobilized in situ on the sensor surface 
by injecting 50 μg/ml viruses in MilliQ water for approximately 12 min, followed by a 3 min 
wash with 20 mM CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate). 
The second flow channel was used as a reference and was injected with MilliQ water only, 
followed by washing with CHAPS. The baseline was observed for at least 10 min before 
sample injections. PolyK-SIINFEKL or SIINFEKL peptides were then injected into both flow 
channels of the flow cell in parallel, with increasing concentrations. 
7.4.13. Irradiation of cells (I) 
To test the combination of oncolytic adenoviral treatments and radiotherapy in vitro, cells 
were irradiated 24 hours after virus infection with 4, 8 or 10 Gy. The cells in 96-well plates 
were placed in a 1-cm thick plastic phantom bottom filled with 1 cm of water. Irradiation 
was performed at the HUCH Department of Oncology with a medical linear accelerator 
(Clinac 600 C/D, Varian Medical Systems, Palo Alto, CA) in a 6 MV photon beam using a 
dose rate of about 4 Gy/min (400 MU/min).  
7.5. In vivo studies 
All animal experiments were performed with permission from the Experimental Animal 
Committee of the University of Helsinki and the Provincial Government of Southern 
Finland. Mice were obtained at 3-6 weeks of age and quarantined at least 1-2 weeks 
before experiments were started. Mice were kept in standard cages with constant food 
and water supply. The health status of the mice was monitored daily and as soon as signs 
of pain or distress were evident, they were euthanized. Mice were, at the latest, 
euthanized when a single tumor reached an average diameter of 17 mm, or 15mm in 
experiments where the mice had two tumors. Euthanasia was done by using CO2 and neck 
dislocation. During the experiments mice were anesthetized either with isoflurane 
inhalation or with i.p. injection of 0.5 mg/kg medetomidine and 50 mg/kg ketamine diluted 
in 0.9% sodium chloride. In all the experiments, the formula (length × (width)2 × 0.5) was 
used to calculate the tumor volumes. 
7.5.1. Syngeneic melanoma models (I, II, IV) 
The in vivo efficacy and immunogenicity of the viruses were tested in immunocompetent 
C57BL/6 mice bearing syngeneic melanoma tumors. Mice were obtained from Harlan 
Laboratories Inc. (Indianapolis, IN, USA) or from Scanbur (Karlslunde, DK) for Study IV. 
67 
 
In Study I, 5-week-old C57BL/6 female mice (N = 7 per group) received 1x105 B16-OVA cells 
subcutaneously on a shaved flank (one tumor per mouse). In the “mild” regimen 
experiment, the virus was injected intratumorally at 108 VP/tumor on days 0, 1, 4 and 5 
and in the “high” regimen experiment the same amount of virus was given every other day 
(a total of 7 times) starting when tumors reached the size of ~4x4 mm. 
In Study II, B16-OVA melanoma tumors were established by injecting 1 × 105 B16-OVA cells 
subcutaneously into one flank of 10-week-old female C57BL/6J mice (N = 12 per group). 
Tumors (one tumor per mouse, ~4×4 mm in diameter) were injected i.t. with vaccinia 
viruses in a volume of 50 μl on day 0 with 3 × 106 pfu/tumor and on day 2 with 1 × 106 
pfu/tumor. Mock tumors were injected with PBS only. In the re-challenging experiment 
where the mice received a second tumor contralaterally, either B16-OVA cells or B16-F10 
cells 3 x 105 cells, were injected 10 days after the first virus treatment. 
In Study IV, melanoma tumors were injected into both flanks of C57BL/6 mice. The number 
of tumor cells injected into each flank was: 3 x 105 for B16-OVA, 1 x 105 for B16-F10 and 2 x 
106 for SK-MEL-2. The treatment of tumors started when tumors reached an average 
diameter of 4 mm. In all the experiments the mice were administered the virus three times 
per day, on days 0, 2 and 4 with 1 x 109 VP/tumor. 
7.5.2. Human prostate cancer xenograft model (I) 
To study the efficacy of the Ad5/3-Δ24-hTNF? virus in Study I, human xenografts were 
established by injecting 5 × 106 PC-3MM2 cells subcutaneously into the flanks of 6-week-
old male NMRI nu/nu mice (N = 6 per group) obtained from Scanbur (Karlsunde, Denmark). 
Tumors (two tumors per mouse, ~5x5 mm in size) were treated i.t. with a volume of 50 μl 
for four times on days 0, 1, 4 and 5 with 108 VP/tumor and control tumors were injected 
with PBS only.  
7.5.3. Humanized mice (II, IV) 
To gain better understanding of the immunogenicity and efficacy of the viruses in a more 
translational system, we used mice with human peripheral blood mononuclear cells 
(PBMCs) and human melanoma tumors. For these studies highly immunodeficient NSG 
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were obtained from The Jackson Laboratory (Bar 
Harbor, Maine, CA, US). Human melanoma cells (HS294T in Study II or SK-MEL-2 in Study 
IV) were injected subcutaneously into both flanks of the NSG mice, 5 × 106 of HS294T cells 
or 2x106 of SK-MEL-2 cells per flank. When tumors reached the average size of 4×4 mm in 
size, human PBMCs were injected intravenously into the tail vein in 200 μl of PBS, 2 × 107 
cells/mouse. Two days later virus treatments were started. In Study II, tumors were treated 
on days 0 and 6 with 1 × 106 pfu/tumor in volume of 50 μl, mock mice were treated with 
PBS only. In Study IV, tumors were treated on days 0, 2 and 4 with 2x108 VP/tumor in 50 μl 
of NaCl, mock mice received NaCl only. Part of the mice were left without PBMCs as a 
study control lacking the immune system. 
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7.5.4. Irradiation of mice (I) 
In Study I, mice received two times 2-Gy whole-body irradiation 24 hours after virus 
treatments. Mice were kept awake in standard plastic cages during the irradiation. 
Irradiation was performed with a medical linear accelerator (Clinac 600 C/D, Varian 
Medical Systems, Palo Alto, CA, US) in a 6 MV photon beam using a dose rate of about 4 
Gy/min (400 MU/min). 
7.6. Ex vivo studies 
7.6.1. Analysis of immune cells from organs (I, II, IV) 
After euthanizing the mice with CO2 and neck dislocation, tumors, spleens and lymph 
nodes of treated mice were collected into tubes containing 10% RPMI-1640 medium, and 
the tubes were kept on ice until further processing. Organs were smashed through 70-μm 
cell strainers and single cell suspensions were stained with fluorochrome-conjugated 
monoclonal antibodies and analyzed using a FACSAria (BD Biosciences) or Gallios 
(Beckmann Coulter) flow cytometer and FlowJo software (TreeStar, Ashland, OR, US). To 
study tumor-specific T cells from B16-OVA tumor bearing mice, APC-conjugated SIINFEKL 
MHC-I pentamer (PROIMMUNE, Oxford, UK) was used together with a FITC-conjugated 
anti-mouse CD8 and a PE-conjugated anti-mouse CD19 antibodies respectively to gate the 
CD8+ cell population and to subtract unspecific binding of the pentamer to B cells. Other 
antibodies used in the studies are described in detail in the corresponding publications. 
7.6.2. ELISpot assay (II) 
The number of IFNγ producing T cells were studied from spleens of vaccinia virus treated 
C57BL/6 mice bearing B16 tumors. A mouse IFN-γ ELISpotPLUS (ALP) kit (Mabtech, 3321-
4APT) was used according to manufacturer´s instructions. Splenocytes were stimulated for 
40 hours with PepMix™ VACV (vaccinia virus) peptide pool (MVA093L, JPT), ovalbumin 
peptide SIINFEKL (P93, Proimmune), gp100 peptide KVPRNQDWL (P1333, Proimmune) or 
TRP-2 peptide SVYDFFVWL (P185, Proimmune) in a concentration of 50 ng/well. 
Concanavalin A (Sigma-Aldrich) was used as positive control (500 ng/well). ELISpot plates 
were read and evaluated by ZellNet Consulting, Inc. (Fort Lee, NJ, US). 
7.6.3. Analysis of apoptotic and necrotic cells in tumors (I) 
Tumors were smashed through a 70-μm cell strainer to obtain single cell suspension and 
the cells were cultured in 10% RPMI-1640 medium overnight. Cells were then stained and 
analyzed with a TACS Annexin V-FITC kit (Trevigen Inc., Gaitherburg, MD, US) and BD Accuri 
C6 flowcytometer (BD Biosciences) according to manufacturer´s instructions. 
7.6.4. DNA extraction (III) 
Genomic DNA was extracted from patient blood clot samples by using a QiAmp Blood Mini 
Kit (Qiagen, Venlo, NL). First the samples were thawed in a 37°C water bath and then the 
69 
 
clots were transferred into clot spin basket filters (Qiagen, Germany). Samples were spun 
through the filter by centrifugation (2000 rcf, 5 min., RT). Qiagen QiAmp Blood Mini Kit 
DNA extraction protocol was used for the DNA extraction. DNA was eluted in nuclease free 
water (Amresco LLC, Solon, OH, USA) and stored in -20°C freezer until genotype analysis. 
DNA concentrations were measured by using NanoDrop ND-1000 (Thermo Fisher Scientific, 
Wilmington, DE, USA). For genotype analyses DNA samples were diluted in nuclease free 
water (Amresco) to obtain a final concentration of 1 ng/μl. 
7.6.5. Genotyping of FcγR polymorphisms (III) 
In Study III, all the patients for whom there were available blood samples were included in 
the genotyping. Patients were genotyped for two different Fc gamma receptor 
polymorphisms, FcγRIIa-H131R (rs1801274) and FcγRIIIa-V158F (rs396991) using TaqMan 
technology on Applied Biosystems’ (AB) 7500 Fast Real-Time PCR system (Applied 
Biosystems Inc., CA, USA). Probes and primers (TaqMan SNP Assays for rs1801274 and 
rs396991) were ordered from Applied Biosystems. Genotyping was performed by 
manufacturer´s instructions. Briefly, polymerase chain reactions were prepared in 
MicroAmp Fast Optical 96-well Reaction Plates (AB) in final volume of 25 μl. The reaction 
mixes consisted of 2X TaqMan Genotyping Master Mix (AB) and 20X TaqMan SNP Assay 
Mix (AB) for either FcγRIIa or FcγRIIIa polymorphism. A total of 10 ng of genomic template 
DNA sample was added per well. Each sample was set up in triplicate. Nuclease free water 
(Amresco) was used as No Template Control (NTC). The following PCR program was used: 
initiation at 60°C for 2 minutes and AmpliTaq Gold Enzyme activation at 95°C for 10 
minutes followed by 45 cycles of denaturation at 92°C for 15 seconds and annealing and 
extension at 60°C for 1 minute, allelic discrimination plate read was performed at 60°C for 
1 minute. The FcγR genotypes were determined using Allelic Discrimination protocol in the 
Sequence Detection System (SDS) software provided by Applied Biosystems. 
7.6.6. PBMC extraction (II, IV) 
Human peripheral blood mononuclear cells (PBMCs) were isolated from a buffy coat. Buffy 
coat blood was diluted 1:1 with PBS, and PBMCs were isolated by Ficoll-Paque PLUS (GE 
Healthcare, Little Chalfont, UK) gradient centrifugation according to manufacturer´s 
instructions. 
7.6.7. HLA typing of PBMCs and tumor cell lines (II, IV) 
First genomic DNA was extracted from the HS294T tumor cell line and human PBMCs for 
HLA typing. Qiagen DNeasy blood and tissue kit (Qiagen, Venlo, NL) was used to extract 
DNA by manufacturer´s instructions and the HLA genotyping and analysis was carried out 
in an EFI (European Federation for Immunogenetics) accredited HLA Laboratory in 
Haartman Institute, University of Helsinki. The genotyping of HLA-A, -B and -C genes were 
performed using sequence specific primers (Olerup SSP HLA-A-B-C Combi Tray, Applied 
Biosciences, Stockholm, SE). The reactions were performed according to manufacturers’ 
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instructions providing at least four-digit resolution (for example, HLA-A*01:01). PCR 
reactions from agarose-gel were evaluated manually and the alleles were called with 
SCORE software. The HLA alleles were assessed using HLA nomenclature release 3.5.0 
(IMGT/HLA database) and carefully interpreted by two persons. 
7.6.8. Cross-presentation experiment (IV) 
Fresh spleens were collected from naïve C57BL/6 mice and smashed through a 70 μm cell 
strainer. Red blood cells were lysed by incubating samples with 5 ml of ACK lysing buffer 
(Life Technologies) for 5 minutes at room temperature. Then, splenocytes were washed 
and prepared for the assay (2x106 cells in 800 ul of 10% RPMI-1640 culture media for each 
condition). A total of 200 ul of SIINFEKL, polyK-SIINFEKL, SIINFEKL-polyK or SIINFEKL-AHX-
polyK peptide dilutions (0.19 μg/μl) was added to splenocytes. The PeptiCRAd complex was 
prepared as described above. After 2 hrs of incubation, cells were washed with PBS and 
stained with either APC anti-mouse H-2Kb bound to SIINFEKL -antibody or APC Mouse IgG1, 
κ Isotype Ctrl (Biolegend, San Diego, CA, US). After 30 minutes of incubation on ice, 
samples were washed and analyzed by flow cytometry. 
7.7. Statistics 
In Studies I, II and IV GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, US) was used 
to determine the statistical differences between study groups. Usually two-tailed Student’s 
t-test was used to determine differences in the in vitro and ex vivo experiments, but two-
way ANOVA was used in some cases in Study IV (statistical analyses used in study IV are 
explained in detail in the figure legends of the article). A nonparametric Mann–Whitney U-
test was used to determine statistical differences between in vivo study groups. The area 
under the curve (AUC) was used in Study IV to determine the size of the tumors of 
humanized mice. Kaplan-Meier survival curves and log rank statistics were used to 
compare survival of the treated mice. In Study III the Pearson´s Chi-square (χ2) test was 
used to assess Hardy-Weinberg equilibrium of genotype and allele frequencies by using the 
Online Encyclopedia for Genetic Epidemiology studies (OEGE) Hardy-Weinberg equilibrium 
calculator (Rodriguez, Gaunt & Day 2009). CubeX (Cubic Exact Solution) software (OEGE - 
Online Encyclopedia for Genetic Epidemiology studies) and EM (expectation-maximization) 
algorithms (Excoffier & Slatkin 1995) were used to analyze linkage disequilibrium between 
the two polymorphic loci. The χ2 test was used to compare outcomes of the patients 
according to FcγR polymorphisms. Kaplan-Meier survival estimations (Kaplan & Meier 
1958) and log-rank statistics (Mantel 1966) were used to determine the differences in the 
overall survival (OS) and median time to death. The statistical data were obtained by using 
IBM SPSS Statistics 20 software for Windows (SPSS Inc., Chicago, IL, US).  
Results are presented as mean ±SD, or as mean ±SEM for tumor growth. All P values were 
two-sided and considered statistically significant when ≤ 0.05. * P <0.05, ** P <0.01, *** P 
<0.001, **** P <0.0001. 
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8. RESULTS AND DISCUSSION 
8.1. Boosting immunogenicity and cytotoxic potential of an 
oncolytic adenovirus by arming with TNFα (I) 
In Study I we developed a new oncolytic adenovirus that expresses human tumor necrosis 
factor alpha aiming at enhancing the cancer-killing potency and the immunogenicity of the 
virus. 
8.1.1. Characterization of the TNFα expressing Ad5/3-Δ24-hTNFα in vitro 
We successfully generated a new chimeric oncolytic adenovirus that expresses human 
TNFα (Ad5/3-Δ24-hTNFα) (Figure 10). This virus was designed to have adenovirus serotype 
3 knobs on the Ad5 backbone, since switching the Ad5 knob into Ad3 knob has previously 
been shown to enhance the infection rate of cancer cells compared to wt Ad5 virus (Tuve 
et al. 2006, Krasnykh et al. 1996, Kanerva et al. 2002a, Kanerva et al. 2003). To make the 
virus selectively replicative in cancer cells, 24 base-pairs were deleted from its E1A region. 
It has already been shown several years ago that this Δ24 deletion reduces killing of normal 
cells drastically and thus makes the virus relatively safe to use (Pesonen, Kangasniemi & 
Hemminki 2011). 
 
Figure 10. A schematic view of the genome of the double-targeted human TNF-alpha 
expressing oncolytic adenovirus Ad5/3-Δ24-hTNFα. (Hirvinen et al. 2015, Human Gene 
Therapy [Study I]) 
TNFα has been used in cancer treatment for decades, but most attempts have failed due to 
systemic toxicity of TNFα (Mocellin et al. 2005, McLoughlin et al. 2005, Corti 2004). Recent 
studies have therefore focused on local delivery of TNFα. A replication deficient adenovirus 
expressing hTNFα (TNFerade, GenVec Inc.) has been studied in clinical trials, but it failed to 
show good enough efficacy in the phase III trial (Mauceri et al. 2009, Fisher 2011). We 
believe it may have been because of the non-replicative system used. Delivering genes by 
an oncolytic vector that can both lyse the infected cells and also multiply the transgene 
expression is a huge benefit compared to a non-replicating vector that can produce only 
one gene product per vector. Thus, we wanted to generate a replication-competent 
oncolytic adenovirus that expresses TNFα from its E3 gp19K region. Intratumoral 
administration of this Ad5/3-Δ24-hTNFα virus was hypothesized to result in high local 
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concentrations of TNFα in the tumor site; however, without systemic toxicity due to tumor-
selective replication of the virus. 
To study the functionality of the newly generated virus we first measured the expression of 
human TNFα by the virus in two different human cell lines, the A549 lung adenocarcinoma 
cell line and the 293 embryonic kidney cells that feature transgenic E1A expression. The 
amount of hTNFα secreted was determined from the supernatants at several time points 
after virus infection by a Cytometric Bead Array (Figure 11). The hTNFα levels were 
increased with time even up to 659 ng/ml in A549 cells and up to 279 ng/ml in 293 cells 72 
hours after infection with Ad5/3-Δ24-hTNFα. The almost three-fold difference between the 
two cell lines also shows the selectivity of the viral replication, since the TNFα production 
was more prominent in a cancer cell line (A549) than in a transformed “normal” cell line 
(293). We also measured TNFα production in a murine melanoma cell line B16-OVA to 
define whether the virus can be tested later in syngeneic in vivo tumor models. In the 
murine cells the expression levels of hTNFα were much lower, rising only up to 83 pg/ml 72 
hours after infection most probably due to the fact that adenoviruses are quite species-
specific and do not produce infective virions in foreign species (Jogler et al. 2006). The 
levels of hTNFα were detectable at around 24 to 36 hours after the infection in human cells 
and 48 hours p.i. in mouse cells.  
 
Figure 11. Expression of human TNFα in 293, A549 and B16-OVA cells. Cells were infected 
with 10 VP/cell of either Ad5/3-Δ24-hTNFα virus or the control virus Ad5/3-Δ24. 
Supernatants were collected at indicated time points and FACSArray analysis was 
performed to quantify human TNFα. (Hirvinen et al. 2015, Human Gene Therapy [Study I]) 
After we confirmed that the virus is able to express TNFα, we wanted to determine if the 
produced cytokine is also biologically functional. The functionality was tested in a TNFα-
sensitive cell line, a mouse fibroblast cell line WEHI-13VAR, which die in the presence of 
TNFα and actinomycin. We infected the cells with different doses of Ad5/3-Δ24-hTNFα 
virus and a control virus TNFα (Ad5/3-Δ24). The viability of Ad5/3-Δ24-hTNFα infected cells 
decreased with increasing viral dose while controls survived which proves that hTNFα 
produced by the virus is biologically active (Figure 12). 
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Figure 12. Biological functionality of the virus was checked by adding supernatant from 
Ad5/3-Δ24-hTNFα or Ad5/3-Δ24 infected A549 cells onto WEHI-13VAR cells. WEHI-13VAR 
cells are sensitive to TNFα when cultured in actinomycin D containing medium. Cell viability 
was measured by MTS assay. (Hirvinen et al. 2015, Human Gene Therapy [Study I]) 
Next we wanted to determine if the insertion and function of the hTNFα transgene in the 
viral genome have an impact on the cell killing efficiency of the virus. We tested the 
oncolytic potency of the virus in the human cancer cell lines PC-3MM2, A549, UT-SCC8 and 
MDA-MB-435 and the mouse cell line B16-OVA by infecting them with different amounts 
of Ad5/3-Δ24-hTNFα or the Ad5/3-Δ24 control and measured the cell viability by MTS 
assay. Interestingly, Ad5/3-Δ24-hTNFα killed the tumor cells even faster than the control 
virus did, so at least the insertion of the gene did not hinder oncolysis by the virus. Also, as 
stated above, the virus produced high concentrations of TNFα in cancer cells, which may 
be the mechanism behind the observed enhanced cytotoxicity compared to the control 
virus. It has indeed been known for a long that at high local concentrations TNFα displays 
anti-tumor properties (Fiers 1991, Mocellin et al. 2005). 
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Figure 13. In vitro tumor-killing efficacy of Ad5/3-Δ24-hTNFα. Oncolytic efficacy of Ad5/3-
Δ24-hTNFα measured by MTS cell viability assay in different tumor cell lines. (Hirvinen et al. 
2015, Human Gene Therapy [Study I]) 
TNFα has the ability to induce direct tumor cell death by inducing apoptosis (Ashkenazi & 
Dixit 1998, Salako et al. 2011) and necrosis (van Horssen, Ten Hagen & Eggermont 2006, 
Laster, Wood & Gooding 1988). Thus, we measured the amount of early apoptotic cells 
(Annexin-V+) and late apoptotic/necrotic cells (PI+) after virus infection in different cancer 
cell lines (A549, PC-3MM2 and B16-OVA). The levels of both early and late 
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apoptotic/necrotic cells were elevated in all tested cell lines infected with the Ad5/3-Δ24-
hTNFα virus compared to controls but no significant difference was found between the 
TNFα-expressing and non-expressing virus (Figure 14). 
 
Figure 14. The amounts of early apoptotic cells (above) and late apoptotic or necrotic cells 
(below) 48 hours after virus infection were analyzed by flow cytometry from PC-3MM2, 
A549 and B16-OVA cell lines. FITC-labeled Annexin-V was used to indicate the early 
apoptotic cells and PI (propidium iodide) the necrotic or late apoptotic cells. (Hirvinen et al. 
2015, Human Gene Therapy [Study I]) 
We and others have recently shown that immunogenic cell death is one important 
mechanism for tumor eradication by oncolytic viruses (Kanerva et al. 2013, Parviainen et 
al. 2014, Diaconu et al. 2012, Workenhe & Mossman 2014). When we measured 
immunogenic cell death markers, i.e. the exposure of calreticulin (CRT) on the cell 
membrane, and the release of adenosine triphosphate (ATP) and the nuclear protein high-
mobility group box 1 (HMGB1) in virus-treated tumor cells, we observed that ATP release 
was significantly increased in all human cell lines (PC-3MM2, A549, EJ) treated with Ad5/3-
Δ24-hTNFα compared to Ad5/3-Δ24. Also CRT exposure on the surface of Ad5/3-Δ24-
hTNFα treated cells and the HMGB1 release were elevated but not significantly (Figure 15). 
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Figure 15. Expression of immunogenic cell death markers upon Ad5/3-Δ24-hTNFα 
infection. a) ATP was measured from supernatants of cells infected with 100 VP/cell, 12 
hours post infection with an ATP luciferase kit. b) Calreticulin exposure on cell surface was 
measured from cells infected with 100 VP/cell, 12 hours post infection (or 48 hrs p.i. for 
B16-OVA) with flow cytometry. c) HMGB1 (High-mobility group protein B1) excretion was 
measured from supernatants of cell cultures infected with 100 VP/cell, 24 hours post 
infection with ELISA. (Hirvinen et al. 2015, Human Gene Therapy [Study I]) 
To summarize, the in vitro results of the studies with Ad5/3-Δ24-hTNFα, we can conclude 
that the TNFα expressed from Ad5/3-Δ24-hTNFα virus is biologically functional and capable 
of inducing efficient tumor cell killing. It also increases release of markers indicating 
immunogenic cell death. 
8.1.2. In vivo efficacy and immunogenic potential of the Ad5/3-Δ24-hTNFα 
After showing the efficacy of the virus in vitro, we started in vivo studies. The in vivo 
oncolytic activity of Ad5/3-Δ24-hTNFα was tested in a prostate cancer xenograft model. 
Groups of nude mice (NMRI nu/nu) were injected with PC-3MM2 human prostate cancer 
cells subcutaneously. These prostate cancer cells were chosen for the xenograft 
experiment based on the good results seen in the in vitro cell killing assays, and because of 
the aggressive nature of this cell line, to be able to show the power of the virus in a 
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challenging model. When the tumors reached an average diameter of 4-5mm the mice 
were injected intratumorally 1x108 VP/tumor of virus (or PBS) on days 0, 1, 4 and 5. Results 
showed that the tumors were significantly smaller (P < 0.001 at day 40) in the Ad5/3-Δ24-
hTNFα-treated mice compared to the control virus, and most of the Ad5/3-Δ24-hTNFα-
treated tumors were fully cured within 40 days after the first virus injection (Figure 16). 
However, soon thereafter regrowth of some of the treated tumors was observed. This may 
be because the treatments were only given during the first five days of the experiment and 
actually the amount of virus administered per tumor during the treatments was quite low, 
only 4 x 108 VP/tumor in total. Also the lack of adaptive immune cells in nude mice most 
probably explains the regrowth of the tumors: nude mice do not develop memory cells 
against the tumor, thus some tumor cells that are still left can resume growing after the 
effect of the virus disappears. To maintain the tumor-eradicating potency of the virus in 
immunocompromised animals, repeated administration of the virus would be needed. 
However, in immunocompetent mice and in humans neutralizing antibodies against the 
virus may hinder the repeated use of the same virus (Zaiss, Machado & Herschman 2009), 
thus use of different Ad serotypes or totally different viruses could maintain the treatment 
efficacy. In addition, the group of mice treated with Ad5/3-Δ24-hTNFα had significantly 
longer survival compared to other groups (P = 0.0002).  
 
Figure 16. In vivo efficacy of Ad5/3-Δ24-hTNFα in a xenograft model. a) Nude mice 
bearing PC-3MM2 tumors were treated intratumorally with PBS (Mock) or with 1x108 
VP/tumor of Ad5/3-Δ24 or Ad5/3-Δ24-hTNFα virus on days 0,1,4 and 5. Tumor growth was 
measured over time. b) Survival of nude mice bearing PC-3MM2 tumors was followed over 
time. Mice were treated with PBS or viruses as in a). Mice were euthanized when tumors 
exceeded 1.5 cm in diameter. (Hirvinen et al. 2015, Human Gene Therapy [Study I]) 
We also determined the amount of apoptotic and necrotic cells in the treated PC-3MM2 
tumors of the nude mice, but no statistical difference was found between the Ad5/3-Δ24-
hTNFα and Ad5/3-Δ24-treated groups (Figure 17). Perhaps the viral replication itself is 
already such a powerful inducer of tumor cell death by these mechanisms (Bartlett et al. 
2013) that TNFα does not bring much additional effect and benefit. The efficacy of the 
hTNFα-producing virus therefore more probably has an impact via a general inflammation 
reaction induced by TNFα in the Ad5/3-Δ24-hTNFα-treated mice followed by activation and 
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recruitment of NK cells into the treated tumors (Fiers 1991). NK cells have been shown to 
play a central role in tumor suppression after oncolytic adenovirus treatments (Cerullo et 
al. 2012). It would be interesting to further determine whether the efficacy of Ad5/3-Δ24-
hTNFα was in fact because of NK cell infiltration to tumors. 
 
Figure 17. The amounts of apoptotic and necrotic cells in the treated tumors were analyzed 
by flow cytometry. FITC-labeled Annexin-V was used to indicate the early apoptotic cells, 
and PI (propidium iodide) the necrotic or late apoptotic cells. (Hirvinen et al. 2015, Human 
Gene Therapy [Study I]) 
As the very crucial role of the adaptive immune system is now well recognized in 
determining the long-term efficacy of OV therapies (Sobol et al. 2011), we continued to 
study the efficacy of our TNFα-virus in an immunocompetent mouse model. We performed 
studies with C57BL/6 mice with syngeneic melanoma tumors (B16-OVA) to study the 
immunological responses induced by the Ad5/3-Δ24-hTNFα virus in vivo. It has been shown 
that mouse TNFα receptor TNF-RI binds both human and mouse TNFα (Fiers 1991, 
Cauwels, Fiers & Brouckaert 1996), so human TNFα is active in mice, but with less activity 
than in humans (Han et al. 2007, Asher et al. 1987, Talmadge et al. 1988). We tested two 
different regimens of virus, “mild” and “high”. In the “mild” regimen, the mice were 
treated intratumorally with 1x108 VP/tumor on early days (days 0, 1, 4 and 5), whereas in 
the “high” regimen the mice received the virus every other day (days 0, 2, 4, 6 and 8). The 
tumor growth was significantly slower with both regimens in the Ad5/3-Δ24-hTNFα-treated 
group of mice compared to the Ad5/3-Δ24 treated group (“mild” P <0.0001 and “high” 
<0.01) (Figure 18); however the tumors were not completely eradicated. Because human 
adenovirus does not replicate in murine cells, the tumor-suppressing effect was likely due 
to the inserted transgene, hTNFα. The B16-OVA cell line has actually been reported to be 
quite insensitive to TNFα (Fransen et al. 1986) and it is also a very aggressively growing cell 
line, which may explain the relatively low efficacy seen in these experiments.  
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Figure 18. Effects of the expressed hTNFα in immunocompetent mice. C57BL/6 mice 
bearing syngeneic B16-OVA tumors were treated intratumorally with PBS (Mock) or with 
1x108 VP/tumor of Ad5/3-Δ24 or Ad5/3-Δ24-hTNFα virus a) on days 0, 1, 4 and 5 or b) every 
other day on days 0, 2, 4, 6 and 8. Tumor growth was measured over time. (Hirvinen et al. 
2015, Human Gene Therapy [Study I]) 
The B16-OVA cell line expresses chicken ovalbumin (OVA), a foreign protein to the mouse 
system, which can be detected by an OVA-peptide specific MHC-I pentamer antibody in 
flow cytometric assays. Because TNFα has been reported to activate and recruit 
lymphocytes (Fiers 1991, Calzascia et al. 2007), we were interested in studying whether our 
TNFα-virus can increase T cell infiltration into the tumors of treated mice. Usage of the 
B16-OVA model enabled us to determine the degree of tumor-specific immunity developed 
in the treated mice by analyzing the OVA-specific (anti-tumor) cytotoxic T cells. We 
characterized the immune responses in tumors, spleens and lymph nodes collected from 
the mice 9 days after the first virus treatment (Figure 19). To our delight, we observed that 
the amount of CD8+ cytotoxic T cells was increased in the TNFα-virus treated tumors 
compared to mock and Ad5/3-Δ24 treated tumors (P < 0.05). Moreover, the amount of 
CD19+ cells (B cells) was significantly elevated in the Ad5/3-Δ24-hTNFα treated tumors 
compared to mock (P < 0.05). However, although increased amounts of OVA-specific 
(tumor-specific) T cells in the Ad5/3-Δ24-hTNFα treated tumors could be observed, the 
differences were not statistically significant compared to controls.  
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Figure 19. Immune cells in tumors, spleens and lymph nodes of C57BL/6 mice bearing 
B16-OVA tumors. General CD8+ cytotoxic T lymphocytes (CTLs), tumor-specific (OVA-
specific) CTLs and CD19+ B cells were measured from a) tumors, b) spleens and c) inguinal 
lymph nodes of mice treated every other day with PBS (mock) or with 1x108 VP/tumor of 
Ad5/3-Δ24 or Ad5/3-Δ24-hTNFα virus. The organs were collected 9 days after the first virus 
injection and then smashed through a filter, cultured overnight, and analyzed by flow 
cytometry. (Hirvinen et al. 2015, Human Gene Therapy [Study I]) 
In spleens and lymph nodes of the treated mice we did not find any differences in the 
amounts of infiltrated immune cells; however, the tumor-draining lymph nodes were 
visibly bigger in the Ad5/3-Δ24-hTNFα treated mice (Figure 20) compared to control virus 
suggesting higher activation of immune responses. 
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Figure 20. a) Picture of the tumor draining and non-tumor side inguinal lymph nodes of the 
treated mice on day 13 after the first virus injection. b) The sizes of the lymph nodes were 
measured from the images using Image J software. 
We measured the production of hTNFα in the tumors collected 10 days after the first virus 
treatment; the mean amount of human TNFα in the Ad5/3-Δ24-hTNFα-treated tumors was 
878 pg/ml (SD ±665). As leakage of TNFα in high concentrations into circulation has been 
shown to lead to severe toxic consequences, such as septic shock and even death (Mueller 
1998, Schiller et al. 1991, Fiers 1991), we measured the amount of hTNFα also in the serum 
of the treated mice at several time points (on days 4, 8 and 10 after the first virus 
injection). No significant amounts of hTNFα in blood circulation were observed after the 
Ad5/3-Δ24-hTNFα treatments (Figure 21), even though hTNFα was quite high in the 
tumors. The fact that hTNFα produced by the virus seems to stay mostly in the tumors and 
not leak into circulation indicates that the treatment is safe when injected intratumorally 
and should not lead to systemic toxicity even with higher doses. 
 
Figure 21. Human TNFα levels in tumor lysates and sera. C57BL/6 mice bearing B16-OVA 
tumors treated i.t. with PBS or viruses (on days 0, 1, 4 and 5) were analyzed for hTNFα 
levels by cytokine bead array. (Hirvinen et al. 2015, Human Gene Therapy [Study I]) 
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TNFα has been reported to induce secretion of other cytokines too (at least GM-CSF, IFN-
gamma, IL-6, IL-1 and IL-8) (Fiers 1991, Balkwill 2009), which together with the production 
of endothelial adhesion factors can activate and recruit various immune cells (neutrophils, 
macrophages, eosinophils, NK-cells and lymphocytes) to attack the TNF production site 
(tumor in our case). To determine if hTNFα produced by the virus would induce secretion 
of other cytokines, serum was collected from the treated mice at different time points (9 
and 13 days after the first treatment) and analyzed for the cytokine levels (mGM-CSF, mIL-
6, mIFN-  and mIL-1α) by Cytometric Bead Array (Figure 22). We also measured the 
cytokines in the tumors 13 days after the first treatment. All in all, the results showed that 
there were no differences in the cytokine amounts between the treatment groups on the 
selected days. Maybe these sampling points were timely too far from the first treatment 
and perhaps elevated amounts could be observed at earlier time points. However, these 
results indicate that there is no systemic toxicity related to the Ad5/3-Δ24-hTNFα therapy, 
in contrast to earlier reports, where elevated, long-lasting concentrations of these pro-
inflammatory cytokines in blood correlated with treatment-related toxicity (Tarrant 2010). 
The results of the in vivo studies presented here show that arming the oncolytic adenovirus 
with hTNFα results in enhanced anti-tumor efficacy in mice. The results suggested that the 
enhanced tumor-killing potency at least partly was due to an increased infiltration of 
immune cells into the treated tumors, but more thorough studies (e.g. histological studies) 
of the mechanisms-of-action of the virus would be needed to fully understand its efficacy. 
TNFα is known to increase extravasation of viruses to tumors through activation of a Rho 
A/Rho kinase pathway (Seki et al. 2011), thus it should be investigated whether the TNFα 
production by the TNF-virus increases viral uptake in the treated tumors. Moreover, many 
cell types are known to become highly susceptible to the cytotoxic effects of TNFα after 
viral infection (Fiers 1991), which may also explain the effect of our viral construct. 
8.1.3 Combining Ad5/3-Δ24-hTNFα with radiotherapy 
TNFα has been reported to also have an ability to sensitize cells to radiation (Balkwill 
2009). Therefore, we wanted to test whether combining the Ad5/3-Δ24-hTNFα treatment 
with radiation would result in enhanced tumor cell killing. First, we tested the combination 
treatment in vitro with three cell lines (A549, PC-3MM2 and B16-OVA) (Figure 23). The 
cells were infected with low dose of viruses (0.1 VP/cell) or with PBS (mock) and then 
irradiated with different doses (0, 4, 8 and 10 Gy) 24 hours later. Cell viability was 
measured by MTS assay. For unknown reason the irradiation itself had no effect on cell 
viability regardless of dose. There was also no significant difference between Ad5/3-Δ24-
hTNFα and Ad5/3-Δ24 infections with any of the cell lines. These results are fairly 
surprising since it was shown by Rajecki et al. that with 15 Gy irradiation and with the same 
dose of virus (0.1 VP/cell) the cell viability dropped to around 30 percent (Rajecki et al. 
2009). It could, however, be that 10 Gy, the highest dose we used, was not enough to kill 
the cells and perhaps we should have used higher radiation doses.  
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Figure 22. Cytokine concentrations in sera and tumor lysates. Levels of different cytokines 
(mouse GM-CSF, mouse IFN-gamma, mouse IL-6 and mouse IL-1α) were measured from a) 
tumor lysates (13 days after the first virus injection) and from serum samples b) 9 and c) 13 
days after the first virus injection) with a cytokine bead array. The samples were from 
C57BL/6 mice bearing B16-OVA tumors treated every other day on days 0, 2, 4, 6 and 8 
with PBS, Ad5/3-Δ24 or Ad5/3-Δ24-hTNFα. (Hirvinen et al. 2015, Human Gene Therapy 
[Study I]) 
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Figure 23. In vitro tumor cell killing in combination with radiation. Cell killing was 
measured with MTS assay in A549, PC-3MM2, and B16-OVA cells after treatment with 
different doses of irradiation (0, 4, 8 and 10 Gy). Cells were treated with growth medium 
only (mock) or with Ad5/3-Δ24-hTNFα or Ad5/3-Δ24 (0.1 VP/cell) 24 hours before 
irradiation. Statistical significances are against mock. (Hirvinen et al. 2015, Human Gene 
Therapy [Study I]) 
Despite the disappointing results in vitro, we however continued to study the combination 
therapy in vivo. To this end, we first performed an experiment with a prostate cancer 
xenograft model (nude mice bearing PC-3MM2 tumors) (Figure 24). The mice were first 
treated intratumorally with viruses (or PBS for mock) two days in a row (days 0 and 1) and 
then they received the first round of irradiation (2-Gy whole-body irradiation). Thereafter 
mice were allowed to recover for one day, and the same treatment scheme was repeated 
(virus treatment on days 4 and 5 and irradiation on day 6). The virus doses used per 
injection were 1x108 VP/tumor. In this prostate cancer xenograft model, we saw a clear 
reduction in tumor growth in the Ad5/3-Δ24-hTNFα -treated group compared to the 
Ad5/3-Δ24 group (P < 0.01 at day 34). Combining the Ad5/3-Δ24-hTNFα therapy with 
radiation really boosted the effect of irradiation alone (mock) or the empty control virus. 
Maybe this is, indeed, as mentioned above, due to TNFα -mediated sensitization of the 
cells to the cytotoxic effects of irradiation. To investigate this, we analyzed the amount of 
apoptotic and necrotic cells in the tumors by flow cytometry (Figure 25). We compared the 
results to those from a similar experiment done without irradiation (see Figure 17). We 
noticed that indeed, the combination therapy using radiation and the Ad5/3-Δ24-hTNFα 
virus increases the amount of necrotic/late apoptotic cells (P < 0.01), which may partly 
explain the drastic tumor growth control seen in this group of mice (Figure 24). 
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Figure 24. Tumor growth after combination treatment with virus and radiation in the 
prostate cancer xenograft model. Nude mice bearing PC-3MM2 tumors were treated 
intratumorally with PBS (mock) or 1x108 VP/tumor of Ad5/3-Δ24 or Ad5/3-Δ24-hTNFα virus 
on days 0, 1, 4 and 5. On days 2 and 6, the mice received 2-Gy whole-body irradiation. 
Tumor growth was measured over time. (XRT=irradiation). (Hirvinen et al. 2015, Human 
Gene Therapy [Study I]) 
 
Figure 25. Apoptotic and necrotic PC-3MM2 tumor cells in irradiated and non-irradiated 
tumors. The amount of early apoptotic and late apoptotic or necrotic cells at day 8 after 
the first virus infection with and without 2 times 2Gy irradiation were analyzed by flow 
cytometry from PC-3MM2 tumors of the nude mice. FITC-labeled Annexin-V was used to 
indicate early apoptotic cells and PI (propidium iodide) necrotic or late apoptotic cells. 
(Hirvinen et al. 2015, Human Gene Therapy [Study I]) 
We also studied the combination therapy in a syngeneic melanoma model in 
immunocompetent mice (C57BL/6 mice bearing B16-OVA tumors) with a treatment 
scheme identical to that used in the prostate cancer xenograft model. In this 
immunocompetent model, tumor growth was significantly reduced (P < 0.05) in the Ad5/3-
Δ24-hTNFα treated group compared to mock-treated group, but there was no significant 
difference between Ad5/3-Δ24-hTNFα treated and Ad5/3-Δ24 treated groups (Figure 26). 
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The lack of efficiency of Ad5/3-Δ24-hTNFα may be because of the known radioresistant 
nature of melanomas (Fertil & Malaise 1985); however, the duration of the follow-up 
period in this experiment was so short due to the aggressive nature of the B16-OVA cell 
line that no definitive conclusions can be drawn.  
 
Figure 26. Tumor growth after combination treatment with radiation in a syngeneic 
melanoma model. C57BL/6 mice bearing B16-OVA tumors were treated intratumorally 
with PBS (mock) or with 1x108 VP/tumor of Ad5/3-Δ24 or Ad5/3-Δ24-hTNFα virus on days 0, 
1, 4 and 5. On days 2 and 6 the mice received 2-Gy whole-body irradiation. Tumor growth 
was measured over time. (Hirvinen et al. 2015, Human Gene Therapy [Study I]) 
In summary, in Study I we showed effective tumor cell killing by the Ad5/3-Δ24-hTNFα 
virus both in vitro and in vivo, which was associated with signs of immunogenic cell death. 
The virus also enhanced recruitment of adaptive immune cells to the infection site. We saw 
some potential for combining the Ad5/3-Δ24-hTNFα therapy with radiation: it was shown 
to result in enhanced tumor growth control and increased necrotic tumor cell death. 
Further studies to discover the mechanisms-of-action of the virus and deeper insight into 
its effects on the immune system should be conducted. Because TNFα is known to cause 
selective permeabilization of tumor vasculature and thereby increase the uptake of 
therapeutic agents into tissues (Seki et al. 2011, Balkwill 2009), a combination therapy with 
chemotherapeutics would also be worth considering.  
 
8.2. Improving the vaccine and adjuvant potency of oncolytic 
vaccinia virus by arming with self-recognizing receptor DAI (II) 
Vaccinia viruses (VVs), like adenoviruses, are one of the most extensively used viruses in 
immunotherapy studies and have a long track record of safety as well as a fast replication 
cycle making them intriguing vectors for oncolytic virotherapy. However, VVs encode 
several immunosuppressive genes and are thus well prepared to hide from the host 
immune system, which hampers their applicability as immunovirotherapeutics. Therefore, 
in Study II we developed a new oncolytic vaccinia virus that expresses a pattern recognition 
receptor DAI (DNA-dependent activator of interferon-regulatory factors) to improve the 
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immunostimulatory potency of vaccinia virus for enhanced activation of anti-tumor 
immune responses. We hypothesized that arming a cancer therapy virus with a receptor 
that regulates and induces the production of a number of different immunostimulatory 
molecules would generate a more robust immunological response than just arming the 
virus with a single cytokine (Lladser et al. 2011, Smith et al. 2013). This fierce immune 
response could eventually break the immunosuppressed conditions often found in 
advanced tumors (Schreiber, Old & Smyth 2011, Devaud et al. 2013, Igney & Krammer 
2002) and in VV infected tissues (Smith et al. 2013). 
8.2.1. Is DAI able to sense vaccinia virus infection? 
PRRs, such as toll-like receptor 2 (TLR2) (Zhu, Huang & Yang 2007, Quigley et al. 2009) and 
TLR8 (Martinez, Huang & Yang 2010), as well as AIM2 (Rathinam et al. 2010) have been 
identified as mediators of innate immune responses against vaccinia virus. However, none 
of these mediators is known to trigger type I interferon expression, which however is 
known to be elicited upon VV infection. Zhu et al. showed that an additional, as yet 
unidentified TLR-independent pathway also contributes to the response (Zhu, Huang & 
Yang 2007). A little later, Takaoka et al. demonstrated that a cytosolic DNA sensor called 
DAI (also known as DLM-1 or ZBP1) can induce type I interferons upon binding to double-
stranded DNA (Takaoka et al. 2007). Since DNA is normally contained in the nucleus of a 
cell, it uses cytosolic PRRs, such as DAI as indicators of a viral infection. Indeed, DAI has 
recently been reported to sense at least adenoviral (Schulte et al. 2013) and HSV DNA 
(Triantafilou, Eryilmazlar & Triantafilou 2014, Pham et al. 2013). Because the whole life 
cycle of VV is retained in the cytosol of the host cell, we hypothesized that DAI could be a 
sensor also for VV infection and play a role in the induction of innate immune responses. 
In Study II, we first examined the role of DAI in controlling infection with live vaccinia virus. 
We used Jurkat cells silenced for DAI by stable transfection of a plasmid encoding siRNA 
against DAI. As a control we used Jurkat cells expressing siRNA against luciferase. We 
observed that when the cells were infected with VV (vvdd-GFP), IFNβ production, as 
analyzed by IFNβ gene expression (qPCR) and protein expression (ELISA) after VV infection, 
was significantly reduced in the DAI-silenced cells (P = 0.005 and P = 0.002, respectively) 
(Figure 27a and b). On the contrary, in control cells, IFNβ production increased 2.7-fold 
compared to uninfected cells. 
Type I interferons activate interferon regulatory factors (IRFs). This promotes synthesis and 
secretion of pro-inflammatory cytokines through the NF-κB pathway. Thus, we investigated 
whether DAI would have an effect on the secretion of cytokines also after VV infection. We 
measured interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα) secretion in the 
supernatants of infected and uninfected modified Jurkat cells 24 hours after infection 
(Figure 27c). Prior to infection, the cytokine levels were very low or undetectable in both 
cell lines. After VV infection Jurkat-psiRNA-luc cells showed significantly higher Il-6 (P = 
0.04) and TNFα (P = 0.01) concentrations compared to DAI-silenced cells. These results 
suggest that DAI might be an important mediator of innate immunity during vaccinia virus 
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infection, which moreover suggests utility of this PRR as an adjuvant for VV vectors to 
boost innate immune responses followed by possible activation of adaptive immunity. 
Actually, recently Dai et al. reported that a newly discovered cytosolic DNA sensor called 
cGAS can also trigger type I IFN responses after modified vaccinia virus Ankara (MVA) 
infection through STING-mediated pathway in conventional murine dendritic cells (Dai et 
al. 2014).  This just shows that little is still known about vaccinia virus immunity and that 
our finding of DAI – vaccinia virus interaction is only one of the many ways vaccinia viruses 
interact with their hosts. 
 
Figure 27. DAI mediates induction of type I interferon and cytokine release during VV 
infection. Jurkat cells silenced for DAI with psiRNA-DAI or control cells transfected with 
psiRNA-luc were infected with vvdd-GFP and IFN-β was quantified by a) qPCR and b) ELISA. 
c) Il-6 and TNFα was measured by FACSarray from the supernatant before (-VV) and 24 
hours after vvdd-GFP infection (+VV). 
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8.2.2. In vitro oncolytic efficacy of DAI-armed vaccinia virus 
The finding that DAI can induce activation of innate immune responses during VV infection 
encouraged us to generate a novel oncolytic vaccine for cancer immunovirotherapy; our 
approach uses an oncolytic vaccinia virus construct that rapidly replicates specifically in 
tumor cells and expresses DAI at the infection site. Since the virus amplifies the expression 
of a receptor that senses viral DNA and triggers cytokine expression, the generated virus is 
a self-amplifying system that can boost viral immunogenicity and cellular immune 
responses at the tumor site regardless of cellular expression levels of DAI.  
We cloned two oncolytic VVs, one coding for human (vvdd-tdTomato-hDAI) and the other 
coding for mouse DAI (vvdd-tdTomato-mDAI) (Figure 28). The viruses are of the Western 
Reserve strain and double-deleted for the viral thymidine kinase (TK) gene and for the 
vaccinia growth factor (VGF) gene (Parviainen et al. 2014, McCart et al. 2001, Guse et al. 
2010). These deletions make the virus able to replicate only in cancer cells where the 
corresponding pathways are mutated and constantly activated (Thorne et al. 2007, Buller 
et al. 1988) (see Figure 7). The viruses also express tdTomato, a red fluorescent protein for 
imaging purposes and biosafety concerns (Parviainen et al. 2014, Shaner et al. 2008). 
Figure 28. Schematics of the generated double-deleted oncolytic vaccinia viruses 
expressing DAI and tdTomato. (Hirvinen et al. 2016, Molecular Therapy – Oncolytics [Study 
II]) 
The functionality of the viruses, vvdd-tdTomato-hDAI and vvdd-tdTomato-mDAI, was 
tested in tumor cell killing assays (MTS viability assays) with several cancer cell lines 
(human PC-3MM2, A549, HS294T, SK-MEL-2, A2058 and murine B16-OVA cells). The cancer 
cell killing potency of the DAI-viruses was compared to a control virus without DAI 
expression (vvdd-tdTomato). We found no difference in the cell-killing efficacy between 
the DAI-virus and the control; hence we can conclude that the inserted transgene at least 
does not hinder oncolytic activity of the virus (Figure 29).  
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Figure 29. Cancer cell-killing efficacy in vitro. MTS cell viability assays were performed in 
several human and mouse cancer cell lines 5 days after infection with vvdd-DAI or control 
virus. (Hirvinen et al. 2016, Molecular Therapy – Oncolytics [Study II]) 
8.2.3. Effects of vvdd-tdTomato-DAI infection on cellular gene expression  
Next we studied the effect of DAI expression by the virus on the gene expression profile of 
infected cells. We infected human melanoma cells (HS294T) and human monocyte cells 
(THP-1) with vvdd-tdTomato-hDAI or with the control virus vvdd-tdTomato (0.1 pfu/cell). 
Sixteen hours after infection, whole genomic mRNA was extracted and a wide-genome 
gene expression profile was analyzed and the gene expression levels were compared to 
non-infected cells (mock). In the DAI-virus infected cells, there was approximately a 7-fold 
increase in the expression levels of DAI in both cell lines (7.4 and 7.2 in THP1 and HS294T, 
respectively) compared to control cells infected with unarmed virus, as expected. 
Differentially expressed genes were plotted by BACA representing tools (Fortino, Alenius & 
Greco 2015) according to different biological processes (Figure 2 of Study II). The BACA plot 
analysis revealed highly differing expression patterns in the THP-1 monocyte cell line 
infected with DAI-expressing or the non-expressing viruses. An ingenuity pathway analysis 
(IPA) showed that the most up-regulated genes in the DAI-virus infected cells belong to 
important immunological pathways, including maturation of dendritic cells, 
communication between the innate and adaptive immune systems and virus sensoring 
PRRs (Supplementary Figure S2 of Study II). These findings are very intriguing because they 
show that DAI has the ability to alter the immunogenicity of an oncolytic vaccinia virus and 
it can induce activation of genetic pathways related to innate and adaptive immune 
systems. For instance the notion that DAI has potential to activate pathways belonging to 
DC activation is intriguing because we know that oncolysis can release tumor-associated 
antigens to the microenvironment, to be further  presented to T cells by DCs followed by 
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possible activation of adaptive, tumor-specific immunity (Miller & Fraser 2003, Nakamori 
et al. 2004). 
8.2.4. In vivo efficacy and immunogenicity of vvdd-tdTomato-mDAI in 
syngeneic mouse melanoma model 
We then studied the in vivo efficacy of the DAI-virus in an immunocompetent murine 
melanoma model. The immunogenic potency of the DAI-virus was tested in vivo using an 
aggressive syngeneic melanoma model. C57BL/6 mice bearing subcutaneous B16-OVA 
tumors (12 mice/ group, one tumor/ mouse) were treated intratumorally with vvdd-
tdTomato-mDAI or the control vvdd-tdTomato or PBS (mock) two times on day 0 and 2. 
Tumor growth in mice treated with mDAI-expressing virus was significantly (P < 0,001) 
reduced compared to mice treated with the control virus (Figure 30); in fact the majority of 
tumors treated with mDAI-virus were completely cured, which is a very promising result in 
such an aggressive tumor model.  
 
Figure 30. In vivo efficacy of i.t. vvdd-tdTomato-mDAI in treatment of syngeneic B16-OVA 
melanomas. Immunocompetent C57BL/6 mice bearing B16-OVA tumors (1 tumor/mouse, 
n=12 mice/group) were treated intratumorally with PBS (mock) or with viruses on days 0 
and 2. (Hirvinen et al. 2016, Molecular Therapy – Oncolytics [Study II]) 
To study the induction of immune responses after vvdd-DAI treatments, we collected 
tumors of some of the mice (4/group) 12 days after the first virus treatment. Infiltration of 
T cells (CD8+, CD4+ and tumor-specific (OVA-specific) cytotoxic T cells) were analyzed by 
flow cytometry. We did not observe significant differences in the amounts of T cells 
between the groups, probably due to the low number of tumors analyzed. But there was a 
positive trend towards an increased amount of T cells in mDAI-virus treated tumors 
(Figures 3b and c of Study II).  
Anti-tumor immunity induced by the vvdd-tdTomato-mDAI was also determined in 
untreated distant tumors. This was tested by re-challenging the treated mice by injection 
of a second tumor of same origin. We did not treat the mice anymore; we only monitored 
whether the second tumor would grow or not, i.e. if systemic immunity was generated 
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against the tumor that would prevent the growth of new tumors. We actually re-
challenged part of the mice with exactly the same tumor cell line (B16-OVA) and the rest of 
the mice with B16-F10 cells, which is a parental line of B16-OVA and without expression of 
the immunogenic chicken ovalbumin protein. We gladly saw that the mice, whose first 
primary tumor had been treated with vvdd-tdTomato-mDAI, completely rejected the 
engrafted second B16-OVA tumor, whereas in mice not treated with virus (mock) or 
treated with the control virus secondary tumors developed (Figure 31).  
 
Figure 31. Growth of untreated distant tumors after vvdd-mDAI therapy. C57BL/6 mice 
first received one B16-OVA tumor, which was treated on days 0 and 2. Ten days after the 
first treatment, the mice were re-challenged with another tumor. The second tumor was 
not treated; only the tumor growth was monitored. (Hirvinen et al. 2016, Molecular 
Therapy – Oncolytics [Study II]) 
The treatment with the mDAI-virus was also able to control, at least to some extent, the 
growth of a secondary B16-F10 tumor as only half of the mice developed a second tumor, 
whereas all the mice treated with the control virus or PBS developed a second tumor 
(Figure 4C of Study II). These results suggest that the DAI-virus treated mice had developed 
systemic anti-tumor immunity. This immune response was mostly directed towards the 
immunogenic foreign OVA protein, as deduced from the tumor growth results; however 
immunity against other tumor-specific antigens would probably develop as well. To 
investigate this, we collected the spleens of the treated, re-challenged mice and analyzed 
the amount of IFNγ producing (i.e. activated) T cells in each animal group by ELISpot assay. 
We pulsed the splenocytes with SIINFEKL peptide (OVA-specific peptide) and with peptides 
derived from the natural melanoma-associated antigens TRP-2 (SVYDFFVWL) and gp100 
(KVPRNQDWL) to analyze anti-tumor T cell responses. To also analyze the anti-viral 
responses, we challenged the cells with vaccinia peptides.  
The anti-tumor T cell responses were increased in the DAI-virus treated mice, especially 
when the mice were re-challenged with the B16-OVA tumor cell line (Figure 32), and 
intriguingly, we also saw responses against the clinically relevant melanoma antigens TRP-2 
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and gp100. Interestingly, the anti-viral responses were relatively similar in both vvdd-
tdTomato and vvdd-tdTomato-mDAI treated mice (Figure 32), even though the 
mechanism-of-action of the virus was hypothesized to rely on enhanced recognition of the 
virus DNA and thereby lead to induction of enhanced immune responses in the infection 
site (i.e. tumor). 
We showed that the DAI-armed vaccinia virus can significantly reduce tumor growth and 
has potential to induce T cell infiltration and to activate tumor-specific immunity in 
immunocompetent mice with B16 melanoma tumors. We also showed that systemic anti-
tumor response induced by the DAI-virus may even control growth of distant non-treated 
tumors. However, to be able to draw any definitive conclusions about anti-tumor immunity 
in the DAI-virus treated mice, these experiments should be repeated with larger groups to 
increase the statistical power.  
 
Figure 32. IFNγ producing T cells after vvdd-mDAI therapy. Splenocytes from mice 22 days 
after virus treatments were cultured with tumor-associated or virus-derived peptides for 36 
hours and the amount of activated T cells was assessed by ELISpot. Cumulative spot count 
and representative pictures of the ELISpot wells of B16-OVA re-challenged mice are shown. 
(Hirvinen et al. 2016, Molecular Therapy – Oncolytics [Study II]) 
8.2.5. In vivo efficacy of vvdd-tdTomato-hDAI in humanized mice 
To illustrate the translational potency of the DAI-virus in treatment of human cancers we 
performed a study engrafting mice with human melanoma tumors (HS294T) and some 
elements of the human immune system. We injected HS294T cells into the flanks of highly 
immunosuppressed NSG mice and allowed the tumors to grow until injectable. We then 
injected human peripheral blood mononuclear cells (PBMCs) obtained from a healthy 
donor into the tail vein of the mice to partially reconstruct the human immune system. 
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PBMCs (HLA-A*03*32, -B*07*27, -C*06*07) and the tumor cells (HLA-A*01*25, -B*07*08, 
-C*07*07) were partly HLA-matched. We then treated the tumors two times with vvdd-
hDAI or controls. vvdd-hDAI treatments resulted in significant inhibition of tumor growth (P 
< 0.001) (Figure 33a). Indeed, the treatment efficacy was absent in mice that had not 
received human PBMCs (Figure 33b), i.e. lacked matching cellular immunity, suggesting an 
important role for T-cell/HLA interactions in tumor eradication by the DAI-virus.  
Because the immune cells and tumor cells were not completely HLA-matched, there was 
undoubtedly risk of alloreactivity, i.e. graft-versus-host responses, which also could have 
affected tumor growth (observed as slow growth of untreated tumors). However, the mock 
group controls the effect of viruses and therefore, regardless of the possible alloreactivity 
the effect of DAI-virus could be determined. To be able to rule out the graft-versus-host 
reactions, completely matched tumors and immune cells should be used in these 
humanized mouse models. This, however, would require samples from actual cancer 
patients, which at this point could not be obtained.  
 
Figure 33. In vivo efficacy of vvdd-hDAI in a humanized mouse melanoma model. a) 
Growth of human melanoma HS294T tumors in human PBMC engrafted NSG mice after virus 
treatments on days 0 and 6. b) Comparison of the tumor growth in   hPBMC-engrafted mice and 
mice that did not receive hPBMCs. (Hirvinen et al. 2016, Molecular Therapy – Oncolytics 
[Study II]) 
To further elucidate the possible mechanism behind the enhanced anti-cancer efficacy of 
the hDAI-virus, we analyzed the relative amounts of human CD8+ and CD4+ T cells by flow 
cytometry in tumors, spleens and lymph nodes of treated mice 18 days after the first 
treatment. There was increased infiltration of human cytotoxic cells in tumors of vvdd-
hDAI treated mice compared to control virus treated mice (P < 0.01) (Figure 34).  
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Figure 34. Presence of human T cells in the tumors of vvdd-hDAI treated humanized mice. 
Human CD8+ and CD4+ T cells were analyzed by flow cytometry from the HS294T human 
melanoma tumors 18 days after the first virus treatment. (Hirvinen et al. 2016, Molecular 
Therapy – Oncolytics [Study II]) 
There was also a trend (not significant) towards an increased presence of T lymphocytes in 
the spleens and blood of the DAI-virus treated mice (Figure 6B and 6C of Study II). Also 
Lladser et al. have shown that DAI is an efficient genetic adjuvant for DNA vaccines; they 
showed enhanced induction of antigen-specific T cell responses after DAI incorporation 
(Lladser et al. 2011).  
In summary, in Study II we generated a novel oncolytic virotherapy platform for cancer 
immunotherapy. The engineered oncolytic vaccinia virus expresses a DAI protein, a 
molecular pattern sensor able to bind VV DNA produced in the cytoplasm of infected cells 
and effectively boost innate immune responses during infection. Insertion of the DAI 
transgene was well tolerated and did not hinder the oncolytic potency of the virus. Most 
importantly, the DAI-expressing virus showed improved efficacy and immunogenicity in 
vivo both in immunocompetent murine and human melanoma models. Expression of a 
receptor that recognizes viral DNA seems to be a potent and novel way to improve the 
adjuvant potency of viral drugs. This platform has potential applications in vaccine design 
where improved immunogenicity and efficacy are beneficial. We hypothesized that arming 
the virus with a receptor that induces multiple immunostimulatory molecules would 
generate a more robust immunological response than just arming the virus with a single 
cytokine; therefore, it would be interesting in the future to compare the efficacy of this DAI 
expressing virus with some other oncolytic VVs that express a single cytokine or other 
immunostimulatory molecules. 
 
8.3. FcγR polymorphisms favorable to cancer therapy: Identification 
of patients with increased responsiveness to oncolytic 
adenovirus treatments (III) 
With the increasing experience accumulating from studies with oncolytic viruses and 
different cancer patient populations, it is becoming clear that there is wide variance in 
treatment responsiveness between patients. A similar phenomenon has also been 
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observed with other immunotherapeutics including monoclonal antibodies (Rodriguez et 
al. 2012) and cancer vaccines (Weng, Czerwinski & Levy 2007, Wang et al. 2010). Oncolytic 
viruses are nowadays considered immunotherapeutics as well, and the immune system is 
increasingly being reported as an important entity governing the efficacy of OV therapies 
(Kanerva et al. 2013, Cerullo et al. 2010, Diaconu et al. 2012, Alemany & Cascallo 2009). 
Thus, genetic and phenotypic differences in the immune system between patients might at 
least in part explain the variance seen in the response to oncolytic virotherapy. Fc gamma 
receptors (FcγRs) are key players in the immune defense against infections and 
malignancies (van Sorge, van der Pol & van de Winkel 2003), and polymorphisms occurring 
in these receptors have been associated with both the disease severity (van Sorge, van der 
Pol & van de Winkel 2003, Li et al. 2009) and the responsiveness to immunological cancer 
therapies (Clynes et al. 2000, Musolino et al. 2008). As oncolysis by viral infection of cancer 
cells also seems dependent on cooperation with a patient’s immune system, we wanted to 
analyze in Study III whether patient FcγR genotypes would dictate and correlate with 
responsiveness to oncolytic adenovirus treatments, and if these polymorphisms could 
perhaps serve as prognostic and/or predictive biomarkers in oncolytic virotherapy to 
better enable stratification of patients for the selected therapy. To implement this we 
genotyped more than 200 cancer patients, who had undergone adenovirus therapy, for 
two prominent Fc gamma receptor (FcγR) polymorphisms. 
8.3.1. Genotypic frequencies of polymorphisms  
We identified Fc gamma receptor genotypes of 235 patients treated with oncolytic 
adenoviruses in the Advanced Therapy Access Program (ATAP) conducted in Docrates 
Cancer Center in Helsinki from 2007 to 2011. The patients had various advanced cancers 
refractory to conventional therapies (see Table 5). DNA was extracted from blood clot 
sample leftovers from the samples previously collected for monitoring efficacy and safety 
implications from the serum. We genotyped the patients for two FcγR single nucleotide 
polymorphisms (SNPs), FcγRIIa-H131R and FcγRIIIa-V158F, by TaqMan-based qPCR. 
Samples were run in triplicate. Genotyping was successful in 233 patients; the quality of 
the extracted DNA was too poor in two samples and we were unable to obtain reliable 
genotyping results; therefore these two patients were excluded from the study.  
The obtained frequencies of FcγRIIa and FcγRIIIa polymorphisms did not differ significantly 
from the expected ratios of the Hardy-Weinberg equilibrium with χ2=0.72 (P<0.5) and 
χ2=0.01 (P<0.9), respectively. The distribution of FcγRIIa and FcγRIIIa genotypes obtained in 
our study population was also relatively similar to those previously reported for Caucasian 
(Zhang et al. 2007, van der Pol et al. 2003, Leppers-van de Straat et al. 2000, Van Den Berg 
et al. 2001, Applied Biosystems a, Applied Biosystems b) and Finnish (Sarvas, Vesterinen & 
Makela 2002) populations (Table 6). This confirms the reliability of the genotyping 
performed in this study.  
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We observed a weak linkage disequilibrium (LD), i.e. non-random distribution of alleles, 
between these two polymorphic receptor loci by using a 2-locus linkage disequilibrium 
analysis (D’=0.28; P<0.01) (Table 6). This is in line with previously reported studies in Dutch 
(van der Pol et al. 2003) and Spanish (Morgan et al. 2006) populations. 
Table 6. Observed FcγR allotype frequencies and linkage disequilibrium statistics 
 
(Hirvinen et al. 2013, J. Trans Med [Study III]) 
8.3.2. Correlations of FcγR genotypes with OV treatment efficacy and 
patient survival 
The role of FcγR polymorphisms in determining the efficacy of immunotherapies is 
increasingly recognized. Therefore, we assessed the association of FcγRIIa and FcγRIIIa with 
clinical response to, and survival post oncolytic adenovirus therapy. 
We first correlated the different FcγR genotypes (FcγRIIa-HH, HR or RR, and FcγRIIIa-VV, VF 
or FF) with the overall survival (OS) of the patients (i.e. time from the first treatment with 
oncolytic adenoviruses until the end of the follow-up period or death). The survival 
estimations were performed for each genotype using Kaplan-Meier analysis. The median 
OS in the study cohort was 130 days. We did not observe statistically significant differences 
in OS between any of the FcγRIIa/IIIa genotypes (FcγRIIa HH vs. HR vs. RR, P=0.335; FcγRIIIa 
VV vs. VF vs. FF, P=0.193) (Figure 35).   
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Figure 35. FcγRIIa or FcγRIIIa genotype correlations with patient survival. Kaplan-Meier 
estimates of overall survival by (a) FcγRIIa-H131R and (b) FcγRIIIa-V158F genotypes. 
Survival time is presented in days after the first treatment with oncolytic adenovirus. Total 
N of patients included in the analyses is 233. Censored refers to patients still alive at the 
time of performing the analysis. CI = confidence interval. (Hirvinen et al. 2013, J. Trans Med 
[Study III]) 
Moreover, we wanted to determine if the FcγR polymorphisms would correlate with 
clinical response to the treatments. In order to do this, we categorized the patients into 
two groups based on their tumor imaging and tumor marker data: i) Disease control (DC) 
group, i.e patients with stable disease or better and ii) patients with Progressive disease 
(PD). As with survival correlations, we did not find any differences in the distribution of the 
clinical responses between patients with different genotypes (Figure 36).  
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Figure 36. Clinical outcome of patients treated with oncolytic adenoviruses by (a) FcγRIIa-
H131R and (b) FcγRIIIa-V158F genotypes. Objective clinical outcome could be determined 
for 134 patients. DC= disease control (i.e. stable disease or better); PD= progressive disease. 
Correlations were analyzed by χ2 test. (Hirvinen et al. 2013, J. Trans Med [Study III]) 
Thus, in summary, no correlation was found between the individual FcγR genotypes to 
survival or clinical response. Before conducting the correlation studies we were expecting 
“strong-binding” genotypes (FcγRIIa-HH and FcγRIIIa-VV) to predict response to therapy, 
because we thought that more efficient effector cells would clear the Ab-coated tumor 
cells faster. Many advanced tumors have however gained an ability to escape from the 
host immune system by lowering the expression of tumor-associated antigens on their 
surface. Therefore, these tumors are no longer recognized as foreign and thus not bound 
by IgG, which makes the tumors “invisible” for the FcγR-bearing effector cells, thus 
explaining why the “strong-binding” genotypes showed no association with the outcome 
parameters or better survival.  
8.3.3. Correlation of FcγR genotype combinations with survival and 
outcome after OV therapy 
Different classes of FcγRs mediate Ag-Ab complex binding in a cell-specific manner, for 
example, FcγRII is mostly found on antigen presenting cells, while FcγRIII is more relevant 
for this activity of NK cells (Li et al. 2009). FcγRs function in concert with each other and 
their interplay defines the function of the effector cell (Nimmerjahn & Ravetch 2008). Also, 
co-expression of different FcγRs is supposed to result in a synergistic activation of the 
effector cells leading to enhanced efficacy for IC clearance (Li et al. 2009). Hence, we aimed 
to study the effects of multiple different genotype combinations of the allelic FcγRIIa-
H131R and FcγRIIIa-V158F polymorphisms on patient survival and treatment outcome. 
There are nine possible genotype combinations of FcγRIIa and FcγRIIIa (Table 7). 
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Table 7. Observed frequencies of genotype combinations in the study cohort. 
 
(Hirvinen et al. 2013, J. Trans Med [Study III]) 
We first assessed the survival estimations for all nine possible genotype combinations 
using Kaplan-Meier analysis (Figure 37).  
Interestingly, there was one genotype combination, FcγRIIIa-VV plus FcγRIIa-HR (VVHR), 
that stood out as a prognostic marker for poor survival after oncolytic adenovirus 
treatments (Figure 37h). The survival estimate after oncolytic virotherapy for VVHR 
patients was significantly (P = 0.032) shorter than for patients with any other genotype 
combinations with a median of 113 days (95% CI: 54.1-171.9) versus 138 days (95% CI: 
112.6-163.4), respectively (Figure 38). 
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Figure 37. Survival estimates of each FcγR genotype combination. Overall survival of 
cancer patients plotted for each FcγR genotype combination versus others (Kaplan-Meier 
estimate). (a) FFHH (n=24), (b) FFHR (n=61), (c) FFRR (n=39), (d) VFHH (n=30), (e) VFHR 
(n=39), (f) VFRR (n=22), (g) VVHH (n=7), (h) VVHR (n=10), (i) VVRR (n=1). Censored refers to 
patients still alive at the time of performing the analysis. (Hirvinen et al. 2013, J. Trans Med 
[Study III]) 
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Figure 38. Survival estimate of VVHR genotype combination in oncolytic adenovirus 
treatments. Kaplan-Meier estimate of OS after the first treatment with oncolytic 
adenovirus until death or end of follow-up as plotted by VVHR genotype combination versus 
all others. The OS estimation for patients with VVHR genotype combination is significantly 
(P = 0.032) worse than with any other genotype combination, implying application in 
oncolytic adenovirus therapy. (Hirvinen et al. 2013, J. Trans Med [Study III]) 
To clarify if the VVHR genotype combination was predicting survival only in oncolytic 
virotherapy or was a useful measure for predicting OS of cancer patients in general, we 
compared the survival after cancer diagnosis between VVHR patients and all other 
genotypes. No significant correlation was found between the analyzed groups (P = 0.248) 
indicating that the VVHR genotype is not prognostic for cancer patients per se, but only in 
the context of oncolytic virotherapy (Figure 39).  
To investigate whether the VVHR genotype combination is also predictive for patient 
outcome after the oncolytic adenovirus treatments, we performed correlations of the 
clinical data (i.e. imaging and tumor marker data) with the genotype combinations versus 
all other patients (Figure 40). Unfortunately, outcome evaluation data was available only 
for five patients with the VVHR genotype combination, thus lowering the statistical power 
of the analysis. However, there was a trend towards a poor outcome estimate for the 
VVHR patients supporting the similar data of poor OS estimate in the survival analysis.  
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Figure 39. Survival estimate of VVHR genotype combination after cancer diagnosis. 
Kaplan-Meier estimate of patient survival from the year of cancer diagnosis until the year 
of death or last follow-up plotted as VVHR genotype combination against all other 
combinations. Results reveal that the VVHR genotype is not prognostic per se. (Hirvinen et 
al. 2013, J. Trans Med [Study III]) 
 
Figure 40. Clinical outcome of patients with VVHR genotype combination versus all 
others. Objective clinical outcome could be determined for 134 patients. Outcome data was 
available only for 5 patients with the VVHR genotype combination. Correlations were 
analyzed by χ2-test. (Hirvinen et al. 2013, J. Trans Med [Study III]) 
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FcγRIIIa receptors are mainly expressed on natural killer cells (Ravetch & Bolland 2001). 
Together with CTLs, NK cells have a crucial role in determining the efficacy of oncolytic 
viruses (Alvarez-Breckenridge et al. 2012). NK cells can mediate tumor cell killing in an 
antibody-dependent manner by ADCC (van Sorge, van der Pol & van de Winkel 2003). 
Instead, FcγRIIa receptors are widely distributed on many immune cell types, but are 
considered to be prominent on phagocytic cells, including antigen presenting cells (APC) 
(Jefferis & Lund 2002). Decent presentation of tumor-associated antigens by APCs is a key 
for induction of long-term T cell memory against tumors.  
We hypothesized that perhaps the strong binding to tumor cells of FcγRIIIa-VV -expressing 
NK cells causes effective ADCC and the tumor cell is eliminated fast by NK cells also 
resulting in fierce anti-viral ADCVI (antibody-dependent cell-mediated virus inhibition) 
(Forthal & Moog 2009) before the virus has had time to replicate. Hence, such highly 
efficient NK cell response and only an intermediate antigen-presentation by FcγRIIa-HR 
expressing APCs of VVHR individuals may reduce the efficacy of OV therapy, and therefore 
this genotype combination is predictive of poor survival post OV therapy. We could 
speculate that individuals with VVRR would have an even worse survival estimate due to 
the even “weaker-binding” FcγRIIa-RR genotype. Unfortunately there was only one patient 
with such genotype combination in the study cohort, so we had no opportunity to verify 
this result.  
8.3.4. Studies on the effect of different arming molecules on survival of 
patients with different FcγR genotypes  
Most of the patients included in this study had been treated with viruses armed with 
immunostimulatory transgenes (GM-CSF-armed viruses: 71.9 % and CD40L-armed viruses: 
15.7 %). As shown in several clinical studies already (Ranki et al. 2014, Andtbacka et al. 
2015, Burke et al. 2012), arming oncolytic viruses with effectors like GM-CSF or CD40L can 
be beneficial for patients due to the ability of these molecules to recruit immune cells to 
the tumor site. Armed viruses were also beneficial (P < 0.0005) for the patients of this 
study cohort (Figure 41), with both insert molecules. The treatment benefit was even 
clearer if the patient received both the GM-CSF and CD40L-bearing virus during the 
treatment (Figure 41d).  
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Figure 41. Overall survival of patients irrespective of their FcγR genotypes as correlated 
with the type of virus used. OS estimates of patients treated with (a) armed viruses vs. 
unarmed viruses, (b) GM-CSF-armed viruses vs. other viruses, (c) CD40L-armed viruses vs. 
other viruses and (d) patients who received both GM-CSF and CD40L-armed viruses during 
their treatment. 
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It has been shown that many inflammatory and costimulatory molecules, including GM-CSF 
and CD40L can alter FcγR expression and FcγR-mediated immune responses. GM-CSF and 
IFN-γ have been shown to increase the expression of FcγRIIa and FcγRIIIa (Hartnell, Kay & 
Wardlaw 1992, Capsoni et al. 1991, Rossman et al. 1993) thus activating biological activity 
of effector cells. In contrast, some studies have shown that immunostimulatory molecules 
may distract and downregulate FcγR-mediated immune functions (Kruger et al. 1996, 
Buckle & Hogg 1989, Huang et al. 2011). Therefore we wanted to determine whether the 
inserted effector molecule also has an impact on the survival of patients who have 
different FcγR genotypes and genotype combinations (see all results from Study III article, 
Table 2 and Supplementary Table S3). Our results revealed two genotype combinations, 
FcγRIIIa-FF + FcγRIIa-HR (FFHR) and FcγRIIIa-FF + FcγRIIa-RR (FFRR), which were beneficial if 
the patient also received GM-CSF-armed viruses (P < 0.004 and P < 0.006, respectively) 
(Figure 42a and b). In contrast, treatment of these patients with unarmed viruses 
correlated with significantly shorter survival after OV therapy (P < 0.0005 and P = 0.016, 
respectively). Additionally, treating FcγRIIIa-FF + FcγRIIa-HH (FFHH) individuals with a 
CD40L-armed virus resulted in more prolonged survival compared to treatment with other 
viruses (P = 0.047) (Figure 42c). As, however, this genotype group treated with the CD40L-
armed virus only included four patients the reliability of the results remains limited.  
Interestingly, all those genotype combinations (FFHR, FFRR, and FFHH) whose treatment 
with the recombinant viruses was found to be beneficial contained the FcγRIIIa-FF 
genotype. Due to these “weak-binding” receptors on their NK cells, their tumors may exert 
less innate resistance to NK-cell -mediated killing. When a potent NK recruitment signal is 
eventually provided, i.e. by virally produced GM-CSF or CD40L, NK anti-tumor efficacy may 
increase. So, it can be speculated that a hypothetical lower baseline activity of the NK cells 
is compensated by the immunostimulatory features of GM-CSF and CD40L resulting in 
immunological activation that eventually results in longer survival in individuals with FFHR, 
FFRR, and FFHH genotype combinations. 
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Figure 42. Correlation of patient survival with different FcγR polymorphisms and the 
differently armed viruses revealed three genotype combinations beneficial to treatment 
outcome. Kaplan-Meier analyses show the effect of insert (GM-CSF, CD40L, or unarmed) on 
genotype combinations. Calculations were made by first restricting the study population to 
individual genotype combinations and then comparing the OS between treatment virus 
types vs. others. (Hirvinen et al. 2013, J. Trans Med [Study III]) 
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In summary, in Study III we found one genotype combination (FcγRIIIa-VV + FcγRIIa-HR) 
predictive of poor overall survival after oncolytic adenovirus therapy. Additionally some 
genotype combinations were found to be beneficial for treatments with cytokine-armed 
oncolytic adenoviruses: FcγRIIIa-FF + FcγRIIa-HR (FFHR) and FcγRIIIa-FF + FcγRIIa-RR (FFRR) 
for GM-CSF-armed viruses and FcγRIIIa-FF + FcγRIIa-HH (FFHH) for CD40L-viruses. These 
results suggest the possibility that FcγRs may play a role in the efficacy of oncolytic 
adenovirus therapies; however the study cohort was quite small and very heterogeneous, 
thus, to draw any definitive conclusions on the influence of FcγR polymorphisms on OV 
therapy responsiveness, the correlations should be repeated in a larger and more 
controlled study population. Nevertheless, our study is one of the first studies designed to 
find predictive biomarkers for oncolytic virotherapies to enable better selection of patients 
for clinical studies, which I think is the best way to optimize the treatment efficacy and 
safety.  
 
8.4. Development of a novel oncolytic vaccine platform (PeptiCRAd) 
which carries tumor-associated antigens on the adenoviral 
surface to induce tumor-specific immune responses (IV) 
In Study IV we developed a novel strategy to customize oncolytic adenovirus therapies to 
adapt the therapy to individual characteristics of different tumors. We engineered a viral 
platform where tumor-specific peptides can be attached onto the viral capsid (PeptiCRAd) 
so as to allow development of cancer eradicating tumor-specific immunity (European 
patent (EU PCT/EP2015/060903) “Modified adenovirus for cancer vaccines development” 
was filed). 
8.4.1. In vitro characterization of the modified peptides and the PeptiCRAd 
complex 
Development of a tumor-specific CTL response is a key to achieve efficient and long-lasting 
eradication of cancer. In order to acquire such a response, tumor-associated antigens 
(TAAs) need to be available for antigen presenting cells to be cross-presented to T cells. To 
enhance the availability and presentation of tumor antigens, we developed a method to 
deliver peptides efficiently into tumors using an adenovirus as a vector. The adenovirus 
serves as an adjuvant e.g. by inducing release of cytokines. Moreover, lysis of the tumor 
cells caused by replication of the virus may improve the tumor killing efficacy directly as 
well as by enabling spreading of other TAAs to the tumor surroundings. 
Our first aim in Study IV was to develop a method to attach tumor-associated peptides 
onto the adenoviral surface. The protein capsid of the adenovirus is known to be 
negatively charged (Fasbender et al. 1997) (Supplementary Figure 1 of Study IV). We thus 
modified the peptides to become positively charged, so that they would adhere to the 
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negatively charged capsid by electrostatic interactions. To make the peptides positively 
charged, a poly-lysine (polyK) chain was covalently added to the peptide sequence.  
To verify the concept of our novel platform, we used a well-known model peptide, 
SIINFEKL, an MHC-I epitope of chicken ovalbumin (OVA). We first analyzed whether the 
positively charged polyK-modified SIINFEKL peptide (Figure 2a of Study IV) is able to bind to 
the virus surface. The surface of plasmon resonance (SPR) analysis plate was then coated 
with oncolytic adenovirus (OAd) (Supplementary Figure 2 of study IV) and increasing 
amounts of the lysine-modified or unmodified SIINFEKL peptide were added onto the plate 
and the net charge of the formed complex was measured (Figure 43 left panel). The SPR 
analysis revealed that the unmodified peptide was unable to bind onto the virus (Figure 43 
left panel, dashed line), whereas a concentration-dependent interaction was observed 
with the modified peptide (Figure 43 left panel, solid line) demonstrating that addition of 
the polyK chain to a peptide sequence is a feasible method to attach peptides onto 
adenovirus capsid. 
Next, we studied how the amount of polyK-peptide attached to the virus affects the size 
and charge of the Ad-peptide complex (Figure 43, right panel). The size (hydrodynamic 
diameter) of the complex was measured by dynamic light scattering (DLS) (Figure 43 right 
panel, solid line). Also the charge (zeta-potential) of the complex was determined with 
different peptide-virus μg ratios (Figure 43 right panel, dashed line) (OAd alone, 1:5 
OAd:peptide, 1:50, 1:100 and 1:500). The size of naked adenovirus is ~100 nm, and the 
surface charge of Ad is negative (-29.7±0.5 mV). The charge of the complex was observed 
to reach saturation with 1:50 virus-peptide ratio at approx. +18 mV. With low peptide 
concentration (1:5) the size of the complex increased to 800±13.5 nm, because of the 
heavy aggregation of the complexes close to neutral charge. Although the charge of the 
complex was seen to plateau beyond 1:50 Ad-peptide ratio, the size of the complex was 
close to a normal-sized adenovirus only at the highest peptide concentration (1:500 ratio). 
Hence, 1:500 was estimated to be the optimal mass ratio and was chosen to coat the 
adenovirus.  
These results showed that the oncolytic adenovirus capsid could be coated with positively 
charged peptides to form a complex that we call PeptiCRAd (Peptide-coated Conditionally 
Replicating Adenovirus).  
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Figure 43. Physical characterization of the interaction between the modified SIINFEKL 
peptide and oncolytic adenovirus. Virus-peptide interaction was measured by Surface 
Plasmon Resonance. An APTES Silica SiO2 sensor was coated with OAd (Ad5-Δ24) and 
increasing concentrations (0.15, 0.3, 0.6, 1.2, 2.4 and 7.2 μM) of either SIINFEKL (dashed 
line) or polyK-SIINFEKL (solid line) were injected into the flowing system (left panel). OAd 
was incubated with polyK-SIINFEKL using different OAd-peptide (μg) ratios. Zeta potential, 
i.e. the charge of the complex (dashed gray line) and hydrodynamic diameter, i.e. size of the 
complex (solid black line) were determined. The averages of three consecutive 
measurements are shown in the right panel. (Capasso et al. 2015, OncoImmunology [Study 
IV]) 
To trigger an effective immune response, peptides need to be taken up, processed and 
efficiently cross-presented by APCs to T cells on the MHC molecules. Cross-presentation is 
a process that allows presentation of exogenous antigens (e.g. tumor antigens) on MHC-I 
and thus priming of cytotoxic (CD8+) T cells. Normally exogenous antigens would be 
presented on MHC-II and the process would require infection of dendritic cells (Rock & 
Shen 2005). Cross-presentation is agreed to be an important mechanism by which tumor-
specific CTL immunity is developed after many immunotherapies, such as OV therapy and 
peptide vaccinations (Fehres et al. 2014). 
Therefore, we investigated whether modification of the peptide affects its cross-
presentation and if the position of the polyK chain (i.e. on the N- or C-terminus of the 
peptide sequence) affects the efficiency of the cross-presentation. To this end, we 
performed a cross-presentation assay where we pulsed splenocytes (from C57BL/6 mice) 
with either the natural unmodified SIINFEKL (positive control) or its two different lysine-
extended versions: polyK-SIINFEKL (N-terminus extended) and SIINFEKL-polyK (C-terminus 
extended). Also an extended SIINFEKL containing an N-terminal amino caproic residue 
(AHX) was included in the assay as a negative control. AHX is a well-known lysine analogue, 
an unnatural D-amino acid that cannot be processed by the proteasome. To assess the 
cross-presentation of SIINFEKL we used an antibody that specifically recognizes MHC-I 
loaded with SIINFEKL (Deng et al. 1998) and analyzed the amount of SIINFEKL-presenting 
cells by flow cytometry. A total of 98.5% of the splenocytes pulsed with the unmodified 
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SIINFEKL cross-presented the peptide. Intriguingly, also the N-terminal poly-lysine-
containing peptide was effectively presented (94.5%). In contrast, when the splenocytes 
were pulsed with the C-terminal SIINFEKL-polyK, the cross-presenting only 27.1% of the 
splenocytes were able to present the peptide (Figure 44a). We speculate that the low 
cross-presentation of the C-terminally modified peptide might result from a slower 
proteasomal cleavage pathway, which requires that the antigen first escapes from the 
phagosome, then undergoes proteasomal degradation in the cytosol to be processed by 
endoplasmic reticulum (ER) aminopeptidases, before the mature peptide finally can be 
loaded on MHC-I molecules and exposed onto the cell membrane (Heath & Carbone 2001). 
On the other hand, as the N-terminally-modified peptide is perhaps processed faster, 
directly by the ER aminopeptidases (van Endert 2011), it could therefore be directly 
processed inside the phagosomes leading to more rapid and efficient presentation. These 
results made us choose the N-terminally-extended version (polyK-SIINFEKL) for further 
studies. 
Next we investigated whether the polyK-SIINFEKL peptide could be efficiently cross-
presented when complexed onto the surface of the adenovirus. Results showed that the 
peptide is cross-presented as efficiently as the free peptide (Figure 44b). 
 
Figure 44. Cross-presentation of modified SIINFEKL analogues. Spleens were collected 
from C57BL/6 mice (H2-Kb). a) Splenocytes were pulsed with unmodified SIINFEKL (positive 
control), aminocaproic acid-containing SIINFEKL-AHX-polyK (negative control), C-terminus 
extended SIINFEKL-polyK or with N-terminus extended polyK-SIINFEKL. Cells were stained 
with an APC-conjugated anti-H2-Kb SIINFEKL-binding antibody. b) Splenocytes were infected 
with of OVA-PeptiCRAd (100 vp/cell + 37.5 μg of peptide) or pulsed with 37.5 ug of SIINFEKL 
(positive control) or polyK-SIINFEKL. Samples were extensively washed and analyzed by flow 
cytometry using the same antibody as in panel a). (Capasso et al. 2015, OncoImmunology 
[Study IV]) 
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Then, in order to test if coating of the oncolytic adenovirus would hinder the oncolytic, i.e. 
tumor cell killing potency, we infected different cancer cells with PeptiCRAd or with 
uncoated oncolytic adenovirus (Ad5-Δ24) and measured the cell viability by MTS assay 
(Figure 45a). We saw no difference in the cell killing efficacy between the coated or 
uncoated viruses, thus the peptide coating does not affect the oncolytic efficacy of the 
oncolytic adenovirus.  
We also wanted to determine if PeptiCRAd was capable of infecting cancer cells efficiently. 
We performed an ICC immunocytochemistry assay to measure the amount of infected cells 
after PeptiCRAd or AD5-Δ24 infection (Figure 45b). Interestingly, we observed increased 
infectivity (P < 0.01) of two (CACO-2 and A2058) of the three tested cell lines by PeptiCRAd 
compared to the naked virus. This is most probably because the cell membrane is 
negatively charged, hence the positive charge of the PeptiCRAd complex helps 
internalization into the cells. It has also been shown by others that transduction of the 
adenovirus is increased when complexed with natural positively charged cell penetrating 
peptides (Nigatu et al. 2013) or if coated with polycationic polymers and/or cationic lipids 
(Fasbender et al. 1997).   
 
Figure 45. Oncolytic potency and infectivity of PeptiCRAd. a) Cell viability assay in different 
malignant cell lines. b) Infectivity assay by immunocytochemistry. The average number of 
spots per visual field is presented. (Capasso et al. 2015, OncoImmunology [Study IV]) 
In summary, the in vitro studies on PeptiCRAd show that we are able to coat oncolytic 
adenoviruses with polyK-modified peptides and the coating does not hinder the oncolytic 
potency nor the cross-presentation of the peptide and that the coating even increases the 
infectivity of the virus. 
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8.4.2. In vivo immunity and efficacy of PeptiCRAd in mouse melanoma 
models  
To study the anti-tumor efficacy and immunity promoted by PeptiCRAd, we first used a 
murine model of melanoma over-expressing chicken ovalbumin (B16-OVA). B16-OVA cells 
were injected s.c. in the flanks of C57BL/6 mice and the established tumors were treated 
i.t. either with OVA-PeptiCRAd (i.e. PolyK-SIINFEKL-coated OAd), a non-complexed OAd in 
combination with SIINFEKL, OAd alone, peptide alone (SIINFEKL) or saline (mock). The 
experiment was first performed with a regular oncolytic adenovirus bearing the 24 bp 
deletion in E1 (Ad5-Δ24) (Supplementary Figure 3 of Study IV) and then repeated with a 
CpG-riched adenovirus (Ad5-Δ24-CpG) to boost the immunity even further (Figure 46). 
PeptiCRAd significantly reduced the growth of the syngeneic tumors compared to mock 
treatment or the mixture of OAd and SIINFEKL peptide (P < 0.01). The average volume of 
the tumors in the OVA-PeptiCRAd-treated mice was lower than in all other groups on day 
16 (120.4±31.6 mm3 versus 697.7±350 mm3 in mock; 255±61.5 mm3 in SIINFEKL; 
713.7±292.6 mm3 in Ad5-Δ24-CpG; 489.7±73.2 mm3 in Ad5-Δ24-CpG+SIINFEKL). 
 
Figure 46. Anti-tumor efficacy of OVA-PeptiCRAd in vivo. C57BL/6 mice (n= 6-8) with 2x 
B16-OVA tumors were treated i.t. with: saline solution (mock), peptide alone (SIINFEKL), 
virus alone (Ad5-Δ24-CpG), virus and peptide mix (Ad5-Δ24-CpG+SIINFEKL) or PeptiCRAd 
complex (OVA-PeptiCRAd). Treatment of mice was three times total (days 0, 2 and 7). 
Tumor volume is presented. (Capasso et al. 2015, OncoImmunology [Study IV]) 
To assess the immunological effects of PeptiCRAd we collected the spleens, draining lymph 
nodes and tumors of the treated mice. We measured the levels of SIINFEKL-specific (i.e. 
OVA-specific, tumor-specific) CD8+ T cells in the organs by flow cytometry. We observed 
increased amounts of tumor-specific T cells in the samples from the organs of PeptiCRAd 
treated mice, although the differences were not statistically significant. (Figure 47, upper 
panel). 
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Figure 47. Immunological analysis of antigen-specific CD8+ T-cells and dendritic cells after 
OVA-PeptiCRAd treatment. Above: Tumors, spleens and the inguinal lymph nodes from 
mice were collected 16 days after virus treatments and SIINFEKL-specific CD8+ T-cells were 
determined by flow cytometry. Below: Fold change of dendritic cells with mature 
phenotype (CD19-CD3-CD11c+CD86high) cross-presenting SIINFEKL on their MHC-I molecules. 
(Capasso et al. 2015, OncoImmunology [Study IV]) 
To study the potential of PeptiCRAd to trigger antigen-presentation in vivo we evaluated by 
flow cytometry the amount of mature dendritic cells (CD19- CD3- CD11c+ CD86high cells) 
presenting the SIINFEKL peptide on MHC-I in the spleens of the mice. Sixteen days after the 
first virus treatment, the mice treated with PeptiCRAd showed significantly increased 
amounts of mature SIINFEKL-presenting DCs (P < 0.05) compared to mice treated with the 
non-complexed Ad5-Δ24-CpG+SIINFEKL (Supplementary Figure 4b of study IV). The amount 
of mature DCs was also evaluated at an early time point, 7 days after the first treatment. 
When compared between the early (day 7) and the late (day 16) time points, the biggest 
increase in the DC levels were in the amounts of mature, cross-presenting DCs in the 
PeptiCRAd group (9.67-fold change) (Figure 47, panel below).  
Targeting multiple tumor antigens is important in order to limit the escape of malignant 
cells from the immune surveillance (Matsushita et al. 2012) and to combat the variability of 
tumor cells (Andersen & Ohlfest 2012). Indeed, it could be shown quite recently that 
patients who responded to multiple tumor epitopes had a significantly better treatment 
outcome estimate (Walter et al. 2012). In addition, a multivalent approach would be 
especially useful in the case of tumors where one HLA allele is down-regulated (Carretero 
et al. 2008). Hence, we designed experiments to address whether a double-coated 
PeptiCrad is more effective than a PeptiCRAd coated with only a single peptide. We also 
wanted to know if we are able to induce anti-tumor responses with clinically relevant 
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melanoma antigens (gp100 and TRP-2) in analogy to the SIINFEKL model peptide used in 
the proof-of-concept studies. We chose an SVYDFFVWL peptide (TRP-2180-188; restricted to 
the murine MHC-I molecule H-2Kb) and KVPRNQDWL peptide (human gp10025-33; restricted 
to the murine MHC-I molecule H-2Db) (Joffre et al. 2012), both expressed by B16-F10 cells 
(Sijts & Kloetzel 2011). We injected B16-F10 mouse melanoma cells into the other flank of 
C57BL/6 mice and treated the established tumors with i) saline solution (mock), ii) naked 
oncolytic virus (Ad5-Δ24-CpG), iii) single-coated hgp100-PeptiCRAd, iv) single-coated TRP-
2-PeptiCRAd, and v) double-coated TRP-2-hgp100-PeptiCRAd. The double-coated 
PeptiCRAd was shown to significantly reduce (P < 0.001) the growth of the treated tumors 
compared to both the mock and the hgp100-PeptiCRAd groups (Figure 48, left panel).  
We also tested whether systemic immunity was triggered by PeptiCRAd whether it would 
be able to also control growth of distant, untreated tumors. To demonstrate this, we 
injected B16-F10 cells in one flank of the treated mice (described above) and followed the 
development of the second tumor (Figure 6A of Study IV). We saw that the multivalent 
PeptiCRAd bearing two autologous tumor antigens was able to significantly inhibit the 
growth of the second tumor compared to the treatments with naked virus or saline (P < 
0.01) (Figure 48, right panel). A clear reduction of the primary and secondary tumor 
growth was observed in mice treated with TRP-2-hgp100-PeptiCRAd compared to TRP-2-
PeptiCRAd and hgp100-PeptiCRAd, however, the differences were not statistically 
significant. 
 
Figure 48. PeptiCRAd loaded with natural tumor antigens inhibits regrowth of previously 
treated tumors but also engraftment of new distant melanoma tumors. C57BL/6 mice 
bearing B16-F10 melanoma tumors were treated with viruses coated with natural 
melanoma-associated peptides. The growth of the treated tumors (left) and the size of the 
untreated secondary tumors (right) are shown. (Capasso et al. 2015, OncoImmunology 
[Study IV]) 
We also analyzed tumor-specific T cell responses against both epitopes by pentamer 
staining and flow cytometry analysis of spleens and lymph nodes of the treated mice. The 
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highest cumulative amount of epitope-specific CD8+ T cells was found in the mice treated 
with TRP-2-hgp100 PeptiCRAd (Figure 49). 
 
Figure 49. Tumor-specific T cell responses after multivalent PeptiCRAd therapy. Spleens 
and inguinal lymph nodes were collected and the levels of TRP-2 and hgp100 specific CD8+ 
T-cells were determined by Class-I pentamer staining. The amount of epitope-specific CD8+ 
T-cells found in each organ was normalized against the mock and is presented as 
cumulative relative response for each experimental group. (Capasso et al. 2015, 
OncoImmunology [Study IV]) 
These results from the syngeneic murine melanoma model indicate that PeptiCRAd has 
potential to increase tumor-antigen presentation and thus activation of adaptive immune 
responses against cancer. Our data shows that targeting two antigens simultaneously (TRP-
2 and gp100) increases the anti-tumor efficacy of the PeptiCRAd platform.  
8.4.3. Efficacy and immunogenicity of PeptiCRAd in humanized mice 
Finally, we wanted to test the efficacy of PeptiCrad in a model closer to a clinical scenario: 
the humanized mouse model in which components of the human immune system were 
egrafted into immunodeficient mice. As in the Study II, we first injected human melanoma 
cells (SK-MEL-2) s.c. into the flanks of highly immunodeficient NSG (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) mice, which lack mature T cells, B cells and functional NK cells, and are 
deficient in cytokine signaling, leading to efficient engraftment of human blood cells. When 
the tumors reached a palpable size, HLA-A3 matched human PBMCs from a healthy donor 
were engrafted into the mice. Subsequently, the mice were treated i.t. with PeptiCRAd, 
uncoated virus or saline solution (mock). For coating the PeptiCRAd in this experiment, we 
chose a polyK-modified epitope derived from melanoma-associated antigen A1 (MAGE-
A196-104; SLFRAVITK), which is a peptide already used in peptide vaccine clinical trials 
(Toungouz et al. 2001). We also chose a GM-CSF-expressing adenovirus (Ad5-Δ24-GM-CSF), 
because GM-CSF viruses are the most frequently used OVs in clinical trials at the moment 
(Breitbach et al. 2015a, Andtbacka et al. 2015, Senzer et al. 2009, Vassilev et al. 2015, 
Burke et al. 2012). GM-CSF also enables better stimulation of the immune system. 
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Treatments with the MAGE-A1 PeptiCRAd resulted in reduced growth of the human 
melanoma tumors in immunodeficient mice engrafted with human PBMCs (Figure 50) and 
a complete cure was obtained in all the mice, while in control mice without human 
immune cells, no difference was observed between PeptiCRAd and the uncoated virus 
(Figure 7C of Study IV) underscoring the important role of the immune system in defining 
the efficacy of PeptiCRAd. 
 
Figure 50. Efficacy of PeptiCRAd in humanized mice bearing human melanomas. NGS 
mice with human melanoma tumors (SK-MEL-2) and engrafted with human PBMCs (N=6 
tumors/group) were treated intratumorally on days 0, 2 and 4 with: i) saline solution 
(mock); ii) Ad5-Δ24-GMCSF; iii) MAGE-A1 PeptiCRAd. a) The tumor volume is presented. b) 
For each group of mice, the area under the curve (AUC) relative to the size of the tumors is 
presented. (Capasso et al. 2015, OncoImmunology [Study IV]) 
To analyze whether anti-tumor immunity developed in the treated mice, we collected the 
spleens at the end of the experiment (17 days after the first treatment), stained the cells 
with a MAGE-A1 pentamer and ran the flow cytometric analysis. We found more human 
MAGE-A1-specific CD8+ T cells in the spleens of PeptiCRAd treated mice (Figure 51) (n.s.). 
Unfortunately, we could not analyze the T cells in the tumors (which would be more 
relevant when assessing anti-tumor immune responses), since the tumors were completely 
cured in the PeptiCRAd group in this experiment. 
In summary, in Study IV, we were able to develop a method to coat an oncolytic 
adenovirus with tumor-associated, MHC-I restricted peptides by electrostatic interaction 
and showed the efficacy and immunogenic potency of the PeptiCRAd platform in several in 
vivo models. The PeptiCRAd platform is a very quick and easy way to generate tumor-
antigen carrying viruses and it overcomes the difficulties of genetic or chemical 
modifications previously used for the same purposes. It is also easy to customize and it 
allows targeting of multiple antigenic entities simultaneously, which enables to compete 
with the heterogeneous and continuously evolving tumor environment. In addition, we 
have shown that the PeptiCRAd platform can be used also for efficient tumor delivery of 
complex of L-carnosine peptide drug, a natural anti-tumor peptide drug. This peptide-
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adenovirus complex showed enhanced anti-tumor efficacy compared to OAd or L-
carnosine treatment separately (Garofalo et al. 2016).  
 
Figure 51. Tumor-specific T cells in the spleens. At day 17, spleens of the treated NSG mice 
were collected and the amount of MAGE-A1 specific CD8+ T cells was analyzed by flow 
cytometry. (Capasso et al. 2015, OncoImmunology [Study IV]) 
Our results suggest that administration of tumor-specific peptides in combination with an 
oncolytic virus serving as an adjuvant may increase the efficacy of cancer treatment, 
compared to treating with virus or peptide alone. Our results are consistent with the 
recent study by Li et al. where they show that adjuvant-antigen complexes are more 
effective than the single components because of a superior targeting of APCs (Li et al. 
2013). It is increasingly understood that personalized approaches are needed to increase 
the efficacy and, most importantly, to reduce the side effects associated with use of 
unspecific cancer therapies. We think our PeptiCRAd platform could be used in the future 
as a carrier and adjuvant for patient- and tumor-specific peptides to trigger fierce anti-
tumor immunity in a personalized manner.  
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9. CONCLUSIONS AND FUTURE PROSPECTS 
The strategies introduced in this thesis for the improvement oncolytic virotherapies fit in 
the prevailing trends of a new era of cancer therapies: Immunotherapy and personalized 
medicine.  
The thesis studies showed how the enhancement of the immunogenic potential of 
oncolytic viruses can improve the immune reactivity against cancer and hence potentiate 
the efficacy of virotherapies. This is in line with the results of other studies using viruses 
that have been armed with immunostimulatory molecules (Breitbach et al. 2015a, Bartlett 
et al. 2013, Ranki et al. 2014, Pesonen et al. 2012b, Cerullo et al. 2010). It has been realized 
that oncolysis alone is not powerful enough to trigger tumor responses, the 
immunosuppressive tumor environment needs to be counteracted and reshaped in order 
to be able to achieve antitumor responses critical for achieving long-term control against 
cancer (Lichty et al. 2014). 
At the moment it seems that we are living in the golden times of immunotherapies. New 
strategies to enhance anti-tumor immune responses are currently being avidly 
investigated. Checkpoint inhibitors, which block the inhibitory signals to immune cells 
enabling activation of anti-tumor immune responses, are now generally accepted as critical 
immunotherapeutic agents studied extensively, both as single agents and in combination 
with other therapies. They are also being tested in a combination with oncolytic viruses 
(Rojas et al. 2015). It was just recently shown that combination of oncolytic Newcastle 
Disease Virus with a CTLA-4 blocker led to rejection of pre-established distant B16 tumors 
and the therapeutic effect was associated with tumor infiltration with activated CD8+ and 
CD4+ cells (Zamarin & Pesonen 2015). Also we have previously shown that anti-CTLA-4 
antibody expressed by an oncolytic adenovirus enhances the cancer killing potency of the 
virus (Dias et al. 2011). Ongoing clinical trials are testing one of the leading cancer 
virotherapy agents, T-Vec (trade name Imlygic, Amgen), a herpes simplex virus expressing 
GM-CSF, with the novel immune checkpoint inhibitors ipilimumab (anti-CTLA-4) 
(NCT01740297) and pembrolizumab (anti-PD-1) (NCT02263508) (Zamarin & Pesonen 2015, 
Ascierto, Marincola & Atkins 2015). 
Taken together, it is fairly easy to realize that combination therapies, involving both 
conventional and novel therapies, will be the future of cancer treatment. Also in this thesis 
(in Study I), I came to better understand the synergism that is possibly gained by combining 
two different strategies, oncolytic adenovirus treatment and radiotherapy. Oncolytic 
viruses have the potential to exert additive or even synergistic effects with various other 
treatments, like chemotherapy (Nguyen, Ho & Wan 2014, Liikanen et al. 2013) or different 
cell-based immunotherapies (Song 2013, Tahtinen et al. 2015), since they can act as 
adjuvants and they have the ability to release tumor antigens by cell lysis (in-situ vaccines). 
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The common ideology of cancer medication is shifting from a “one-dose-fits-all” concept to 
personalized medicine, and in the future drugs and treatments will most probably be 
increasingly patient-tailored, and the dosing and choice of a drug will take patient’s 
genomics and the tumor microenvironment into account (Gasparini & Longo 2012, de Wit 
et al. 2015, Park et al. 2015). As for most cancer therapies, as well as for oncolytic 
virotherapies, it is common that the treatments are not equally efficient for all patients. 
Currently there is a lack of useful markers that would help in selecting the patient 
population that most probably benefits from the OV treatments, thus, Study III of this 
thesis focused on finding new biomarkers to predict the treatment efficacy. However, the 
steps towards optimization of tailored therapies still require discovery of new biomarkers, 
insight and detailed knowledge of tumor biology and immunology, further development of 
faster pharmacogenetic analyses, and wider collaboration and communication between 
experts in different fields: biologists, medical doctors, bioinformaticians, pharmacists, IT 
specialists, in essence, the actors between the bench and bedside, etc. These 
developments would most probably lead to generating highly patient-tailored drugs and 
approaches that could even be individually customized to each tumor of the patient. If 
(and when) the methods to screen tumor-specific antigens (peptides) (Admon & Bassani-
Sternberg 2011) from individual cancer patients grows quicker and more efficient to use, it 
would be possible to also quickly generate efficient, highly specific therapeutic cancer 
vaccines. Our novel platform developed in Study IV to carry tumor-associated peptides on 
a surface of a virus (PeptiCRAd) already provides an easily customizable and highly-
effective immunity-triggering vector for this purpose. 
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